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Introduction
In this thesis, we present our research concerning metabolic disturbances in primary Sjögren 
syndrome (pSS). pSS is a systemic autoimmune disease, which is characterized by lymphocytic 
infiltration of the secretory glands. The symptoms of pSS include sicca syndrome (dry eyes and/
or oral cavity) and systemic manifestations, such as pulmonary, articular, renal and neurological 
involvement. Systemic involvement is not always easy to recognize by the physician in a com-
plex disease as pSS, since symptoms can be non-specific. Renal involvement is common in pSS 
with distal renal tubular acidosis (dRTA) as major manifestation, which is a known complication 
of pSS. dRTA is a urinary acidification defect leading to a metabolic acidosis and alkaline urine. 
Furthermore, dRTA is associated with decreased bone mineral density (BMD) leading to hyper-
calciuria and nephrolothiasis.
In chapter 1 and 2 we reviewed the current knowledge about pSS and dRTA, respectively. We 
evaluated in chapter 3 the prevalence of dRTA in pSS patients by performing a urinary acidifi-
cation test. Consequently, we evaluated in chapter 4 the BMD in pSS patients and the effect of 
dRTA on BMD. 
Studies in patients with systemic lupus erythematosus have reported a higher BMD in patients 
using HCQ compared to patients without HCQ treatment. In our cohort, 69% of the pSS pa-
tients was using HCQ. Therefore, we evaluated the effect of HCQ on bone cells in vitro. 
In chapter 5 and 6 we report the effects of HCQ on human osteoblasts and osteoclast in vitro, 
respectively. Also, we propose a mechanism of action for the effects of HCQ on both bone cells. 
Finally, in chapter 7 and 8 we summarized all chapters and we will discuss our data more in 
depth. Also, we proposed new future research directions.
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beyond the dryness 
From pathophysiology to diagnosis 
and treatment
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Abstract
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, characterized by lym-
phocytic infiltration of the secretory glands. This process leads to sicca syndrome, which is the 
combination of dryness of the eyes, oral cavity, pharynx, larynx and/or vagina. Extraglandular 
manifestations may also be prevalent in patients with pSS, including cutaneous, musculoskele-
tal, pulmonary, renal, hematological and neurological involvement. The pathogenesis of pSS is 
currently not well understood, but increased activation of B cells followed by immune complex 
formation and autoantibody production are thought to play important roles. pSS is diagnosed 
using the American-European consensus group (AECG) classification criteria which include 
subjective symptoms and objective tests such as histopathology and serology. The treatment 
of pSS warrants an organ based approach, for which local treatment (teardrops, moistures) and 
systemic therapy (including non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, 
disease-modifying antirheumatic drugs (DMARDS) and biologicals) can be considered. Biolog-
icals used in the treatment of pSS mainly affect the total numbers of B cells (B cell depletion 
(Rituximab)) or target proteins required for B cell proliferation and/or activation (e.g. B cell ac-
tivating factor (BAFF)) resulting in decreased B cell activity. 
The aim of this review is to provide physicians a general overview concerning the pathogenesis, 
diagnosis and management of pSS patients.
           Chapter 1
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Introduction
Sjögren’s syndrome (SS) is a relatively common systemic autoimmune disease characterized by 
lymphocytic infiltration of the secretory glands. This process leads to sicca syndrome, which 
is the combination of dryness of the eyes, oral cavity, pharynx, larynx and/or vagina 1. Sicca 
syndrome is often accompanied by symptoms resulting from systemic involvement. SS can be 
present as a primary disease without any other accompanying symptoms (primary Sjögren syn-
drome, pSS). When SS presents as a secondary disease with other autoimmune diseases such as 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis, it is then 
called secondary SS (sSS) 2,3.  The prevalence of sSS is highest in RA patients and estimated to be 
around 20% 2,4. In this review we will focus on pSS. 
Epidemiology
A large Norwegian population based study estimated the prevalence of pSS in individuals aged 
40–44 years at 0.44 (95% CI 0.34–0.57) using the European criteria 5. This study also demon-
strated that individuals aged 71–74 years compared to those aged 40–44 years had an 8.07 
times higher prevalence rate of pSS using the European criteria. Two large cross-sectional 
popula tion based surveys performed in the United Kingdom estimated the prevalence of pSS 
using the revised European criteria at 1.6 (95% CI 9–26) and 0.14 (95% CI 0.02–0.51), respec-
tively 6,7. A prospective study from Slovenia between 2000 and 2002 estimated the incidence 
of pSS at 3.9 per 100,000 (95% CI 1.1–10.2), in a total cohort of 599,589 subjects 8. The in-
cidence of pSS was noted to be ten times higher in women compared to men from Slovenia. 
Another prospective study performed in Greece identified 422 new cases of pSS in a population 
of 488,435 from 1982 to 2003, with a reported incidence of 5.3 per 100,000 (95% CI 4.5–6.1) 
9. In this population women were affected 20 times more likely than men. However, as many 
symptoms are non-specific, prevalence may be under- and overestimated. 
Pathogenesis
The pathogenesis of pSS is incompletely understood but appears to be multifactorial. Although 
T cells were originally considered to be the key players in the autoimmune process, there is now 
growing evidence that B cells play at least an equally important role in the pathophysiology of 
1
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pSS (Figure 1). In the next section we will discuss in more detail the known and potential roles 
of the different immune cells in the pathogenesis of pSS.
Genetics
The first studies reporting associations between gene polymorphisms in pSS were case–con-
trol studies based on data from studies performed in SLE. These candidate gene studies mainly 
reported positive associations between pSS and polymorphisms in IRF5 (a crucial tran scription 
factor of the type I IFN pathway) and poly morphisms in STAT4 (a signal transducer and activator 
of transcription 4, a protein involved in the type II IFN pathway), which are both involved in the 
interferon pathways 10–14. In 2013, two genome-wide association studies (GWAS) in pSS were 
published 15,16. 
Figure 1 – A simplified overview of the pathogenesis of pSS with the targets for biologicals 
An unknown cause (suggested to be a virus or immune complexes) may lead to activation of pDCs and DCs resulting 
in increased levels of interferons. Interferon-induced BAFF production leads to increased B cell proliferation and 
differentiation with autoantibody production as result.
Abbreviations: pDC, plasmacytoid dendritic cell; DC, myeloid dendritic cellTh1, T-helper 1 cell; IFN, interferon; B, B 
cell; PC, Plasma cell; Tfh, Follicular  T-helper cell
             Chapter 1
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GWAS is a powerful method offering the ability to screen thousands of regions of DNA. Lessard 
et al. analyzed over 10,000 subjects from Europe (controls and pSS patients) and identified seven 
genetic loci surpassing the statistical threshold 16. These loci included MHC-II loci, IRF5, STAT4, 
IL12A, BLK, CXCR5, and TNIP1. The strongest association was with the HLA-II locus, STAT4 and 
IRF5, which have all been previously identified by the candidate gene studies. In addition, this 
study reported three new genes (IL12A, BLK, and CXCR5) being significantly associated with pSS 
compared to controls and play important roles in immune signaling. The other GWAS in pSS was 
performed in China and included 1090 healthy controls and 597 pSS patients  15. In addition to 
MHC class II genes, three other genes were identified. The most strongly associated gene in this 
Chinese cohort was GTF2I, which acts as a general transcription factor. Other significantly as-
sociated genes included MHC-II genes, STAT4, and TNFAIP3. Although additional confirmatory 
studies are needed, these results suggest that the Chinese and European pSS patients may have 
different risk associated genes.
T cells in pSS
The presence, and sometimes predominance, of CD4+ T cells in salivary gland infiltrates un-
derlines their potential contribution to the pathogenesis of pSS 17. A meta-analysis showed the 
association between pSS and several major histocompatibility complex class 2 (MHC2) alleles 
suggesting that autoantigen presentation is important in the pathogeneses of pSS 18. Th1 cells 
are hypothesized to be the main subtype contributing to pathogenesis, since they interact with 
the MHC2 molecules initiating an immune response. In addition, pro-inflammatory Th1 cell 
cytokines (e.g. IL-1β, IL-6, tumor necrosis factor-α and interferon-γ) are increased in saliva of 
patients with pSS 19. Furthermore, a study in 2009 reported a pSS-like syndrome in mice with 
IL-12 overexpression, which is known to induce Th1 cell differentiation 20. Besides Th1 cells, the 
number of T helper 17 (Th17) cells are also increased at sites of inflammation in salivary gland 
biopsies of pSS patients 21. IL-17, produced by Th17 cells, is increased in both serum and salivary 
glands of patients with pSS as compared to healthy controls 22. Co-expression of IL-17 and IL-18 
has been associated with increased severity of pSS, probably due to maintaining the inflamma-
tory process 21,23. Furthermore, regulatory T cells (Treg) have been identified in salivary glands 
of pSS patients and the increased presence of these cells has been associated with higher grade 
1
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of inflammation in the local lesions 24,25. Tregs are known to have suppressive effects on the 
proliferation and function of effector T cells. It has been reported that the number of circulating 
Tregs are increased, while their function does not seem to be impaired in pSS, which suggests 
that Tregs are compensatory involved in pSS by lowering the autoimmune response 26.
B cells in pSS
B cells are adaptive immune cells that are responsible for antibody secretion and antigen pre-
sentation. B cells differentiate in the bone marrow. One of the key factors in this process is B 
cell activating factor (BAFF). BAFF is a cytokine that promotes B cell proliferation, maturation 
and survival and is primarily induced by type I and type II interferons 27,28. Interferon I is mainly 
produced by plasmacytoid dendritic cells (pDCs) but also myloid dendritic cells can produce 
it. Type II interferon is produced by T cells 23,29. It has been suggested that certain viruses (e.g. 
Epstein-Barr) and immune complex formation activate Toll-like receptors (TLRs) (e.g. TLR 3, 7 
and 9), leading to activation of the innate immunity and interferon production. Although an in-
creased activity in TLR pathway has been reported in pSS, a specific cause (virus or immune com-
plex) has not yet been identified 30,31. In pSS patients, 55% have an increased IFN type I activity 
versus 4.5% in healthy controls 32. The presence of this so-called ‘IFN type I signature’ in mono-
cytes of patients with pSS was shown to be associated with higher EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI), the presence of biological markers of activity (increased levels 
of IgG and/or hypocomplementia) and increased levels of BAFF mRNA in monocytes 32. Circu-
lating and salivary gland tissue levels of BAFF are significantly elevated in patients with pSS, 
which is associated with increased disease activity but also with higher risk of development of 
B cell lymphoma 33–35. These findings support the hypothesis that innate immune system activa-
tion contributes to an autoimmune response by the adaptive immune system. Since BAFF is one 
of the links between innate and adaptive immune responses, it could be a potential target for 
therapy in pSS. The first results of studies on anti-BAFF therapy (belimumab) show a significant 
decrease in disease activity after twelve months of treatment as measured by the ESSDAI 36. 
Upon antigen recognition in the germinal center, B cells proliferate and differentiate (e.g. class 
switching) into antigen specific B cell 37. In pSS, germinal centers are reported in the epithelium 
of non-lymphoid tissues such as the salivary glands as well 38. The formation of germinal centers 
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is probably important in the pathogenesis of pSS due to promotion of chronic stimulation and 
activation (by follicular T helper cells) of B cells. Phosphatidylinositol 3–kinase (PI3K) activity 
is increased in B cells suggesting that PI3K inhibitors may be new therapeutic agents in pSS 39. 
Preliminary data from a mouse study showed positive effects of PI3K inhibitors on inflamma-
tion in salivary glands 40. Currently, the first clinical trial with PI3K inhibitors has started in pSS.
Patients with pSS often present with high levels of serum IgA and/or IgG 41. Hyperglobulinemia 
may lead to the formation of immune complexes with the potential to precipitate in major or-
gans leading to (irreversible) damage 42.
In addition, the presence of autoantibodies (anti-Ro52, anti-Ro60 and anti-La) are included 
in the diagnostic criteria set for pSS, but also other autoantibodies (e.g. anti-acetylcholinere-
cepter antibodies) are thought to play a role in the pathogenesis 43–46. The presence of these au-
toantibodies is associated with early onset disease, parotid gland enlargement, extraglandular 
manifestations and lymphocytic glandular infiltration 23,47. 
In sum, it remains unclear how these changes in the adaptive immune system lead to the clinical 
manifestations of pSS. The traditional view that chronic inflammation results in tissue destruc-
tion of the exocrine glands will only partially contribute to the pathogenesis of pSS. There is a 
poor correlation between the amount of damage observed in tissue biopsies and the measured 
decrease in fluid production, as the reduction in salivary production is often larger than expect-
ed from both clinical and histological appearance 43. 
Clinical presentation
There is not a standard clinical presentation for pSS, as many patients have various degrees 
of systemic involvement at the time of presentation. The symptoms of pSS can be divided into 
three groups, 1) sicca syndrome, 2) systemic manifestations and 3) general symptoms.
1) Sicca syndrome
Sicca syndrome is the combination of dryness of the eyes (xeropthalmia), oral cavity (xerosto-
mia), pharynx and/or larynx, which are the classical symptoms of pSS. In woman, also vaginal 
dryness is a common feature of pSS  48. These symptoms are part of the American-European 
1
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classification criteria (AECG) of 2002 for the diagnosis pSS and occur in more than 95% of pa-
tients (43). The positive predictive value of the AECG criteria is between 54-77% and the neg-
ative predictive value is between 94-98% as compared to the classification criteria of 1986 43. 
Xerostomia may lead to secondary problems like oral candidiasis (33%), dental carries (65%) 
and periodontal disease 49,50. Xerophtalmia may result in chronic irritation and destruction of 
the corneal epithelium and ocular infections. Additionally, sicca syndrome also includes hoarse-
ness, non-productive cough, skin dryness and, in woman, dyspareunia 51,52. Patients with pSS 
experience a significantly decreased quality of life compared to subjects with sicca syndrome 
without autoimmune features as measured by the SF-36 depression scale 53,54.
2) Systemic manifestations
Approximately 71% of the patients with pSS present with extraglandular manifestations (Table 
1) 55. Of those, malignant lymphoma has the highest mortality 56. A large cohort study reported a 
nearly 5-fold higher relative risk in pSS patients with a life-time risk of approximately 10%  57,58. 
The most common subtype is mucosa-associated lymphoid tissue (MALT) lymphoma often seen 
in the parotid glands, which is usually a low-grade indolent neoplasm 59,60. Clinical risk factors 
include persistent, unilateral salivary gland enlargement, lymphadenopathy, splenomegaly, skin 
vasculitis, cryoglobulinemia and the development of glomerulonephritis 61,62. Laboratory-as-
sessed biological risk factors for lymphoma in pSS include cryoglobulinemia, lymphopenia (es-
pecially low total numbers of  CD4+ T cells), hypocomplementia, increased serum BAFF and the 
presence of a monoclonal component in serum  61,63. Articular involvement in pSS predominant-
ly consists of symmetric, intermittent, nonerosive arthropathy 64,65. Arthritis is less common 
and occurs in approximately 16% of pSS patients and mostly involves proximal interphalangeal 
joints (35%), metacarpal-phalangeal joints (35%) and wrists (30%) 65,66. Approximately 10-20% 
of pSS patients develop interstitial lung disease (ILD) 67. In general, patients will have evidence 
of both airway disease and ILD by radiographs (plain X-ray and/or CT-scan) and pulmonary bi-
opsy 67. 
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Domain Prevalence (%) Clinical manifestations Investigations
Lymphadenopathy 
58,59
10 persistent, unilateral salivary gland 
enlargement; lymphadenopathy; 
splenomegaly; skin vasculitis
Serology, biological 
markers, biopsy
Glandular 112 30-50 Þrm, diffuse, nontender, swelling of mostly 
the parotid gland
-
Articular 64,66 50 Arthralgia; arthritis Radiography
Skin 114–116 23-67 Xerosis; Raynaud phenomenon; annular 
erythema, erythema nodosum; livedo 
reticularis; lichen planus; vitiligo; granuloma 
annulare; vasculitis
Biopsy (if required)
Lungs 67,69,70 10-20 dry cough; nasal dryness; dyspnea,; 
interstitial lung disease
Radiography, CT, 
pulmonary function
Kidneys 73,74,117 30 Distal renal tubular acidosis; nephrogenic 
diabetes insipidus; proximal tubular 
acidosis; hypokalemia
Systematic renal tests, 
acid loading test, biopsy
Muscles 118,119 44 Myalgia; muscle weakness; myositis Biopsy
Peripheral 
nervous system 
81,120,121
10 painful, burning dysesthesias in the distal 
extremities; sensory ataxic neuropathy; 
axonal sensorimotor polyneuropathy; 
mononeuritis multiplex; cranial 
neuropathies; radiculoneuropathy; 
autonomic neuropathy
EMG 
Central nervous 
system 80,122
20-25 motor or sensory deÞcits; seizures or 
cerebellar syndromes; psychiatric 
abnormalities; dementia and spinal cord 
involvement; subacute aseptic meningitis; 
chorea; optic neuritis; cognitive dysfunction
EMG, MRI,  
CSF investigation, 
psychiatric analysis
Haematological 41 20 Normochromic, normocytic anemia; 
thrombocytopenia; mild leukopenia; 
lymphopenia
Biochemical tests, bone 
marrow
Biological 41,123 36-62 Hypergammaglobulinemia; 
hypogammaglobulinemia; 
hypocomplementia; cryoglobulinemia
Serology and biological 
tests, bone marrow
Abbreviations: EMG, Electromyography; CSF, cerebrospinal ßuid; CT, Computed tomography; MRI, Magnetic 
resonance imaging;  
1
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Another study reported that patients with pSS who do not have pulmonary symptoms already 
may have radiographic or computed tomography (CT) scan abnormalities (22%) or an impaired 
pulmonary function test 68. The most frequently observed CT patterns consist of interstitial 
pneumonia, centrilobular abnormalities and lymphoproliferative disease 68. This emphasizes 
that a frequent pulmonary function test or a high-resolution CT-scan should be performed 
in the follow-up of pSS patients with and without pulmonary complaints. The most common 
histopathological phenotype of ILD in pSS is nonspecific interstitial pneumonia (NSIP), which 
has been reported in approximately 45% of the pSS patients with ILD 69,70. ILD is difficult to 
treat and results in an increase of dry cough and dyspnea, leading to significantly decreased 
quality of life. ILD is usually treated with glucocorticoids but other immunosuppressive drugs 
are also available, such as azathioprine, mycophenolate mofetil, cyclophosphamide and cyclo-
sporine 71,72. Furthermore, renal involvement is common and includes a wide spectrum of man-
ifestations, of which interstitial nephritis is the most prevalent followed by distal renal tubular 
acidosis (dRTA) 73,74. Consistent screening for renal function is important since renal failure 
(defined as a glomerular filtration rate < 60 ml/min) occurs in approximately 24% of the pSS 
patients 75.  Additionally, a urinary acidification test should be considered in pSS patients given 
the high prevalence and non-specific symptoms of dRTA. There is no standardized treatment 
of renal involvement in pSS. Glucocorticoids are the treatment of first choice in tubulointer-
stitial nephritis, whereas other immunosuppressive drugs are only shown effective in a small 
study (mycophenolate mofetil) or not effective at all during the induction phase (cyclophospha-
mide) 76,77. dRTA can effectively be treated with potassium citrate for both the symptoms and 
complications of dRTA, by restoring acid-base balance. It is unknown whether treatment with 
corticosteroids in autoimmune disease has a positive effect on dRTA. Neurological involvement 
in pSS includes both the peripheral and central nervous systems and shows many comparisons 
with the clinical course of multiple sclerosis (MS) 78. There are similar immunologic mechanisms 
underlying the pathogenesis of pSS and MS 79. In many patients, neurologic symptoms precede 
the onset of other signs and symptoms of pSS 80,81. In general, intravenous corticosteroids are 
first-line therapy for patients with pSS associated neuropathy. Cyclophosphamide or intrave-
nous immunoglobulins can be used in patients who do not improve with corticosteroids 81–83. 
By performing the ESSDAI in pSS patients on a regular basis, all the above discussed systemic 
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manifestations can be recognized. pSS is also associated with hepatitis C (12%), autoimmune 
thyroid disease (10%), autoimmune chronic active hepatitis (2%) and primary biliary cirrhosis 
(5%), but the ESSDAI does not include these diseases 84,85.  
3) General symptoms
The most prevalent general symptom is fatigue, occurring in up to 70-80% of pSS patients 86.
 Fatigue in pSS has been well studied using the multidimensional fatigue inventory (MFI) on 
which pSS patients scores were two-fold worse on all dimensions as compared to healthy con-
trols 87,88. In addition, chronic pain is often seen in pSS due to accompanying fibromyalgia and/
or polyarthralgia 89. Depression and anxiety are also more common in pSS patients compared to 
healthy controls 90. A study showed that 47% of the working age pSS patients received disability 
compensation, because they were considered to be (partially) unfit for work 91. The same study 
also reports that significantly more patients with the following demographic/disease charac-
teristics receive disability compensation: male patients, patients with a high educational level, 
an increasing number of systemic manifestations and/or the use of artificial saliva and/or HCQ 
53,54,91.
pSS treatment requires a patient-specific approach that accounts for disease severity. In the 
Erasmus MC, we evaluate every pSS patient at least 1-2 times a year. In addition to record-
ing the patient’s self-reported symptoms and conducting a standard physical examination, we 
perform blood tests (including total blood count, liver and renal function, C3, C4 and IgG) and 
urinalysis to screen for organ involvement. In the case of mild disease activity (as measured by 
disease activity scores, ESSDAI), we do not perform additional invasive tests such as scans or 
functional tests (e.g. EMG, pulmonary function). In the case of self-reported symptoms or ab-
normal physical and/or laboratory examinations, additional testing for the presence (or change) 
of organ involvement is required. Also, patients with systemic immunosuppressive treatment 
or with increased organ involvement should be seen more frequently at the outpatient clinic (at 
least once every 3 months) to evaluate whether treatment is effective and potential side effects 
are tolerated.
1
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Diagnosis
The diagnosis of pSS is based on the American-European consensus group (AECG) classification 
criteria for Sjögren syndrome 43. These criteria include: 1) subjective presence of ocular dry-
ness, 2) subjective presence of oral dryness, 3) objective measures of ocular dryness by Schirm-
er’s test or corneal staining, 4) focus score > 2 in a salivary gland biopsy, 5) salivary scintigraphy 
showing reduced salivary flow (1.5 mL in 15 minutes) and/or diffuse sialectasias and 6) positive 
autoantibodies against SS-A and/or SS-B. SS is diagnosed when 4 out of 6 items are present; 
either salivary gland pathology or the presence of autoantibodies against SS-A/SS-B is manda-
tory. 
The specific questions (criteria 1 and 2) should reveal whether eye and mouth symptoms are 
characteristic for pSS and additional tests should be performed. If pSS is suspected, laboratory 
investigations should be performed (e.g. markers for inflammation, systemic biochemical tests, 
serology and haematology) and the patient should be referred to an ophthalmologist for eval-
uation of ocular dryness. Recently, the American Group of Rheumatology (ACR) has developed 
new diagnostic criteria for pSS since the increasing use of (expensive) biologic agents should 
be based on more objective rather than subjective criteria 92. The newly proposed criteria by 
the ACR differ from the AECG criteria by focussing more on objective measurements. There-
fore, ocular and oral dryness are no longer part of the classification criteria. It remains unclear 
whether the new criteria are more sensitive than the AECG criteria. Based on a comparison 
study in 646 subjects, the AECG criteria had an overall sensitivity in the general population 
of 88% compared to 83% of the ACR criteria. On all test characteristics (sensitivity, specificity 
etc.) the AECG criteria scores better compared to the ACR criteria, however, the results are not 
significantly different  93. In conclusion, there is no clear evidence for increased value of the new 
ACR criteria over the old and familiar AECG criteria from the clinical or biological perspective 
93. Currently, the AECG criteria are still the most frequently used in clinical practice and re-
search protocols. In Table 2, we summarize both sets of classification criteria.
Treatment
Patients with pSS should be managed by a multidisciplinary team including at least a clinical 
immunologist/rheumatologist, ophthalmologist and dentist. Extensive clinical trials concerning 
the treatment of pSS are limited and thus, guidelines are lacking. Nowadays, multiple drugs are 
used in the treatment of pSS which can be divided in local and systemic therapy (Table 3).
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Criteria (#) AECG ACR
1 Ocular symptoms: a positive response to at 
least one of the following questions:
- Have you had daily, persistent, 
troublesome dry eyes for more than 3 
months?
- Do you have a recurrent sensation of 
sand or gravel in the eyes?
- Do you use tear substitutes more than 
3 times a day?
2 Oral symptoms: a positive response to at least 
one of the following questions:
- Have you had a daily feeling of dry 
mouth for more than 3 months?
- Have you had recurrently or 
persistently swollen salivary glands as 
an adult?
- Do you frequently drink liquids to aid 
in swallowing dry food?
3 Objective ocular signs - a positive result for at 
least one of the following two tests:
Keratoconjunctivitis sicca with ocular 
staining score ≥3
- Schirmer’s test, (≤5 mm in 5 minutes)
- Rose Bengal score or other dye (≥4 
according to van Bijsterveld's scoring 
system)
4 Labial salivary gland biopsy exhibiting focal 
lymphocytic sialadenitis with a focus score ≥1 
focus/4 mm2
Labial salivary gland biopsy exhibiting focal 
lymphocytic sialadenitis with a focus score ≥1 
focus/4 mm2
5 Salivary gland involvement: objective evidence 
of salivary gland involvement deÞned by a 
positive result for at least one of the following 
tests:
1. Unstimulated whole salivary ßow 
(≤1.5 ml in 15 min)
2. Parotid sialography showing diffuse 
sialectasias, without obstruction in 
major ducts
3. Salivary scintigraphy showing delayed 
uptake, reduced concentration and/or 
delayed excretion of tracer
6 Autoantibodies: presence in the serum of the 
following autoantibodies:
Autoantibodies: presence in the serum of the 
following autoantibodies:
1. Antibodies to Ro (SSA) and/or La (SSB) 
antigens
1. Antibodies to Ro (SSA) and/or La 
(SSB) antigens
Criteria (#) AECG ACR
1 Ocular symptoms: a positive response to at 
least one of the following questions:
- Have y u had daily, persistent, 
troublesome dry eyes for more than 3 
months?
- Do you have a recurrent sensation of 
sand or gravel in the eyes?
- Do you use tear substitutes more than 
3 times a day?
2 Oral symptoms: a positive response to at least 
one of the following questions:
- Have you had a daily feeling of dry 
mouth for more than 3 months?
- Have you had recurrently or 
persistently swollen salivary glands as 
an adult?
- Do you frequently drink liquids to aid 
in swallowing dry food?
3 Objective ocular signs - a positive result for at 
least one of the following two tests:
Keratoconjunctivitis sicca with ocular 
staining score ≥3
- Schirmer’s test, (≤5 mm in 5 minutes)
- Rose Bengal score or other dye (≥4 
according to van Bijsterveld's scoring 
system)
4 Labial salivary gland biopsy exhibiting focal 
lymphocytic sialadenitis with a focus score ≥1 
focus/4 mm2
Labial salivary gland biopsy exhibiting focal 
lymphocytic sialadenitis with a focus score ≥1 
focus/4 mm2
5 Salivary gland involvement: objective evidence 
of salivary gland involvement deÞned by a 
positive result for at least one of the following 
tests:
1. Unstimulated whole salivary ßow 
(≤1.5 ml in 15 min)
2. Parotid sialography showing diffuse 
sialectasias, without obstruction in 
major ducts
3. Salivary scintigraphy showing delayed 
uptake, reduced concentration and/or 
delayed excretion of tracer
6 Autoantibodies: presence in the serum of the 
following autoantibodies:
Autoantibodies: presence in the serum of the 
following autoantibodies:
1. Antibodies to Ro (SSA) and/or La (SSB) 
antigens
1. Antibodies to Ro (SSA) and/or La 
(SSB) antigens
Table 2 – Comparison of the Revised American-European Consensus Group (AECG) Classification cri-
teria and the American College of Rheumatology (ACR) Classification criteria for Sjögren’s syndrome.
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Drug Usual dose Main 
indications
Main contra-
indications
Main side-
effects
Monitoring 
needed
Systemic
Pilocarpin 97,98 20-30mg/day 
orally
Dryness of oral 
cavity
Untreated 
cardiovascular 
condition, untreated 
asthma
Headache, 
transpiration, 
frequent 
miction
NSAID 124 100-150 
mg/day, orally
General 
symptoms 
(mainly 
arthralgia)
Peptic ulcer, GI-
bleeding, IBD, CHF, 
CVA, liver- or renal 
failure.
GI effects, 
dizziness, rash, 
elevated liver 
enzyme test
Six monthly: 
Blood count, 
systemic liver 
and kidney test. 
Cardiovascular 
risk proÞle
Immunomodu
latory 
Hydroxychlor
oquine 100,125
200-400 
mg/day orally
General 
symptoms 
(sicca, arthralgia 
and pain)
Retinopathy, 
breastfeeding
GI effects, 
rash, 
retinopathy, 
neuromyopath
y
Six monthly: 
blood count 
and muscular 
strength 
Yearly: 
complete eye 
examination by 
ophthalmologis
t
Methotrexate 
102
10-20mg/
week orally or 
intramuscular
InsufÞcient 
effect of HCQ 
on chronic 
complaints
Liver and severe 
renal failure, severe 
respiratory failure, 
alcohol abuse, 
pregnant or 
lactating women
GI effects, 
neutropenia, 
liver and renal 
toxicity, 
interstitial 
pneumonitis, 
alopecia
3 monthly: 
blood count 
with 
differentiation, 
systemic liver 
and kidney test.  
Yearly: 
pulmonary 
function
Glucocorticoid
s 71,126
20-40mg/day 
orally or 
intravenous 
1g/day max. 3 
days
Active systemic 
involvement 
(renal, 
pulmonary, 
neurological, 
muscular)
Active infections 
(viral, fungal), ulcus 
ventriculi / duodeni 
Weight gain, 
hypertension, 
osteoporosis, 
diabetes, 
infection, 
neuropsychiat
ric 
reactions
Next outpatient 
visit: Weight, 
arterial blood 
pressure, 
glycaemia, 
bone density
Rituximab 
36,127
1000mg 
intravenous; 
repeat after 2 
weeks. 
30 minutes in 
prior: 100 mg 
methylprednis
olone
Active systemic 
involvement not 
responsive to 
non-biologic 
immunosuppres
sive drugs
Pregnant or 
lactating women, 
active severe 
infection, severe 
CHF
Infections, 
allergic 
reaction
Next outpatient 
visit: Blood 
count with 
differentiation, 
systemic liver 
and kidney test
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Preventive and local therapy
Alcohol and smoking should be avoided and thorough oral hygiene is essential 94,95. Xeropthal-
mia can be managed with preservative-free teardrops and ocular lubricating ointments. Severe 
refractory dryness of the eyes can be treated with cyclosporin 0.05% 96. Patients with xero-
stomia can manage the dry mouth by doing gustatory stimulation (chewing gum) and moisture 
replacement. 
Systemic therapies
The majority of patients use pilocarpine, a muscarinic receptor agonist, which stimulates re-
sidual salivary gland function 97,98. Systemic treatment is indicated when: 1) general symptoms 
(e.g. arthralgia) cannot be managed with local treatment or adjustment of the patient’s lifestyle 
and 2) in case of organ involvement. Non-steroidal anti-inflammatory drugs (NSAIDS) have 
beneficial effects on general symptoms, like arthralgia. When general symptoms become more 
chronic, hydroxychloroquine (HCQ) is indicated 99,100. It has been reported that patients with 
arthralgia benefit from HCQ 99. A recent study shows, however, that fatigue does not improve 
by HCQ treatment 101. In case of more severe organ involvement, other DMARDS or glucocor-
ticoids should be added. Since methothrexate (MTX) is effective in RA, MTX is also used in the 
treatment of arthritis in pSS patients 102. Glucocorticoid treatment is predominantly indicated 
when (severe) cutaneous, pulmonary, renal, musculoskeletal and/or neurological involvement 
occurs 103. In case of insufficient effect of glucocorticoid therapy, glucocorticoid intolerance due 
to side effects and/or to reduce glucocorticoid dose, adding or switching of a DMARD (myco-
phenolate mofetil, cyclosporine A, azathioprine) should be considered. Therapy resistant pSS 
with proven organ damage is an indication to start biologicals, with the B cell as the most prom-
ising target based on the aetiology of pSS. 
Biological therapies
Rituximab is a monoclonal antibody targeting the CD20 molecule (human B lymphocyte-re-
stricted differentiation antigen) expressed on the surface of most B cells, including pre-B and 
mature B lymphocytes leading to B cell depletion 104. Several studies have demonstrated a fa-
vourable effect of rituximab in pSS. Two studies combining 274 pSS patients reported that the 
1
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severity of glandular, articular, renal, neurological, pulmonary and haematological involvement 
was significantly decreased in approximately 60% of the patients after six months 34,105. As a 
consequence of rituximab treatment, serum BAFF levels are increasing in order to stimulate 
B cell maturation, which can be countered by anti-BAFF treatment (belimumab) to achieve a 
longer B cell depletion and associated longer treatment effect 36. Based on these findings and 
the pathophysiology of pSS, combination therapy with belimumab and rituximab would be (an 
expensive) but promising option 36. The combination of rituximab and belimumab may be effec-
tive since this combination leads to an effective depletion of both the tissue and circulating B 
cells as well as a depletion of one of the stimulators (BAFF) required for B cell differentiation. 
Currently, new potential anti B cell therapies are being evaluated in (pre)clinical trials including 
anti-CD40 (decreases antigen presentation by B cells), anti-BAFF receptor (inhibits the effects 
of BAFF), anti-inducible costimulatory ligand (ICOSL, decreases activation of T-cells) and phos-
phoinositide 3-kinase delta inhibitor (PI3Kδ, inhibition of B cell development and activation) 
106–109.
Prognosis
Patients with pSS should be closely monitored to evaluate the development of systemic mani-
festations and the effects of treatment. Compared to the general population, pSS patients have 
an increased mortality risk. The standardized mortality ratio (ratio of observed deaths in the 
study group to expected deaths in the general population, SMR) of pSS patients is on average 
2.86, showing that pSS has an impact on patients’ survival 110,111. The leading cause of mortali-
ty in pSS is lymphoma with a lymphoma-specific SMR of 7.89, associating lymphoproliferative 
disorders directly with death in pSS 56. However, once lymphoma is diagnosed, the prognosis is 
relatively favourable with a 15-year survival of almost 80% 112. Other causes of death in pSS in-
clude vasculitis, renal failure due to glomerulonephritis and infections after the administration 
of immunosuppressive medication 77,113. Morbidity in pSS is mainly due to extreme fatigue and 
the presence of systemic manifestations and should be evaluated for each patient individually. 
Patients with systemic complications and lymphoma development have an increased mortality 
risk. Therefore, risk factors (clinical and biological) for lymphoma and other organ involvement 
(e.g. pulmonary function, renal function, neurological evaluation) should be assessed frequent-
ly. 
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Conclusion
We summarized the clinical aspects of pSS. Physicians should be aware of pSS in patients pre-
senting with sicca or general symptoms since the systemic manifestations are severe and are 
associated with increased morbidity and mortality. The treatment of pSS is effective and in-
cludes both local and systemic therapy. New therapies were developed, such as biologic treat-
ment, of which the effectiveness in pSS should be evaluated. Further research should also focus 
on revealing new aetiological targets for therapy. 
1
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Abstract
Renal acid-base homeostasis is a complex process, effectuated by bicarbonate reabsorption 
and acid secretion. Impairment of urinary acidification is called renal tubular acidosis (RTA). 
Distal renal tubular acidosis (dRTA) is the most common form of the RTA syndromes. Multiple 
pathophysiologic mechanisms, each associated with various etiologies, can lead to dRTA. The 
most important consequence of dRTA is (recurrent) nephrolithiasis. The diagnosis is based on a 
urinary acidification test. Potassium citrate is the treatment of choice. 
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Introduction
Distal renal tubular acidosis (dRTA) is characterized by an impairment of normal urinary acidifi-
cation process in the distal part of the nephron in the presence of a normal glomerular filtration 
rate. The term “distal” implies that acidification by the distal parts of the nephron (connecting 
tubule and collecting duct) are disturbed in contrast to proximal tubular acidosis, in which the 
reabsorption of bicarbonate by the proximal tubule is impaired. The prevalence and incidence 
of dRTA in the population are not known. dRTA is associated with auto-immune diseases such 
as primary Sjögren syndrome and systemic lupus erythematosus 1–3. Prevalence of dRTA in pri-
mary Sjögren syndrome is estimated to be 5-25% 4–7. Recurrent nephrolithiasis and/or chronic 
metabolic acidosis with a randomly measured high urinary pH suggest the presence of dRTA. 
Of patients with dRTA approximately 5% develops nephrolithiasis (mainly calcium phosphate 
stones), while 56% of dRTA patients has significant nephrocalcinosis 8,9. Vice versa, in 41% of 
the patients with calcium phosphate stones dRTA is the underlying condition 10. The availability 
of an effective treatment for dRTA should lower the threshold for testing suspected patients 
11,12. To confirm the diagnosis dRTA an urinary acidification test is recommended using either 
the well-known ammonium chloride test or a recently proposed combination of furosemide and 
fludrocortisone 13..
The aim of this review is to make physicians aware of a disorder in urinary acidification in pa-
tients presenting with a chronic metabolic acidosis and/or nephrolithiasis, especially in case of 
calcium phosphate stones. Both the physiology of renal acid-base regulation and the clinical 
aspects of dRTA will be reviewed.
Acid-base homeostasis
Our basal metabolic reactions and daily food intake lead to acid excess. Carbon dioxide (CO
2
) 
originating from the oxidation of carbohydrates, fats, amino acids and proteins is by far the larg-
est potential source of acid (15.000 mmol/day). CO
2
 is a volatile acid that is removed by pulmo-
nary ventilation, preventing CO
2
 to react with H
2
O to form protons 14. 
Human metabolism also produces nonvolatile acids (e.g. phosphate, sulfate) and nonvolatile 
bases (e.g. bicarbonate), that cannot be excreted by the lungs. Together with acid from our diet 
2
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and intestinal base loss, the body is exposed to approximately 70-100 mmol of nonvolatile acids 
per day 15. The role of the kidney is to excrete this acid excess as well as to monitor arterial pH to 
maintain a normal acid-base balance. 
The kidney can maintain the arterial pH between 7.35-7.45 by preventing loss of filtered bi-
carbonate (4320 mmol/day HCO
3
-) and by net secretion of H+ (70-100 mmol/day). The kidney 
cannot simply secrete this amount of acid, because this would require urinary pH to decrease 
to approximately 1.3. Due to the energetic maximum of H+-ATPase, urinary pH can be maxi-
mally decreased to 4.2, which is not sufficient to clear the acid excess. In order to get rid of the 
acid excess, secreted protons will 1) be titrated by filtered bicarbonate resulting in bicarbonate 
reabsorption, 2) excreted by titratable acids, 3) titrated and excreted by ammonium and 4) ex-
cretion of free protons. 
Proton secretion
The secretion of protons over the apical membrane is for 90% achieved by the so-called Na+-H+ 
exchanger isoform 3 (NHE3), that exchanges sodium for protons over the apical membrane. 
This transporter is present in the proximal tubule, thick ascending limb and distal convoluted 
tubule and is dependent on the basolateral Na+/K+ pump activity. A second mechanism to se-
crete protons is carried out by the vacuolar H+-ATPase located in the distal tubule (10%). The 
vacuolar H+-ATPase is limited to create a chemical gradient of 103 of H+ over the apical mem-
brane. This limitation is caused by a lack of ATP to keep the transporter functioning at a higher 
gradient. The maximally reached gradient over the apical membrane is reflected by a decrease 
of urinary pH from 7.5 to 4.5 16.
Titration of bicarbonate
The kidney filters about 4320 mmol/day of bicarbonate, of which 99.9% is reabsorbed. The 
proximal convoluted tubule is responsible for the reabsorption of 80-85% of filtered HCO
3
- 17. 
Remaining HCO
3
- is reabsorbed further downstream in the nephron. All intraluminal bicarbon-
ate can be protonated and subsequently reabsorbed. This means that the complete reabsorp-
tion of filtered HCO
3
- requires 4320 mmol/day of secreted protons, which is considerably more 
than the 70-100 mmol/day of proton secretion required for neutralizing of nonvolatile acids. 
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However, the process of HCO
3
- reabsorption is not accompanied by net H+ excretion. 
Titratable acid excretion
Secreted protons will also interact with buffers other than HCO
3
-. These buffers originate from 
metabolic reactions. The most significant buffers are phosphate (pKa = 6.8), urate (pKa = 5.8) 
and creatinine (pKa = 5.0). With a lower urinary pH a higher percentage of the buffer will be 
protonated, regardless of the pKa of each buffer. 
In the proximal convoluted tubule are the so-called sodium-phosphate cotransporters (NaPi) 
located, that are responsible for phosphate reabsorption. Early studies already showed that 
these transporters are down-regulated in periods of metabolic acidosis 18. Recent studies indi-
cate that these transporters are directly inhibited by protons resulting in hyperphosphaturia 19. 
Because of its relative high pKa and the pH-dependent reabsorption of phosphate, phosphate 
is an important buffer. The amount of buffer that is ultimately excreted in the urine is largely 
dependent on the GFR and the plasma concentration of the buffer. For example, an average 
individual with a normal plasma phosphate concentration and normal GFR will excrete approx-
imately 30 mmol/day of phosphate  
Regulation of ammonia secretion 
Ammonia (NH
3
) is extremely important as urinary buffer, because of its high pKa of 9, which 
means that almost all the ammonia will be protonated to ammonium (NH
4
+). NH
4
+ is in equi-
librium with NH
3
 and H+ in both the intra- and extracellular space of the nephron. Ammonia is 
produced in every segment of the nephron, but predominantly  in the proximal tubule by the 
metabolism of mitochondrial glutamine (Figure 1) 20. Produced ammonium is secreted by the 
proximal tubule by NHE3 mediated Na+/H+ exchange and Ba2+-sensitive K+ channels (ROMK) 
21,22. Additionally, NH
3
 is transported over the apical membrane by still undefined channels. 
Secreted ammonium will be reabsorbed in the thick ascending limb of Henle’s loop either via the 
K+/H+(NH
4
+) exchanger, or by the Ba2+-sensitive K+ channels (ROMK) or by the Na+-K+-(2Cl-) 
cotransporter (NKCC2) 23. Electroneutral K+/NH
4
+ exchange and diffusive NH
3
 transport across 
the apical plasma membrane by undefined channels take also place, but are less important. Cy-
tosolic NH
4
+ will mainly exit the tubulus cell via the basolateral NHE4 transporter 24. A second 
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mechanism of basolateral NH
4
+ exit may involve dissociation of NH
4
+ to NH
3
 and H+. Transport 
of NH
3
 over the basolateral membrane in the thick ascending limb is presumed to be via dif-
fusion as evidence for a gas transporter for NH
3
 in the thick ascending limb is lacking. How-
ever, the concept that gasses (NH
3
 and CO
2
) and water diffuse over the membranes has been 
questioned over the last years. Instead of diffusion, gasses and water are carried over the mem-
brane by transporters, such as aquaporins and the recently discovered rhesus glycoproteins 25. 
The thick ascending limb buffers intracellular produced protons via basolateral bicar-
bonate transport. This is mediated by the sodium-bicarbonate cotransporter (NBCn1) 
leading to the formation of H
2
CO
3
 26. H
2
CO
3
 will be dissociated into H
2
O and CO
2
, after 
which CO
2
 will be transported over the basolateral membrane into the peritubular lumen.
Ammonium in the peritubular space will be transported in the collecting duct via Na+-K+-AT-
Pase and Rhesus glycoproteins Rhbg and Rhcg 25,27. Intracellular ammonia will be secreted 
over the apical membrane via the Rhcg glycoprotein and becomes available to buffer secreted 
protons 25. Formed ammonium in the collecting tubular lumen is trapped and will be excreted. 
The complex system of ammonia transport through the nephron provides the collecting tubule 
a chemical and concentration gradient over the apical membrane. By altering these gradients, 
ammonia secretion over the apical membrane in the collecting tubule can be regulated to buffer 
the secreted protons. 
Proximal acidification 
As described before, reabsorption of bicarbonate is mainly achieved by proximal convoluted 
tubule cells (Figure 2). Secreted H+ binds to HCO
3
- to form carbonic acid (H
2
CO
3
) in the tubu-
lar lumen. Subsequently, formed H
2
CO
3
 will become H
2
O and CO
2
, a reaction catalyzed by the 
membrane-bound enzyme carbonic anhydrase type 4. Luminal CO
2
 and H
2
O are transported 
over the apical membrane via aquaporin 1 (AQP1) in the proximal tubule, after which they hy-
drate into H
2
CO
3
. This reaction is catalyzed by intracellular carbonic anhydrase type 2 (CAII). 
Intracellular H
2
CO
3
 ionizes to H+ and HCO
3
-, after which HCO
3
- will be transported over the 
basolateral membrane via the Na+-HCO
3
- cotransporter (NBCe-1) 28. Protons remain in the cy-
toplasmatic compartment to be secreted again in the tubular lumen. At the end, this process 
results in the reabsorption of one molecule HCO
3
- and zero net secretion of one molecule of H+.
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Figure 2 – The process of bicarbonate reabsorption in the proximal tubule cell
Filtered bicarbonate is catalyzed by carbonic anhydrase type 4 into carbon dioxide and hydroxide. Carbon dioxide 
is transported over the apical membrane via aquaporin 1 (AQP1) in the proximal tubule, after which it hydrates into 
H2CO3. This reaction is catalyzed by intracellular carbonic anhydrase type 2. Intracellular formed bicarbonate will 
leave the cell via the NBCe-1 transporter localized on the basolateral membrane. 
Abbreviations: PCT, proximal convulated tubule cell; CA, carbonic anhydrase; NHE-3, Na+-H+ exchanger isoform 3; 
NBCe-1, Na+-HCO3- cotransporter,
Distal acidification 
The α-intercalated and principal cells, located in the collecting tubule, are responsible for the 
secretion of protons (Figure 3). The principal cell’s main function is to reabsorb sodium via the 
epithelium Na+ channel (ENaC) located in the apical membrane 29. This causes an electronega-
tive tubular lumen, favoring the secretion of potassium or protons. Proton secretion is achieved 
by the vacuolar H+-ATPase, stored in vacuoles in the cytoplasm of α-intercalated cells. The 
expression of this pump is largely dependent on the electrical gradient over the luminal mem-
brane. The electronegative luminal potential, driven by ENaC activity,  results in expression of 
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Figure 3 – The process of proton secretion in the collecting duct
The principal cell reabsorbs intraluminal sodium creating an electronegative gradient. The alpha-intercalated cells 
contain vacuoles which stores H+-ATPases. These proton pumps are built in the apical membrane for proton secre-
tion. The secretion of protons is enhanced by sodium reabsorption and an electrical gradient. 
Abbreviations: PC, principal cell; αIC, alpha intercalated cell; CA, carbonic anhydrase; ROMK, renal outer medullary 
potassium channel; ENaC, epithelium Na+ channel; AE-1, chloride-bicarbonate cotransporter
H+-ATPase on the apical membrane of the α-intercalated cells and excretion of protons into 
the lumen 27. The protons are generated by intracellular activity of the CAII enzyme, which 
also forms HCO
3
- ions. HCO
3
- will be exchanged with Cl- over the basolateral membrane via the 
chloride-bicarbonate cotransporter (AE-1) 27. Still another ATPase expressed in the apical mem-
brane of the α-intercalated cell, is the H+/K+ exchanger. This exchanger contributes to proton 
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secretion, but is less important than the vacuolar H+-ATPase and is considered to be more rele-
vant for potassium reabsorption. 
Distal renal tubular acidosis 
The characteristic features of distal renal tubular acidosis (dRTA) are the presence of systemic 
acidosis together with the inability to acidify the urine to a pH < 5.3 dRTA is associated with 
many diseases each with their own pathophysiology. To provide a clear overview of the causes 
of dRTA, we divided dRTA in to four groups based on their pathophysiologic defect: 1) voltage 
defect, 2) H+ secretion defect, 3) H+ gradient defect and 4) ammonium generation defect (Table).
Voltage defect
As outlined before an electronegative luminal potential in the collecting tubule contributes to 
proton secretion. The ENaC is responsible for this driving force by reabsorbing Na+. ENaC’s ac-
tivity is predominantly regulated by aldosterone. Apart from regulation of ENaC activity aldo-
sterone can enhance distal urinary acidification by increasing the activity of H+-ATPase in the 
cortical collecting tubule 29,30.
Both genetic and acquired forms of decreased ENaC activity exist. Genetic causes are related 
to mutations in genes encoding for the alpha, beta or gamma subunit of the channel (respec-
tively SCNN1A, SCNN1B, SCNN1G genes), resulting in autosomal recessive pseudohypoaldoste-
ronism type 1. An autosomal dominant form in which the genetic defect (NR3C2) affects the 
mineralocorticoid receptor is also known 31. Acquired forms of decreased ENaC activity are 
more common. They are common due to hypoaldosteronism. The most common cause of hy-
poaldosteronism is hyporeninemia as can occur in diabetes mellitus, renal insufficiency or use 
of nonsteroidal anti-inflammatory drugs or calcineurin inhibitors. Furthermore aldosterone is 
diminished in Addison’s disease. Additionally, medication can directly or indirectly decrease 
ENaC activity (e.g. amiloride, cyclosporine, tacrolimus, lithium, ACE-inhibitors, angiotensin II 
receptor blocker, aldosterone receptor blockers and heparin) 31.
H+ secretion defect
Alpha-intercalated cells are responsible for both generation and secretion of protons. The in-
tracellular enzyme CAII catalyzes the reaction leading to the formation of protons and bicar-
bonate ions. The main proton transporter is the vacuolar H+-ATPase, built in the apical mem-
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brane. The bicarbonate ion is transported over the basolateral membrane by the AE1. A defect 
in one of those subparts of the H+ secreting machinery can lead to dRTA. 
Primary causes for a defect in one of the compartments are due to mutations in genes encoding 
subunits of the vacuolar H+-ATPase (ATP6V1B1 and ATPV6V0A4), resulting in impaired trans-
porter function. These mutations lead to autosomal recessive forms of dRTA that can coexist 
with and without deafness. Also an autosomal dominant form of dRTA is known, caused by a 
mutation of a gene coding for the AE1 (SLC4A1), leading to a decreased number of this trans-
porter in the basolateral membrane. Carbonic anhydrase enzyme type 2 deficiency by genetic 
mutations leads to both proximal and distal RTA 32. Medullary sponge kidney is also a primary 
cause of dRTA, related to the malformation of the distal tubules. The presence of dRTA in these 
patients depends on the number of nephrons affected 33.
Acquired impaired transporter function of the H+ secreting machinery is often associated with 
auto-immune diseases like Sjögren syndrome and systemic lupus erythematosus (SLE). In pa-
tients with primary Sjögren syndrome inhibitory autoantibodies against the CAII enzyme have 
been reported 34. Also certain medications, such as topiramate and acetazolamide, can inhibit 
the function of the CAII enzyme 35. 
H+ gradient defect
Proton secretion is dependent on the H+ gradient over the apical membrane, which is achieved 
by vacuolar H+-ATPase. Notwithstanding an appropriately working vacuolar H+-ATPase, creat-
ing of such gradient is not always successful. This is the case in leaky membrane, sometimes 
seen in patients using amphoterocin B 36,37. In experimental models, amphotericin B increases 
the permeability for protons of the apical membrane in the collecting duct, causing back diffu-
sion of the secreted protons 38,39. 
Ammonium secretion defects (hyperkalemia) 
Ammonium plays a major role in renal urinary acidification. In case of low availability of am-
monium in urine, urinary acid excretion is impaired to a certain pH. The most important cause 
of decreased urinary ammonium is hyperkalemia 40. Hyperkalemia reduces the expression of 
ammoniagenic enzymes and acid transport proteins 41. Additionally, hyperkalemia decreases 
the secretion of ammonia in the loop of Henle and the collecting duct. This probably is due to 
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competition between NH
4
+ and potassium. NH
4
+ and potassium use the same binding spot on 
the transporters in the thick ascending limb (respectively NKCC2 and Na+-K+-ATPase) 42. Hy-
perkalemia will also drive protons from intracellular to extracellular, leading to a decreased con-
centration of protons in the distal tubule cells. 
Clinical presentation
The most common symptom of dRTA is nephrolithiasis and metabolic acidosis. Fatigue is a fre-
quent complaint, possibly related to the metabolic acidosis-induced hyperventilation. Patients 
with chronic metabolic acidosis are prone to develop osteoporosis. Metabolic acidosis affects 
bone by exchanging protons for sodium, potassium, calcium, carbonate and phosphate 43. The 
continuous sequestration of protons in bone stimulates both osteoclast development and os-
teoclast activity. As a consequence bone resorption increases, enhancing release from the bone 
surface of calcium and mineral buffers like bicarbonate and phosphate 43,44. Eventually, this 
mechanism leads to net bone loss and hypercalciuria.
Metabolic acidosis also leads to enhanced proximal tubular reabsorption of citrate resulting in 
hypocitraturia. Alkaline urine in combination with hypocitraturia and hyperphosphaturia pro-
motes calcium phosphate precipitation leading to nephrocalcinosis and/or kidney stones 45.
Additionally, patients with dRTA often develop abnormalities in the potassium balance. In gen-
eral, metabolic acidosis will lead to hyperkalemia as a result of the exchange of protons for intra-
cellular potassium. However, patients with dRTA due to a proton secretion defect tend to waste 
potassium in urine in order to maintain electroneutrality over the apical membrane. Despite 
potassium wasting, these patients usually have normal levels of serum potassium, because of 
potassium movement from intracellular to extracellular. Nevertheless, case-reports have been 
described of patients with dRTA who present to the emergency department with hypokalemic 
paralysis, including respiratory arrest 1,46. 
Incomplete dRTA
Of the RTA syndromes, also an incomplete form of dRTA is known, including patients with 
nephrocalcinosis or urolithiasis but without metabolic acidosis. Patients with incomplete dRTA 
cannot acidify their urine, but a higher amount of NH
4
+ excretion compensates for the acid se-
cretion defect. Donnelly et al. hypothesized that this increased NH
4
+ excretion originates from 
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an increased production and secretion of ammonium in the proximal convoluted tubule. Addi-
tionally, hypocitraturia in these patients is often present. Diagnosis and treatment is the same 
as for complete dRTA 47.
Association of dRTA with autoimmune diseases
It is suggested that dRTA is more prevalent in autoimmune diseases. Shearn et al. reported in 
1965 the first case of distal renal tubular acidosis revealing Sjögren syndrome 48. Both primary 
and secondary Sjögren syndrome is associated with dRTA 4,49–51. Other autoimmune diseases 
such as SLE 52, primary biliary cirrhosis (PBC) 53, autoimmune hepatitis (AIH) 54 and autoimmune 
thyroiditis (AIT) 51 are less common associated with dRTA. The prevalence of dRTA in Sjögren 
syndrome is currently estimated to be 25% 4. The clinical presentation of dRTA in patients with 
an autoimmune disease is similar to those patients without a systemic disease. 
The pathophysiological mechanism of dRTA in relation to autoimmunity remains unclear. Sever-
al reports suggest that autoantibodies against the CAII enzyme 34,55 or the acid-base transport-
ers are involved in the pathogenesis of dRTA in autoimmune disease 56. Recently, Espinosa et al. 
reported that anti-Ro52 autoantibodies from patients with Sjögren syndrome inhibit Ro52 E3 
ligase activity 57. In-vitro inhibition of the ubiquitination process may increase the transcription 
of pro-inflammatory genes leading to local inflammation and tissue damage 57. Interstitial in-
flammation is often found in renal biopsies. 
It is unknown whether treatment with corticosteroids in autoimmune disease has a positive 
effect on dRTA. We advise to treat dRTA in autoimmune diseases with potassium citrate. Po-
tassium citrate is an effective treatment for both the symptoms and complications of dRTA, by 
restoring acid-base balance (see below). Studies about prognosis of dRTA in autoimmune dis-
eases are lacking.
Diagnosis
Urinary acidification was assessed by using the oral ammonium chloride loading test (NH
4
Cl 
test). The complete test takes eight hours and does not require blood testing.  The test can be 
unpleasant, because it can induce gastric irritation, nausea, and vomiting. Thus, there was room 
for the development of a quicker and more patient-friendly urinary acidification test. Walsh et 
al. described in 2007 a urinary acidification test using simultaneous furosemide (40 mg) and 
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fludrocortisone (1 mg) administration 13. Simultaneous administration of furosemide and flud-
rocortisone stimulates the kidney to secrete H+-ions. Furosemide inhibits the NKCC2 co-trans-
porter, resulting in a higher Na+ delivery in the collecting tubule. Fludrocortisone binds and ac-
tivates the mineralocorticoid receptor in the cytoplasm leading to an increased ENaC activity, 
thereby enhancing sodium reabsorption and potassium secretion. Additionally, fludrocortisone 
stimulates the expression of vacuolar H+-ATPase in the apical membrane. Increased sodium 
reabsorption leads to an electronegative luminal potential, which is the driving force for the 
secretion of protons by the vacuolar H+-ATPase in the distal tubule 13.
Walsh et al. compared this new test to the NH
4
Cl loading test in 10 healthy controls. Every con-
trol was capable to acidify their urine to a pH < 5.3. The minimum pH value was 4.92 ± 0.10 after 
furosemide and fludrocortisone administration. 
Both tests had the same result of (impaired) urinary acidification in dRTA patients. All patients 
failed to acidify their urine to a pH < 5.3. The lowest measured pH was 6.59 ± 0.13 after fu-
rosemide/fludrocortisones administration 13. The furosemide/fludrocortisone test was better 
tolerated and lasts shorter it may prefer over the NH
4
Cl test.
Treatment
The main goal of any treatment for dRTA is to reverse the acidosis, which reduces calciuria and 
simultaneously increases citrate excretion. This leads to a lower risk of nephrolithiasis and os-
teoporosis. Currently, potassium citrate (1 to 2 mEq/kg/day) is the treatment of choice for the 
management of patients with dRTA. With potassium citrate, not only a bicarbonate donor is 
provided to treat acidosis, but potassium wasting is compensated simultaneously. Potassium 
citrate treatment in dRTA patients seems to have positive effects on bone mineral density and 
bone cell function 11. Additionally, a recent randomized controlled trial showed that potassium 
citrate increases bone density and reduced fracture risk in healthy elderly without RTA 12. 
Conclusions
In this review we discussed the physiology of acid-base homeostasis and translated this mech-
anism to the RTA syndromes. The pathophysiology is divided in four categories each associated 
with different etiologies. Physicians should test for dRTA in patients with (recurrent) calcium 
phosphate stones and/or a chronic metabolic acidosis. The diagnosis of dRTA is made by using a 
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urinary acidification test, in which the patient is unable to acidify the urine to pH < 5.3. Treat-
ment of dRTA is based on restoring the acid-base balance, which can be achieved with potassi-
um citrate. 
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Abstract
Objectives Our objectives were 1) to analyze the prevalence of distal renal tubular acidosis 
(dRTA) in primary Sjögren syndrome (pSS) and 2) to compare a novel urinary acidification test 
with furosemide and fludrocortisone (FF) with the gold standard ammonium chloride (AMCL) 
to detect dRTA
Methods Urinary acidification was assessed in 57 pSS patients using AMCL and FF. A urinary 
acidification defect was defined as inability to reach urinary pH < 5.3 after AMCL.  
Results The prevalence of complete dRTA (urinary acidification defect with acidosis) was 5% 
(3 out of 57). All three patients had positive SSA/Ro and SSB/La auto-antibodies and impaired 
kidney function. The prevalence of incomplete dRTA (urinary acidification defect without aci-
dosis) was 25% (14 out of 57). Compared to patients without dRTA, patients with incomplete 
dRTA had significantly lower venous pH and serum bicarbonate, and higher urinary pH. SSB/La 
antibodies were more prevalent in the dRTA groups (p < 0.05). Compared to AMCL, the positive 
and negative predictive values of FF were 46 and 82%, respectively. Vomiting occurred more 
often during the urinary acidification test with AMCL than with FF (9 vs. 0, p < 0.05). 
Conclusions Incomplete dRTA is common in pSS and causes mild acidemia and higher urinary 
pH which may contribute to bone demineralization and kidney stone formation. FF cannot re-
place AMCL to test urinary acidification in pSS, but may be considered as screening tool, given 
its reasonable negative predictive value and better tolerability.
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Introduction
Distal renal tubular acidosis (dRTA) is a well-known complication of primary Sjögren syndrome 
(pSS) 1. dRTA is classified as complete or incomplete dRTA 1. Complete dRTA is defined as a 
non-anion gap metabolic acidosis with a urinary pH > 5.3. Patients with incomplete dRTA main-
tain a serum bicarbonate within the normal range, but are unable to acidify their urine after 
an acid load 2. dRTA indicates a failure of the intercalated cells in the kidney collecting duct to 
secrete hydrogen ions 3,4. If the secretion of protons is severely impaired, the secretion of other 
cations, including potassium, is increased to maintain electroneutrality. This explains why com-
plete dRTA is often accompanied by hypokalemia due to renal potassium loss, which may even 
result in hypokalemic paralysis 5–9. Other, more long-term complications of dRTA include osteo-
malacia 10 and kidney stones 11. Therefore, the detection of dRTA is clinically relevant because 
treatment with potassium citrate may prevent these complications 12.
In addition to dRTA, other renal manifestations of pSS may include tubulointerstitial nephri-
tis, proximal RTA and nephrogenic diabetes insipidus 13,14. Proximal RTA is characterized by 
impaired reabsorption of bicarbonate rather than a failure to secrete protons. Proximal RTA 
can be differentiated from dRTA by analyzing if other functions of the proximal tubule are per-
turbed (presence of hypophosphatemia, hypouricemia, glucosuria, tubular proteinuria) or by 
performing a bicarbonate infusion test 15. 
Most of the literature on dRTA in pSS concerns case reports or small case series and therefore 
the true prevalence of dRTA in pSS remains unclear 7,9. The prevalence of pSS in patients with 
new onset dRTA is reported to be 5% 16. Although Bossini et al. analyzed complete and incom-
plete dRTA more systematically in 60 patients with pSS, the AMCL test was only performed in 
12 patients 13. Recently, Walsh et al. proposed an alternative urinary acidification test using the 
single administration of furosemide and fludrocortisone (FF) 17. The combination of furosemide 
and fludrocortisone maximally stimulates urinary acidification because of an increased distal 
delivery of sodium to the collecting duct by furosemide, and a direct stimulation of hydrogen 
secretion by fludrocortisone 17. In this study, FF was shown to be as effective as AMCL to test 
urinary acidification, and was also quicker and better tolerated 17. 
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In the present study we determined the prevalence of both complete and incomplete dRTA us-
ing the AMCL test. Furthermore, we compared the diagnostic performance of the urinary acid-
ification test with FF to the urinary acidification test with AMCL. To do so, we performed both 
the AMCL and FF urinary acidification tests in a large cohort of patients with pSS.
Methods
Study cohort
The study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
(MEC-2013-075). pSS was defined according to the Revised American-European classification 
criteria 18. Additional inclusion criteria for this study included age >18 years, no other under-
lying auto-immune disease and estimated glomerular filtration rate >30 ml/min. Patients with 
pSS were recruited from our outpatient clinic and through the advertisement of this study on 
the website of the Dutch Sjögren patient society (Figure 1). Anti-nuclear antibodies (ANA), 
SSA/Ro52, SSA/Ro60, SSB/La auto-antibodies, and rheumatoid factor were measured in all pa-
tients using previously reported methods 19. The results of salivary gland biopsy were retrieved 
when available. Finally, the EULAR SS Disease Activity Index (ESSDAI) was calculated for all of 
the patients. 
Urinary acidification tests
All subjects underwent both urinary acidification tests using AMCL and FF on separate days 
with a minimum of one week in between the tests. Patients were allowed to continue their med-
ication except for medication interfering with the urinary acidification tests (mineralocorticoid 
receptor blockers, loop diuretics, fludrocortisone). Patients were instructed to fast prior to the 
AMCL test to prevent vomiting; fasting was not necessary prior to the FF test. At baseline, se-
rum and urine were collected followed by the administration of the test medication. AMCL was 
given at a dose of 1 ml/kg body weight accompanied by water and ingested over a period of 
30 minutes to prevent gastric irritation. The FF test included a single oral administration of 40 
mg furosemide and 1 mg fludrocortisone, as described previously 17. In both tests, hourly urine 
samples were collected for six hours to measure urinary pH. Urinary pH was measured imme-
diately by one of the investigators (T.B.) using an electrode pH meter (Hanna HI 991001, Hanna 
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Instruments BV, IJsselstein, The Netherlands). During both tests, patients were monitored for 
nausea and vomiting.
Distal renal tubular acidosis
Complete dRTA was defined as serum bicarbonate < 21 mmol/L, normal anion gap, positive 
urine anion gap, impaired urinary acidification, and the absence of any other known causes for 
dRTA (e.g., medication, hypercalciuria) 1. Incomplete dRTA was defined as an abnormal AMCL 
test accompanied by a serum bicarbonate in the normal range 1. In both the AMCL and the FF 
tests, a urinary acidification defect was defined as the failure to achieve a urinary pH < 5.3 with-
in four hours after intake of the study drugs 17. 
Statistics
All results are expressed as means with standard deviations. Sensitivity, specificity, positive and 
negative predictive values were calculated by comparing the FF test results with the AMCL test 
results, considering an abnormal response to the AMCL test as definition of disease. Compari-
sons of continuous variables between the three groups (no dRTA, incomplete dRTA, complete 
dRTA) were performed using one-way analysis of variance (ANOVA) with the least significant 
difference post-hoc test. Categorical data (presence or absence of auto-antibodies) were an-
alyzed using the Fisher’s Exact test. A p-value < 0.05 was considered significant. All analyses 
were performed in SPSS (version 21, IBM). 
Results
Study cohort and baseline characteristics
The study cohort included 57 patients with pSS (Figure 1). Although 62 patients were invited 
to participate in the study, 5 patients were excluded, because they were unable to complete 
both urinary acidification tests, due to repeated vomiting or because of withdrawal of consent. 
The baseline characteristics of the study cohort are shown in Table 1. Of the 30 patients with a 
retrievable salivary gland biopsy, the mean focus score was 3.1 ± 2.5. In addition to medication 
for pSS, other commonly used drugs in this cohort were renin-angiotensin inhibitors (9 patients) 
and non-steroidal anti-inflammatory drugs (7 patients). 
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Figure 1 – Study cohort
Abbreviations: AMCL, ammonium chloride; pSS, primary Sjögren syndrome
Prevalence of dRTA
Seventeen out of fifty-seven patients were unable to acidify their urine to a pH < 5.3 after AMCL 
(Figure 2A-B). None of these patients used non-steroidal anti-inflammatory drugs, which can 
also cause dRTA 20. Among these 17 patients three patients (Table 1) had a baseline serum bicar-
bonate < 21 mmol/L (16.9 ± 0.58 mmol/L). They were diagnosed as complete dRTA secondary to 
pSS, because they also had a normal serum anion gap (10.3 ± 0.5 mEq/L), a positive urine anion 
gap (+33 ± 9 mEq/L), and no other explanations for dRTA, including medication or hypercalci-
uria. They also showed no signs of proximal renal tubular acidosis, as indicated by the absence 
of hypophosphatemia, hypouricemia, and glucosuria. Although all three patients had prior epi-
sodes of hypokalemia, they were normokalemic at baseline in this study (Table 1);
two patients were receiving potassium supplementation. The remaining 14 patients were di-
agnosed as incomplete dRTA, because they had normal baseline serum bicarbonate, but were
unable to acidify their urine to pH < 5.3. In summary, the prevalence of complete dRTA was 5% 
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(3 out of 57) and the prevalence of incomplete dRTA was 25% (14 out of 57). 
Table 1 – Characteristics of the study cohort
Abbreviations:  EULAR, European League Against Rheumatism; SS, Sjögren’s syndrome
* Salivary gland biopsies were performed in 36/57 patients, but a focus score could be retrieved for only 30 patients; 
Rheumatoid factor was measured in 46/57 patients.
†Other immunosuppressive therapy consisted of azathioprine, colchicine or methotrexate.
¶ Defined as a urine calcium to creatinine ratio > 0.6
The FF test is less sensitive but better tolerated
In order to compare the results of the AMCL test to the novel FF test, we performed both tests 
in the same cohort of patients. Twenty-four patients were unable to acidify their urine to a pH
< 5.3 with the FF test (Figure 2C-D). A comparison between the AMCL and FF tests showed not
only that more patients were unable to acidify their urine to a pH < 5.3 (24 vs. 17 patients), but 
also that six patients did acidify their urine with FF but not with AMCL (Table 2). Considering 
the AMCL test as gold standard, the sensitivity and specificity of the FF test were 65% and 68%
Category Variable Study cohort (N = 57)
Demographics Age, years 57 ± 11
Female gender, n (%) 49 (86)
Antibodies Anti-nuclear antibodies, n (%) 43 (75)
SSA/Ro52, n (%) 43 (75)
SSA/Ro60, n (%) 42 (74)
SSB/La, n (%) 32 (56)
Rheumatoid factor, n (%)* 21/46 (46)
Other tests Positive salivary gland biopsy, n (%)* 25/30 (83)
EULAR SS Disease Activity Index 2.7 ± 2.0
pSS medication Hydroxychloroquine, n (%) 34 (60)
Glucocorticoids, n (%) 4 (7)
Other immunosuppressive drugs, n (%)† 3 (5)
Laboratory values Serum potassium < 3.5 mmol/l, n (%) 0 (0)
Serum bicarbonate < 21 mmol/l, n (%) 3 (5)
Estimated GFR < 60 ml/min, n (%) 9 (16)
Hypercalciuria, n (%)¶ 3 (5)
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Figure 2 – Results urinary acidification test with ammonium chloride or furosemide and fludrocortisone
The four panels (A-D) show the results of the urinary acidification tests with ammonium chloride (A-B) and furose-
mide and fludrocortisone (C-D). The left panels (A and C) show patients who were able to acidify their urine to pH 
< 5.3 during the test. The right panels (B and D) show the patients who were unable to acidify their urine to pH < 
5.3 during the test.
and the positive and negative predictive values were 46% and 82%. Comparison of the side-ef-
fects during both tests showed that vomiting was significantly more common in patients under-
going the AMCL test than in patients undergoing the FF test (9 vs. 0, p < 0.05). The three pa-
tients diagnosed with complete dRTA also failed to reach a urine pH < 5.3 with the FF test. None 
of the patient characteristics reported in Table 1 were different in the six patients with a false
negative FF test (p > 0.05 for all). The six patients used the following drugs: hydroxychloroquine
Table 2 – Comparison of both urinary acidification in patients with primary Sjögren syndrome 
Abbreviations:  FF, furosemide and fludrocortisone; AMCL, ammonium chloride
            Chapter 3
AMCL UpH ≥ 5.3 AMCL UpH < 5.3 Total
FF UpH ≥ 5.3 11 13 24
FF UpH < 5.3 6 27 33
Total 17 40 57
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(n = 4), renin-angiotensin inhibitors (n = 1), and non-steroidal anti-inflammatory drugs (n = 1); 
none of these patients used immunosuppressive drugs.  
Correlation of dRTA with disease parameters
We also analyzed whether acid-base related parameters and kidney function differed between 
patients without dRTA, incomplete dRTA, and complete dRTA (Figure 3). Patients with incom-
plete dRTA had significantly lower values of serum bicarbonate and venous pH and higher val-
ues of urinary pH than patients without dRTA (Figure 3). The three patients with complete dRTA 
had the lowest venous pH, lowest serum bicarbonate, and lowest urinary pH, although the
Figure 3 – Comparison of acid-base related parameters and kidney function
The four panels show the distribution of serum bicarbonate (A), serum creatinine (B), venous pH (C), and urine pH 
(D) under baseline conditions in the three groups. The three groups are classified as ‘no dRTA’ (n = 40), ‘incomplete 
dRTA’ (n = 14), and ‘complete dRTA’ (n = 3). Abbreviations: dRTA, distal renal tubular acidosis; NS, not significant. 
3
Prevalence of distal renal tubular acidosis in primary Sjögren syndrome       

    68
latter was not different from the patients with incomplete dRTA. The patients with complete 
dRTA also had a higher serum creatinine than the two other groups. None of these patients used 
non-steroidal anti-inflammatory drugs. When we analyzed the auto-antibody prevalence in the 
three groups, SS-B/La auto-antibodies were more prevalent in patients with incomplete dRTA 
(79%) and complete dRTA (100%) than in patients without dRTA (45%) (Figure 4). These preva-
lences showed a statistically significant difference only between the patients without dRTA and 
those with incomplete dRTA, probably due to the low number of patients with complete dRTA. 
Figure 4 – Comparison of auto-antibodies
The prevalence of a positive auto-antibody test for SSA/Ro52, SSA/Ro60, or SSB/La is shown for the three groups 
(no dRTA, incomplete dRTA, complete dRTA). Abbreviations: dRTA, distal renal tubular acidosis; N.S., not significant. 
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Finally, we analysed whether the ESSDAI or disease duration were different in patients with 
dRTA (complete and incomplete combined) compared to patients without dRTA. The ESSDAI 
was 3.0 ± 1.9 in dRTA vs. 2.4 ± 1.9 in controls and the disease duration was 13.0 ± 5.0 years in 
dRTA vs. 11.4 ± 8.0 years in controls (p > 0.05 for both).  
Discussion
Our objective was to analyze the prevalence of dRTA in pSS and to compare the diagnostic per-
formance of FF with AMCL in assessing urinary acidification. The prevalence of complete dRTA 
was 5% and that of incomplete dRTA 25%. The prevalence of complete dRTA in this study was 
the same as in the cohort of 60 patients with pSS reported by Bossini et al. 13. All three patients 
with complete dRTA also had reduced kidney function. This may be due to tubulointerstitial 
nephritis which is a common renal manifestation of pSS, although this was not confirmed with 
a kidney biopsy. 
The prevalence of incomplete dRTA in our study was much higher than in the cohort reported 
by Bossini et al. (25% vs. 0%), although they performed the AMCL test in only 12 patients 13. 
Although patients with incomplete dRTA by definition do not have metabolic acidosis, the pa-
tients in our cohort did have mild acidemia and a higher urinary pH at baseline. This is a novel 
finding with potential clinical implications, because even mild acidemia may contribute to bone 
demineralization 12, and higher urinary pH may predispose to kidney stone formation 11. Indeed, 
Arampatzis et al. diagnosed incomplete dRTA in 1 out of 15 males with recurrent calcium stone 
formation 21. Eriksson et al. reported ten patients who presented with dRTA and urolithiasis who 
went on to develop pSS in subsequent years 11.
The higher auto-antibody prevalence in patients with complete and incomplete dRTA may have 
pathophysiological significance. Although auto-antibodies causing dRTA have not been iden-
tified, several reports suggest that auto-antibodies against carbonic anhydrase 22 or acid-base 
transporters 23 are involved in the pathogenesis of dRTA in pSS. If the presence of auto-antibod-
ies causing dRTA is confirmed, screening for these antibodies would facilitate early identifica-
tion and treatment of dRTA.
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tion test with furosemide and fludrocortisone (FF) could replace AMCL 17. We confirmed the 
better tolerability of FF, but, unfortunately, the overall diagnostic performance of FF was poor. 
One exception was the reasonable negative predictive value. Therefore, we believe FF could be 
considered as a first screening test, and AMCL could be reserved for those patients who fail to 
acidify their urine to pH < 5.3 with FF. One caveat with this approach is the possibility of a false 
negative test result. For example, if the FF-test would have been used as initial screening test 
for dRTA in this cohort, dRTA would have been missed in 6 out of 17 patients (35%). Why these 
6 patients had a false negative test result remains unclear, but is probably due to the different 
mechanisms by which urinary acidification is tested (directly giving an acid load vs. indirectly 
stimulating H+ secretion). 
Because it remains unclear if incomplete dRTA always results in complications, it may be ac-
ceptable to miss these false negatives initially. Conversely, early identification of patients with 
a urinary acidification defect could provide a rationale for treatment with potassium citrate, 
which was recently shown to improve bone mineral density even in healthy older adults 12.
Why did the urinary acidification test with FF in the present study perform worse than in the 
initial report by Walsh et al.? One important difference is that half of the patients in the study 
by Walsh et al. had complete dRTA, which is more likely to result in a positive FF test. In addi-
tion, FF was only tested in patients with previously confirmed dRTA and not in patients in whom 
dRTA may be absent, incomplete, or complete. Indeed, in response to Walsh’s report, Viljoen et 
al. reported the results of performing both urinary acidification tests in 10 patients with recur-
rent nephrolithiasis and/or nephrocalcinosis 24. They also identified 3 patients who were able to 
acidify their urine to a pH < 5.3 with AMCL but not with FF. In agreement with our recommen-
dation, Viljoen et al. proposed that the urinary acidification test with FF should be used as initial 
screening test to be followed up by AMCL if urine pH remains ≥ 5.3 24. It is unclear whether the 
FF test should be repeated after a certain period of time in case of a normal test result. There 
are no data to indicate what the disease-free period is after a negative test result. Therefore, at 
present, we recommend to leave it to the discretion of the treating physician to repeat the FF 
test after a few years. 
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The strength of our study is the large cohort of patients with pSS in whom urinary acidification 
was tested functionally, which allowed us to establish the true prevalence of incomplete dRTA. 
A limitation of our study was that we do not know whether the presence of incomplete dRTA 
leads to poorer outcomes during follow-up, because our study was cross-sectional. A prospec-
tive cohort study aiming to determine the clinical significance of incomplete dRTA is currently 
ongoing.  
In conclusion, incomplete dRTA is common in pSS and causes mild acidemia which may poten-
tially contribute to organ damage. FF cannot replace AMCL to test urinary acidification in pSS, 
but may be considered as screening test, given its reasonable negative predictive value and bet-
ter tolerability.
 
 
3
Prevalence of distal renal tubular acidosis in primary Sjögren syndrome       
    72
References
1. Laing, C. M. & Unwin, R. J. Renal tubular acidosis. J Nephrol 19 Suppl 9, S46-52 (2006).
2. Buckalew, V. M., McCurdy, D. K., Ludwig, G. D., Chaykin, L. B. & Elkinton, J. R. Incom   
 plete renal tubular acidosis. Physiologic studies in three patients with a defect in lowering urine  
 pH. Am. J. Med. 45, 32–42 (1968).
3. Wagner, C. A., Devuyst, O., Bourgeois, S. & Mohebbi, N. Regulated acid–base transport in the col 
 lecting duct. Pflügers Arch. - Eur. J. Physiol. 458, 137–156 (2009).
4. Both, T. et al. Everything you need to know about distal renal tubular acidosis in autoimmune   
 disease. Rheumatol Int 34, 1037–1045 (2014).
5. Yılmaz, H., Kaya, M., Özbek, M., ÜUreten, K. & Safa Yıldırım,  Hypokalemic periodic paralysis 
 in Sjogren’s syndrome secondary to distal renal tubular acidosis. Rheumatol. Int. 33, 1879–82  
 (2013).
6. Poux, J. M. et al. Hypokalemic quadriplegia and respiratory arrest revealing primary Sjögren’s   
 syndrome. Clin. Nephrol. 37, 189–91 (1992).
7. Pun, K. K. et al. Hypokalemic periodic paralysis due to the Sjögren syndrome in Chinese 
 patients.  Ann. Intern. Med. 110, 405–6 (1989).
8. Pessler, F. et al. The spectrum of renal tubular acidosis in paediatric Sjögren syndrome. Rheuma 
 tology (Oxford). 45, 85–91 (2006).
9. Ohtani, H. et al. Severe hypokalaemia and respiratory arrest due to renal tubular acidosis in a   
 patient with Sjögren syndrome. Nephrol. Dial. Transplant 14, 2201–3 (1999).
10. Fulop, M. & Mackay, M. Renal tubular acidosis, Sjögren syndrome, and bone disease. Arch. 
 Intern. Med. 164, 905–9 (2004).
11. Eriksson, P. et al. Urolithiasis and distal renal tubular acidosis preceding primary Sjögren’s syn  
 drome: a retrospective study 5-53 years after the presentation of urolithiasis. J. Intern. Med. 
 239, 483–8 (1996).
12. Jehle, S., Hulter, H. N. & Krapf, R. Effect of Potassium Citrate on Bone Density, 
 Microarchitecture, and Fracture Risk in Healthy Older Adults without Osteoporosis: A 
 Randomized Controlled Trial. J Clin Endocrinol Metab (2012). doi:jc.2012-3099 
 [pii]10.1210/jc.2012-3099
13. Bossini, N. et al. Clinical and morphological features of kidney involvement in primary Sjögren’s  
 syndrome. Nephrol. Dial. Transplant. 16, 2328–36 (2001).
14. Shearn, M. A. & Tu, W. H. Nephrogenic diabeetic insipidus and other defects of renal tubular   
 function in Sjoergren’s Syndrome. Am. J. Med. 39, 312–8 (1965).
15. Haque, S. K., Ariceta, G. & Batlle, D. Proximal renal tubular acidosis: a not so rare disorder of mul 
 tiple etiologies. Nephrol. Dial. Transplant 27, 4273–87 (2012).
16. Caruana, R. J. & Buckalew Jr., V. M. The syndrome of distal (type 1) renal tubular acidosis.   
 Clinical and laboratory findings in 58 cases. Medicine (Baltimore) 67, 84–99 (1988).
17. Walsh, S. B., Shirley, D. G., Wrong, O. M. & Unwin, R. J. Urinary acidification assessed by simul  
 taneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride.   
 Kidney Int 71, 1310–1316 (2007).
18. Vitali, C. et al. Classification criteria for Sjogren’s syndrome: a revised version of the European  
 criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61, 554–558  
 (2002).
19. Brkic, Z. et al. Prevalence of interferon type I signature in CD14 monocytes of patients with   
 Sjogren’s syndrome and association with disease activity and BAFF gene expression.   
 Ann. Rheum. Dis. 72, 728–35 (2013).
20. Page, C. B. et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular  
 acidosis. Med. J. Aust. 194, 614 (2011).
21. Arampatzis, S., Röpke-Rieben, B., Lippuner, K. & Hess, B. Prevalence and densitometric 
 characteristics of incomplete distal renal tubular acidosis in men with recurrent calcium 
 nephrolithiasis. Urol. Res. 40, 53–59 (2012).
22. Takemoto, F. et al. Induction of Anti-Carbonic-Anhydrase-II Antibody Causes Renal Tubular Aci 
 dosis in a Mouse Model of Sjögren’s Syndrome. Nephron Physiol. 106, p63–p68 (2007).
23. Bae, E. H. et al. The case. Hypokalemia associated with nephrocalcinosis. Distal renal tubular aci 
 dosis associated with Sjögren’s syndrome. Kidney Int. 75, 443–4 (2009).
24. Viljoen,  a, Norden,  a G. W. & Karet, F. E. Replacing the short ammonium chloride test. Kidney 
 Int. 72, 1163; author reply 1164 (2007).
            Chapter  
  73
3
    74
  75
Bone mineral density in Sjögren syndrome 
patients with and without distal renal 
tubular acidosis 
Tim Both, M. Carola Zillikens, Ewout J. Hoorn, Robert Zietse, Jan A.M. van 
Laar, Virgil A.S.H. Dalm, Cornelia M. van Duijn, Marjan A. 
Versnel, Naomi I. Maria, P. Martin van Hagen, Paul L.A. van Daele
4
    76
Abstract 
Introduction Primary Sjögren’s syndrome (pSS) can be complicated by distal renal tubular aci-
dosis (dRTA), which may contribute to low bone mineral density (BMD).
Aim Our objective was to evaluate BMD in pSS patients with and without dRTA as compared 
with healthy controls.
Methods BMD of lumbar spine (LS) and femoral neck (FN) was measured in 54 pSS patients and 
162 healthy age- and sex-matched controls by dual-energy X-ray absorptiometry (DXA). dRTA 
was defined as inability to reach urinary pH < 5.3 after an ammonium chloride (NH
4
Cl) test. 
Results LS- and FN-BMD were significantly higher in pSS patients compared with controls (1.18 
± 0.21 g/cm2 for patients vs. 1.10 ± 0.18 g/cm2 for controls, P = 0.008 and 0.9 ± 0.16 g/cm2 for 
patients vs. 0.85 ± 0.13 g/cm2 for controls, P = 0.009 respectively). After adjustment for BMI 
and smoking, the LS- and FN-BMD remained significantly higher. Patients with dRTA (N=15) did 
not have a significantly different LS- and FN-BMD compared with those without dRTA (N=39) 
after adjustment for BMI, age and gender. Thirty-seven (69%) pSS patients were using hydroxy-
chloroquine (HCQ).
Conclusions Unexpectedly, pSS patients had a significantly higher LS- and FN-BMD compared 
with healthy controls. Patients with dRTA had similar BMD compared with patients without 
dRTA. We postulate that an explanation for the higher BMD in pSS patients may be the frequent 
use of HCQ.
            Chapter 4
  77
Introduction
Sjögren syndrome (SS) is a prevalent chronic autoimmune disease characterized by impairment 
of exocrine glands and systemic manifestations, affecting between 1% and 3% of the general 
population 1. SS can be present alone (primary Sjögren syndrome (pSS)) or accompanied by 
other autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid ar-
thritis (RA) and is then called secondary Sjögren syndrome (sSS) 2,3. The classical symptoms of 
SS include dryness of mouth (xerostomia), dryness of eyes (xerophtalmia) and less commonly 
dryness of pharynx, larynx and/or vagina 4. Extraglandular manifestations can be divided into 
general symptoms (e.g. fatigue, arthralgia and myalgia) and in systemic manifestations 5. Com-
mon systemic manifestations include renal tubular acidosis 6, non-erosive symmetrical arthritis 
7, interstitial lung disease 8, peripheral polyneuropathy 9, autoimmune thyroiditis 10 and B-cell 
lymphoma 11. 
Distal renal tubular acidosis (dRTA) is one of the less well recognized complications. Recently, 
we reported a considerably high prevalence of dRTA in pSS 6. dRTA is characterized by the in-
ability of patients to lower urinary pH < 5.3 due to a defect in the proton secreting machinery 
of the alpha-intercalated cells in the collecting ducts of the kidney 12. Patients with dRTA have a 
non-anion gap metabolic acidosis with urinary pH ≥ 5.3. 
The association between chronic metabolic acidosis and alteration in bone cell function has 
been demonstrated both in vitro and in vivo 13,14. During metabolic acidosis there appears to 
be an exchange of protons for calcium ions in bone mineral to buffer the excess of protons 13. 
The metabolic effects of dRTA in pSS remain conflicting. Several case-series have shown a low 
bone mineral density (BMD) in patients with dRTA in pSS 15,16. Some recent studies report an 
increased prevalence of low BMD in patients with dRTA 17,18, while other studies did not report 
a significant difference in patients with dRTA 19,20. Epidemiologic data on BMD in SS are lacking.
We hypothesized that BMD is significantly decreased in patients with pSS and especially in 
those with dRTA. Therefore, our aim was to evaluate BMD in pSS patients with and without 
dRTA as compared with healthy controls. 
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Methods
Study cohort
Patients were selected from the outpatient clinic of the department of internal medicine (division 
of clinical immunology) of Erasmus MC in Rotterdam, The Netherlands. pSS was defined according 
to the Revised American-European classification criteria 21. The results of salivary gland biopsy 
were retrieved when available. Additional inclusion criteria for this study included age >18 years 
and an estimated glomerular filtration rate >30 ml/min. The exclusion criteria were: other under-
lying auto-immune diseases, known risk factors for osteoporosis (vitamin D level < 20 nmol/L, 
untreated hyperthyroidism, hyperparathyroidism, use of corticosteroids (prednisone equivalent 
of > 7.5 mg for > 3 months in the last year, use of bisphosphonates, multiple myeloma, mastocy-
tosis). All participants were asked about menopausal status (if applicable), current smoking and 
history of fractures and use of medication (Table 1). Data from BMD in the healthy control group 
were obtained from the ERF (Erasmus Rucphen Family) study database 22. The matching criteria 
for the controls were age and sex. For every pSS patient, three controls were selected. The study 
was approved by the Medical Ethics Committee of the Erasmus Medical Center (MEC-2013-075). 
Informed consent was obtained from every participant. 
Bone mineral density
In all subjects we measured BMD of the lumbar spine (L2-L4) and femoral neck using a dual-energy 
X-ray absorptiometry (DXA) scanner (Prodigy Pro Full P8, enCORE™ Software Platform, GE Med-
ical Systems Lunar, Belgium). Scans were performed according to the manufacturer’s guidelines 
and analyzed according to ISCD rules 23. The healthy control group was scanned with a different 
DXA device from the same type (GE Lunar Prodigy device, GE Healthcare, USA) 24. As described by 
Enneman et al. a cross-calibration was performed using a spine phantom which showed that the 
measurements of the new scanner (the one we used for the patients in the current study) were 
slightly higher by a factor 1.0101 24. Therefore, we divided our results by this factor for comparison 
with the data from the ERF study. BMD was expressed in grams per square centimeters. 
Biochemical parameters
In all patients we measured vitamin D status. Anti-nuclear antibodies (ANA), SSA/Ro52, SSA/
Ro60, SSB/La auto-antibodies, and rheumatoid factor (RF) were also measured in all patients using
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Salivary gland biopsies were performed in 34/54 patients, but a focus score could be retrieved for only 27 patients; 
Rheumatoid factor was measured in 42/54 patients. † Other immunosuppressive therapy consisted of azathio-
prine, colchicine or methotrexate. § Data about previous fractures could not accurately be retrieved. Data are pre-
sented as mean ± standard deviation (SD) and no. (%)
Total 
(N = 54)
No dRTA 
(N = 39)
dRTA 
(N = 15)
Control group 
(N = 162)
Demographics
Age, years ± SD 57.3 ± 10.6 60.1 ± 9.4 50.2 ± 10.5 57.3 ± 10.6
Female gender, n (%) 50 (93) 36 (92) 14 (93) 150 (93)
Body mass index, kg/m2 ± SD 26.8 ± 6.2 26.9 ± 6.2 26.6 ± 6.6 27.3 ± 5.3
Current smokers, n (%) 2 (4) 0 (0) 2 (13) 60 (37)
Postmenopausal, n (%) 36/50 (72) 5/36 (14) 5/14 (36) 119 (69)
Age at menopause, years ± SD 47.4 ± 6.1 47.0 ± 6.5 48.4 ± 4.9 47.9 ± 6.1
Previous fractures, n (%)§ 19 (35) 11 (28) 8 (53) n.a
Disease duration, years ± SD 12.1 ± 7.2 12.2 ± 8.0 11.5 ± 5.6 -
Biochemical
Serum 25-OH-Vitamin D, nmol/L ± SD 70.4 ± 21,8 69.7 ± 22.1 72.5 ± 21.7
Serum intact PTH, pmol/L ± SD 4.3 ± 1.5 4.5 ± 1.5 3.7 ± 1.5
Serum calcium, mmol/L ± SD 2.39 ± 0.08 2.39 ± 0.07 2.38 ± 0.16
Serum phosphate, mmol/L ± SD 1.09 ± 0.15 1.10 ± 0.14 1.06 ± 0.16
Serum creatinine, µmol/L ± SD 76.8 ± 18.6 72.9 ± 11.8 86.7 ± 27.9
Serum PINP, µg/L ± SD 38.6 ± 18.5 41 ± 19.2 32.5 ± 15.4
Serum BAP, µg/L ± SD 14.2 ± 4.1 14.7 ± 4.3 12.8 ± 3.3
Serum NTX, nM BCE ± SD 17.2 ± 4.4 17.3 ± 4.6 16.8 ± 3.8
Immunology
Anti-nuclear antibodies, n (%) 41 (76) 28 (72) 13 (87)
Rheumatoid factor, n (%) 32/42 (76) 21/29 (72) 11/13 (85)
SSA/Ro52, n (%) 42 (78) 29 (74) 13 (87)
SSA/Ro60, n (%) 40 (74) 26 (67) 14 (93)
SSB/La, n (%) 31 (57) 18 (46) 13 (87)
Positive salivary gland biopsy, n (%)¶ 23/27 (85) 14/18 (78) 9/9 (100)
Medications
Hydroxychloroquine, n (%) 35 (69) 23 (59) 12 (80)
Vitamin D supplements, n (%) 11 (20) 9 (23) 2 (13)
Glucocorticoids, n (%) 3 (6) 2 (5) 1 (7)
Other immunosuppressive drugs, n 
(%)†
4 (7) 2 (5) 2 (13)
Table 1 – Characteristics of the study cohort
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previously reported methods 25. Serum was collected before 10:00 AM and analyzed the same 
day. Patients were not instructed to be fasting. The following bone turnover markers (BTMs) 
were measured in patients: serum N-terminal propeptide of type I procollagen (PINP) and se-
rum bone-specific alkaline phosphatase (BAP, both as measures of bone formation) and serum 
N-terminal crosslinking telopeptide of type I collagen (NTX, as measure for bone resorption). 
There were no data available on BTMs in the healthy control group.
Distal renal tubular acidosis
dRTA was defined as an abnormal NH
4
CL test and the absence of any other known causes for 
dRTA (e.g., medication, hypercalciuria) 12. The NH
4
CL test is defined as abnormal if patients fail 
to achieve a urinary pH < 5.3 within four hours after intake of ammoniumchloride (1 ml/kg body 
weight) 26. 
Statistics
All results are expressed as means with standard deviations. Comparisons of the normally dis-
tributed continuous variables between two groups were performed using the student T-test. 
Since BTMs were not normally distributed we compared BTMs between the two groups using 
the Mann-Whitney U test. Linear regression analysis was used to estimate the effect of hav-
ing pSS on BMD before and after adjustment for body mass index (BMI) and smoking. Linear 
regression analysis was used to estimate the effect of having dRTA on BMD before and after 
adjustment for BMI, age and gender. A P-value < 0.05 was considered significant. All analyses 
were performed in SPSS (version 21, IBM). 
Results
Study cohort and baseline characteristics
The study cohort included 54 patients with pSS and the control group consisted of 162 sub-
jects. Initially, 62 patients participated in the study. Eight patients were excluded, including four 
patients who were unable to complete the NH
4
Cl test due to repeated vomiting, one patient in 
whom the DXA-scan was not reliable due to scoliosis and three patients were using bisphospho-
nates. No patients were excluded because of long-term use of corticosteroids and only three 
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patients were using low dose corticosteroids for a medical condition other than pSS. The baseline 
characteristics of the study cohort are shown in Table 1. Similar to previous studies on pSS, our 
cohort has a female:male ratio of approximately 10:1 27. Thirty-seven (69%) patients with pSS 
were using HCQ. In addition to medication for pSS, other commonly used drugs in this cohort 
were vitamin D with calcium supplements (N=11). None of these patients reported a fracture in 
their medical history. 
BMD of pSS patients compared with healthy controls
BMD of fifty-four pSS patients was compared with the age- and sex matched control group of 
162 subjects. The LS- and FN-BMD were significantly higher in the pSS patients compared with 
the healthy control group (1.18 ± 0.21 g/cm2 for pSS patients vs. 1.10 ± 0.18 g/cm2 for the control
group, P = 0.008 and 0.9 ± 0.16 g/cm2 for pSS patients vs. 0.85 ± 0.13 g/cm2 for the control group, 
P = 0.009 respectively) (Figure). After adjustment for BMI and smoking, the LS- and FN-BMD 
remained significantly higher (β = 0.10 ± 0.030 g/cm2, P < 0.001 and β = 0.077 ± 0.022 g/cm2, P < 
0.001) (Table 2). 
Figure – Comparison of BMD between patients and controls
The graph shows the bone mineral density of the lumbar spine and the femoral neck of patients with primary Sjögren 
syndrome (N =54) compared with healthy age- and sex matched controls (N = 162).
Abbreviations: SD, standard deviation; BMD, bone mineral density; LS-BMD, bone mineral density of the lumbar 
spine; FN-BMD, bone mineral density of the femoral neck.
Bone mineral density
LS-BMD FN-BMD
0.0
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2
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Table 2 – Multiple regression analysis of factors related to LS- and FN-BMD between patients (N = 54) vs. 
controls (N = 162)
Abbreviations: Std. error, standard error of the mean; pSS, primary Sjögren syndrome; BMI, body mass index; LS-
BMD, bone mineral density of the lumbar spine; FN-BMD, bone mineral density of the femoral neck. * P 0.01 < 
0.05,  ** P < 0.01
The effect of distal renal tubular acidosis on BMD
Fifteen pSS patients had an urinary acidification defect as measured by the NH
4
CL test. Be-
tween both groups the levels of biochemical parameters and the use of medication were similar 
(Table 1). Patients with dRTA were significantly younger compared with those without dRTA 
(Table 1). Both the LS- and FN-BMD were significantly higher in patients with an urinary acidifi-
cation defect compared with those without an urinary acidification defect (LS: 1.29 ± 0.16 g/cm2 
vs. 1.14 ± 0.21 g/cm2, P = 0.018 and FN: 1.0 ± 0.19 g/cm2 vs. 0.87 ± 0.14 g/cm2, P = 0.007). After 
adjustment for BMI, age and gender, both the LS- and FN-BMD were not significantly higher
Table 3 – Multiple regression analysis of factors related to LS- and FN-BMD between patients with dRTA 
(N = 15) vs. patients without dRTA (N = 39)
Abbreviations: Std. error, standard error of the mean; dRTA, distal renal tubular acidosis; BMI, body mass index; LS-
BMD, bone mineral density of the lumbar spine; FN-BMD, bone mineral density of the femoral neck.
* P < 0.01
Variable LS-BMD FN-BMD
B Std. Error Beta B Std. Error Beta
(Constant) 0.797 0.063 0.587 0.047
    pSS 0.103 0.030 0.237** 0.077 0.022 0.235**
         BMI 0.010 0.002 0.298** 0.009 0.002 0.350**
      Smoking 0.061 0.029      0.147* 0.045 0.021     0.143*
Variable LS-BMD FN-BMD
B Std. error Beta B Std. Error Beta
(Constant) 1.292 0.217 1.175 0.166
    dRTA 0.121 0.064 0.264 0.070 0.049 0.184
         BMI 0.007 0.004 0.220 0.003 0.003 0.113
Gender -0.177 0.100 -0.226 -0.008 0.076   -0.012
       Age -0.003 0.003 -0.157 -0.006 0.002   -0.405*
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 anymore (LS: β = 0.12 ± 0,064 g/cm2, P = 0.065 and FN: β = 0.07 ± 0,049 g/cm2, P = 0.16) (Table 
3). 
Bone turnover markers in pSS patients
In patients with dRTA serum PINP was not significantly higher compared with patients without 
dRTA (P = 0.093). The other marker for bone formation, BAP, was also not significantly different 
between both groups (P = 0.11). The bone resorption marker NTX, was not significantly differ-
ent between patients with and without dRTA (P = 0.92). 
Discussion
In the present study we found that, contrary to expected, pSS patients have significantly high-
er BMD than healthy age- and sex-matched controls. We searched the available literature but 
did not find another study reporting BMD measurements in pSS patients as compared with a 
healthy control group. Studies concerning BMD in autoimmune diseases are mainly performed 
in lupus patients. In agreement with Arampatzis et al. and Pongchaiyakul et al. we found that pa-
tients with an urinary acidification defect did not have a significantly different LS- and FN-BMD 
compared with those patients without an urinary acidification defect 19,20. 
Bushinsky et al. reported a decreased bone mineralization in an acidotic environment in both 
in-vitro and in-vivo studies 13,14. This makes us wonder what the reason is that we did not find a 
lower BMD in patients with dRTA.  
We hypothesize that the observed BMD in pSS patients may be related to the use of hydroxy-
chloroquine (HCQ) which the majority (69%) of patients in our study was using. In case of sys-
temic manifestations, therapy with non-steroidal anti-inflammatory drugs or HCQ is advised. 
HCQ has proven to be effective against fatigue, arthralgia and myalgia 28,29. Lakshminarayanan 
et al. and Mok et al. reported that in lupus the use of HCQ was associated with increased BMD 
of the hip 30,31. In both studies, disease activity and use of corticosteroids were not significantly 
different between both groups. Additionally, Xiu et al. recently reported a reduced osteoclasto-
genesis by TRAF3 degradation due to the effects of chloroquine in mice, which may suggest that 
HCQ has direct effects on bone metabolism 32. Based on these clinical and biochemical studies 
we hypothesize that HCQ may have beneficial effects on BMD. 
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In our cohort, it is unknown how long these patients were treated with HCQ. We also did not 
have information about past use of HCQ in patients, who are not using it currently. Therefore, 
analyzing a possible association between HCQ use and BMD would not be reliable in our co-
hort. To demonstrate whether the use of HCQ has beneficial effects on human bone cells, in vitro 
studies should be performed.
We analyzed whether patients with dRTA also had different BTM measurements compared 
with patients without an urinary acidification defect. Since patients with dRTA had similar LS- 
and FN-BMD compared with those without dRTA, we expected that the BTMs measurements 
would not be significantly different between both groups. Indeed, all three BTMs (PINP, NTX 
and BAP) were not significantly different between patients with and without an urinary acidifi-
cation defect. Unfortunately, we could not compare BTM measurements between pSS patients 
and the healthy control group since data about BTM measurements in the healthy controls is 
lacking.
The strength of this study is that we have reported new data about the BMD values in a large 
cohort of pSS patients. In addition, we analyzed the effects of dRTA, a common complication of 
pSS, on BMD in pSS patients. A limitation of this study is that we used a different DXA scanner 
compared to Zillikens et al. although the type of machine was the same and calibration was per-
formed with a spine phantom, making this an unlikely explanation for our findings 22. 
In conclusion, we found that both the LS- and FN-BMD were higher in patients with pSS than in 
age and sex-matched healthy controls. In addition, LS- and FN-BMD in patients with an urinary 
acidification defect is comparable with patients without an urinary acidification defect. An ex-
planation for the high BMD in pSS patients may be the frequent use of HCQ, but future studies 
will have to confirm whether indeed use of HCQ is associated with higher BMD. 
             Chapter 4
  85
References
1. Peri, Y., Agmon-Levin, N., Theodor, E. & Shoenfeld, Y. Sjögren’s syndrome, the old and the new.  
 Best Pract. Res. Clin. Rheumatol. 26, 105–117 (2012).
2. BAER, A. N., MAYNARD, J. W., SHAIKH, F., MAGDER, L. S. & PETRI, M. Secondary Sjogren’s Syn 
 drome in Systemic Lupus Erythematosus Defines a Distinct Disease Subset. J. Rheumatol. 37,   
 1143–1149 (2010).
3. Hage, M. P., Al-Badri, M. R. & Azar, S. T. A favorable effect of hydroxychloroquine on 
 glucose and lipid metabolism beyond its anti-inflammatory role. Ther. Adv. Endocrinol. Metab. 
 5, 77–85 (2014).
4. Asmussen, K., Andersen, V., Bendixen, G., Schiodt, M. & Oxholm, P. A new model for 
 classification of disease manifestations in primary Sjogren’s syndrome: evaluation in a retrospec 
 tive long-term study. J Intern Med 239, 475–482 (1996).
5. Ng, W.-F. & Bowman, S. J. Primary Sjogren’s syndrome: too dry and too tired. Rheumatology   
 (Oxford). 49, 844–53 (2010).
6. Both, T. et al. Prevalence of distal renal tubular acidosis in primary Sjogren’s syndrome. Rheuma 
 tol. 54, 933–939 (2015).
7. Pease, C. T., Shattles, W., Barrett, N. K. & Maini, R. N. The arthropathy of sj??gren’s syndrome.   
 Rheumatology 32, 609–613 (1993).
8. Deheinzelin, D. et al. Interstitial lung disease in primary Sjögren’s syndrome.    
 Clinical-pathological evaluation and response to treatment. Am. J. Respir. Crit. Care Med.   
 154, 794–799 (1996).
9. Brito-Zerón, P. et al. Classification and characterisation of peripheral neuropathies in 102 pa  
 tients with primary Sj??gren’s syndrome. Clin. Exp. Rheumatol. 31, 103–110 (2013).
10. Jara, L. J. et al. Thyroid disease in Sjögren’s syndrome. Clin. Rheumatol. 26, 1601–1606 (2007).
11. Ambrosetti, A. et al. Most cases of primary salivary mucosa-associated lymphoid tissue lympho 
 ma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br. J. Haematol.  
 126, 43–49 (2004).
12. Laing, C. M. & Unwin, R. J. Renal tubular acidosis. J Nephrol 19 Suppl 9, S46-52 (2006).
13. Bushinsky, D. A., Chabala, J. M., Gavrilov, K. L. & Levi-Setti, R. Effects of in vivo metabolic 
 acidosis on midcortical bone ion composition. Am J Physiol 277, F813-9 (1999).
14. Bushinsky, D. a, Krieger, N. S., Geisser, D. I., Grossman, E. B. & Coe, F. L. Effects of pH on bone   
 calcium and proton fluxes in vitro. Am. J. Physiol. 245, F204–F209 (1983).
15. Aerts, J., Vigouroux, C., Fournier, P., Cariou, D. & Pasquier, P. [Osteomalacia of renal origin 
 disclosing Gougerot-Sjögren syndrome]. La Rev. Med. interne 15, 43–7 (1994).
16. Cherif, E., Ben Hassine, L., Kaoueche, Z. & Khalfallah, N. Osteomalacia as inaugural 
 manifestation of Sjogren syndrome. Case Reports 2013, bcr2013201052-bcr2013201052   
 (2013).
17. Domrongkitchaiporn, S. et al. Bone mineral density and histology in distal renal tubular acidosis.  
 Kidney Int. 59, 1086–1093 (2001).
18. Weger, W., Kotanko, P., Weger, M., Deutschmann, H. & Skrabal, F. Prevalence and characteri  
 zation of renal tubular acidosis in patients with osteopenia and osteoporosis and in non-porotic  
 controls. Nephrol Dial Transpl. 15, 975–980 (2000).
19. Arampatzis, S., Röpke-Rieben, B., Lippuner, K. & Hess, B. Prevalence and densitometric   
 characteristics of incomplete distal renal tubular acidosis in men with recurrent calcium   
 nephrolithiasis. Urol. Res. 40, 53–59 (2012).
20. Pongchaiyakul, C., Domrongkitchaiporn, S., Stitchantrakul, W., Chailurkit, L. O. & Rajatanavin, R.  
 Incomplete renal tubular acidosis and bone mineral density: A population survey in an area   
 of endemic renal tubular acidosis. Nephrol. Dial. Transplant. 19, 3029–3033 (2004).
21. Vitali, C. et al. Classification criteria for Sjogren’s syndrome: a revised version of the European  
 criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61,   
 554–558 (2002).
22. Zillikens, M. C. et al. The role of body mass index, insulin, and adiponectin in the relation   
 between fat distribution and bone mineral density. Calcif. Tissue Int. 86, 116–25 (2010).
23. Schousboe, J. T., Shepherd, J. A., Bilezikian, J. P. & Baim, S. Executive summary of the 2013   
 International Society for Clinical Densitometry Position Development Conference on   
 bone densitometry. J. Clin. Densitom. 16, 455–66 (2013).
24. Enneman, A. W. et al. Effect of Vitamin B12 and Folic Acid Supplementation on Bone Mineral   
 Density and Quantitative Ultrasound Parameters in Older People with an Elevated Plasma   
 Homocysteine Level: B-PROOF, a Randomized Controlled Trial. Calcif. Tissue Int. 96,   
 401–409 (2015).
25. Brkic, Z. et al. Prevalence of interferon type I signature in CD14 monocytes of patients with   
 Sjogren’s syndrome and association with disease activity and BAFF gene expression.   
 Ann. Rheum. Dis. 72, 728–35 (2013).
26. Walsh, S. B., Shirley, D. G., Wrong, O. M. & Unwin, R. J. Urinary acidification assessed by 
 simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chlo 
                                                                   Bone mineral density in Sjögren syndrome  
4
    86
 ride. Kidney Int 71, 1310–1316 (2007).
27. Haugen,  a J. et al. Estimation of the prevalence of primary Sjögren’s syndrome in two age-dif  
 ferent community-based populations using two sets of classification criteria: the Hordaland   
 Health Study. Scand. J. Rheumatol. 37, 30–4 (2008).
28. Fox, R. I., Dixon, R., Guarrasi, V. & Krubel, S. Treatment of primary Sjogren’s syndrome with hy  
 droxychloroquine: a retrospective, open-label study. Lupus 5 Suppl 1, S31-6 (1996).
29. Rihl, M., Ulbricht, K., Schmidt, R. E. & Witte, T. Treatment of sicca symptoms with hydroxychloro 
 quine in patients with Sj??gren’s syndrome. Rheumatology 48, 796–799 (2009).
30. Lakshminarayanan, S., Walsh, S., Mohanraj, M. & Rothfield, N. Factors associated with low bone  
 mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28, 
 102–108 (2001).
31. Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with  
 systemic lupus erythematosus. Lupus 14, 106–112 (2005).
32. Xiu, Y. et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing   
 TRAF3 degradation. J. Clin. Invest. 124, 297–310 (2014).
            Chapter 4
  87
4
    88
  89
Hydroxychloroquine decreases human 
MSC-derived osteoblast differentiation 
and mineralization in vitro 
Tim Both, H. Jeroen van de Peppel, M. Carola Zillikens, 
Marijke Koedam, Johannes P.T.M. van Leeuwen, P. Martin van Hagen, 
Paul L.A. van Daele*, Bram C.J. van der Eerden* 
* Both authors contributed equally to this paper
5
    90
Abstract 
Introduction We recently showed that patients with primary Sjögren Syndrome (pSS) have 
significantly higher bone mineral density (BMD) compared to healthy controls. The majority of 
those patients (69%) was using hydroxychloroquine (HCQ), which may have favorable effects 
on BMD. 
Aims To study the direct effects of HCQ on human MSC-derived osteoblast activity 
Methods Osteoblasts were cultured from human mesenchymal stromal cells (hMSCs). Cultures 
were treated with different HCQ doses (control, 1 and 5 µg/ml). Alkaline phosphatase activity 
and calcium measurements were performed to evaluate osteoblast differentiation and activi-
ty, respectively. Detailed microarray analysis was performed in 5 µg/ml HCQ-treated cells and 
controls followed by qPCR validation. Additional cultures were performed using the cholester-
ol synthesis inhibitor simvastatin (SIM) to evaluate a potential mechanism of action. 
Results HCQ inhibits both MSC-derived osteoblast differentiation and mineralization in vitro. 
Microarray analysis and additional PCR validation revealed a highly significant upregulation 
of the cholesterol biosynthesis, lysosomal and extracellular matrix pathways in the 5 µg/ml 
HCQ-treated cells compared to controls. Besides, we demonstrated that 1 µM SIM also de-
creases MSC-derived osteoblast differentiation and mineralization compared to controls.
Conclusion HCQ suppresses MSC-derived osteoblast differentiation and mineralization in vi-
tro. It appears that the positive effect of HCQ on BMD cannot be explained by a stimulating 
effect on the MSC-derived osteoblast. The discrepancy between high BMD and decreased 
MSC-derived osteoblast function due to HCQ treatment might be caused by systemic factors 
that stimulate bone formation and/or local factors that reduce bone resorption which is lacking 
in cell cultures. 
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Introduction
Hydroxychloroquine (HCQ) is an antimalarial agent now often used in systemic autoimmune 
diseases such as primary Sjögrens Syndrome (pSS), rheumatoid arthritis (RA) and systemic lu-
pus erythematosus (SLE) due to its anti-inflammatory properties 1–3. The pharmacokinetics of 
HCQ has been described extensively but the exact mechanism of action remains unclear 4.  
In addition to its anti-inflammatory effects, the literature concerning the pharmacodynamics of 
HCQ is extensive. In vivo studies showed that HCQ has beneficial effects on the lipid profile of 
patients with RA and pSS by lowering serum levels of low density lipoprotein (LDL) cholesterol, 
triglycerides and total cholesterol as well as increasing high density lipoprotein (HDL) choles-
terol 5, 6. Additionally, HCQ has been associated with beneficial cardiovascular and anticancer 
effects but it is not used for these conditions since there are better alternatives available 7, 8. 
In vitro studies have shown that HCQ is capable of inhibiting Toll-like receptors (TLR) 7 and 9, 
which are involved in the pathogenesis of SLE 9–11. Although Raicevic et al. reported that osteo-
blasts do not express TLR 7 and 9, other studies did show TLR 9 expression in osteoblasts 12–14. 
HCQ has also been identified as an autophagy inhibitor by blocking the degradation of autopha-
gosomes and promoting apoptosis in endometriosis, cervical cancer cells and myeloid leukemia 
15–17. In addition to the effects on autophagosomes, HCQ also acts on lysosomes. Some studies 
reported an increased lysosomal pH by HCQ treatment, which is associated with decreased ly-
sosomal function 18, 19, while other studies did not observe a significant difference in lysosomal 
pH 10, 11. Furthermore, HCQ has been associated with increased lysosomal membrane permea-
bilization (LMP), a process occurring prior to mitochondrial membrane permeabilization (MMP) 
leading to apoptosis 20. 
We recently reported that patients with pSS, of which the majority was using HCQ, had a higher 
bone mineral density (BMD) compared to healthy controls 21. Additionally, we found two stud-
ies showing a positive association between BMD and HCQ use in SLE patients, which was cor-
rected for patient characteristics and disease activity 22, 23, while one study reported a negative 
effect of HCQ on BMD 24. We recently showed that HCQ leads to decreased osteoclast differ-
entiation and activity due to HCQ treatment 25. Based on our previous studies, we hypothesized 
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that HCQ stimulates the activity of the bone forming cells, the osteoblasts, which has not been 
studied before.
Methods
Cell cultures
Human mesenchymal stromal cells (hMSCs; Lonza, Basel, Switzerland) were differentiated into 
osteoblasts as described before 26. Briefly, hMSCs were differentiated into mineralizing osteo-
blasts within 2 to 3 weeks, using dexamethasone and β-glycerophosphate. The media were re-
freshed twice a week and cells were treated without (control) and with HCQ (1 or 5 µg/ml). 
Alkaline phosphatase (ALP) activity was measured at day 7 of culture. Osteoblast mineraliza-
tion was analyzed by measuring the amount of precipitated calcium corrected for total protein 
at day 18 as extensively described before 26. Images were taken during culture to evaluate cell 
morphology. For microarray analysis, osteoblast cultures with and without 5 µg/ml HCQ were 
stopped at day 5. 
Mineralization staining assays
Calcium depositions were visualized with the Alizarin red staining assay as described before 
26. Briefly, cells were fixed with 70% (vol/vol) ethanol and, after washing, stained for 10–20 min 
with alizarin Red S solution. Phosphate depositions were visualized with the von Kossa staining 
assay as described before 26. Cells were washed with water and the wells were stained for 30 
minutes with 5% silver nitrate (in bright daylight), incubated for one minute in 5% sodium car-
bonate in 25% formalin and finally for two minutes in 5% sodium thiosulphate. 
Activation of simvastatin
hMSCs were differentiated to osteoblasts as described before. In addition, cells were treated 
with a dose range from 100 nM to 100 µM simvastatin (SIM; Sigma Aldrich, The Netherlands) 
with and without 5 µg/ml HCQ to evaluate whether the effects of HCQ on both osteoblast dif-
ferentiation and mineralization could be antagonized by SIM. Simvastatin was activated before 
use as previously described 27. Briefly, 5 mg simvastatin was dissolved in 125 µl of 100% ethanol, 
with subsequent addition of 187.5 µl of 0.1 N NaOH. The solution was heated to 50°C for 2 
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hours in a water bath and then activated by neutralizing to pH 7.0 using 0.1 N HCl. The resulting 
solution was brought to a final concentration of 4 mg/ml using distilled water and aliquots were 
stored at 4°C until use.
Immunocytochemistry assays
hMSCs were cultured for 5 days and stained for cytoskeletal actin. Briefly, cells were washed with 
phosphate buffer solution (PBS) and fixed with 10% formalin. PBS + Triton X100 was added for ten 
minutes, followed by blocking aspecific binding sites, using PBS + Tween 0.05% + BSA 1% for 30 
minutes. Cells were then incubated with a rhodamine-conjugated phalloidin antibody for 1 hour at 
room temperature and washed with PBS + Tween 0.05% followed by DAPI staining. Staining of the 
cytoskeleton was visualized under a fluorescent microscope using a 535 nm filter. Additionally, a 
DAPI filter (365 nm) was used to visualize the nuclei and evaluate any apoptotic events (e.g. nuclear 
fragmentation, chromatin condensation). 
For visualization and quantification of focal adhesions, cells were labeled for 1 h with rabbit mono-
clonal anti-vinculin antibody at 1:200 dilution at RT, followed by secondary Alexa Fluor 488 goat 
anti-rabbit IgG at 1:400 dilution for a total of 1 h 28.
Illumina gene chip–based gene expression
Total RNA of hMSCs was isolated as described before 26. Illumina Human HT-12 v4 BeadChip (Il-
lumina, Inc, San Diego, USA) human whole-genome expression arrays were used. RNA integrity of 
isolated RNA was assessed by RNA 6000 Nano assay on a 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA). The RNA of 3 biologic replicates for each condition (control, 1 and 5 µg/ml 
HCQ) was analyzed. The Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) was 
used for RNA amplification of each sample according to manufacturer’s instructions. In short, T7 
oligo(dT) primer was used to generate single-stranded cDNA, followed by a second strand synthe-
sis to generate double-stranded cDNA. In vitro transcription was done to synthesize biotin-labeled 
cRNA using T7 RNA polymerase. The cRNA was column purified and checked for quality by RNA 
6000 Nano assay. A total of 750 ng of cRNA was hybridized for each array using the standard Illu-
mina protocol, with streptavidin-Cy3 (GE Healthcare, Piscataway, NJ, USA) being used for detec-
tion. Slides were scanned on an iScan and analyzed using GenomeStudio (both from Illumina, Inc.).
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Microarray analysis
Background was subtracted from the raw data using GenomeStudioV2010.1 (Gene Expression 
Module 1.6.0, Illumina), and data were processed using the Bioconductor R3.3 lumipackage 
(www.bioconductor.org) 29. The data were transformed by variance stabilization and quantile 
normalization. Probes that were detected at least three times in the experiments (Illumina de-
tection p-value < 0.01) were considered to be expressed and were further analyzed. Differen-
tially expressed probes were identified using Bioconductor Package Limma (www.bioconductor.
org), with adjusted p-values adjusted to reduce the false discovery rate (FDR; p < 0.01) 30. Gene 
ontology (GO) analysis, selected Illumina IDs were analyzed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) 2008 hosted by the National Institute of Aller-
gy and Infectious Diseases (NIAID) at the National Institutes of Health (Bethesda, MD, USA) and 
at GeneMANIA (http://www.genemania.org/). Merging of overlapping GO annotations was per-
formed by using the Reduce and Visualize Gene Ontology (REVIGO) tool (www.revigo.irb.hr) .
Quantitative real-time PCR analyses
The methods used for RNA extraction and cDNA synthesis and real-time (RT) PCR have 
been described previously 26. Real-time qPCR was performed by using the ABI Prism 
7900 sequence detection system (Applied Biosystems), and the results were analyzed us-
ing SDS version 2.3 software (Applied Biosystems). Data are presented as relative mRNA 
levels calculated and corrected for gene expression of the housekeeping gene GAPDH by 
the formula: 2-Δ(Ct of gene of interest - Ct of housekeeping gene). All primers used are summarized in Table 1.
Statistics
All results are expressed as means with standard error of the mean (SEM). Comparisons of the 
continuous variables between three groups (control, 1 and 5 µg/ml HCQ) and two groups (con-
trol and 5 µg/ml HCQ) were performed using the one-way analysis of variance (ANOVA) and 
students T-test, respectively. For ANOVA analysis, the least significant difference post-hoc test 
was used. A P-value < 0.05 was considered significant. All analyses were performed in SPSS 
(version 21, IBM).
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Table 1 – Primer sequences of the analyzed genes
Abbreviations: GO, gene ontology; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; TNC, Tenascin C; ALP, 
Alkaline Phosphatase; ACAT2, Acetyl-CoA Acetyltransferase 2; DHCR7, 7-Dehydrocholesterol Reductase; CTSK, 
Cathepsin K; CTNS, Cystinosin, Lysosomal Cystine Transporter; GPNMB, Glycoprotein Nmb; HMGCR, 3-hy-
droxy-3-methylglutaryl-CoA reductase. 
Results
HCQ inhibits osteoblast differentiation and activity
Osteoblast differentiation, as measured by ALP activity at day 7, was significantly decreased 
dose-dependently between HCQ doses of 1 and 5 µg/ml vs. controls (1.54 ± 0.11 mU/µg for 
HCQ dose 1 µg/ml and 0.8 ± 0.044 mU/µg for HCQ dose 5 µg/ml vs. 2.7 ± 0.15 mU/µg for the 
controls, P < 0.001 for both and P < 0.001 for the dose-dependent trend) (Figure 1A). Mineral-
ization at day 18 was significantly decreased between 5 µg/ml HCQ and controls (0.40 ± 0.015 
nmol/µg vs. 9.75 ± 1.76 nmol/µg, P = 0.011 and P < 0.001 for the dose dependent trend). In fact, 
using the highest HCQ dose, mineralization was virtually absent at 18 days of culture (Figure 
1B). Additionally, using alizarin red and von Kossa stainings, mineralization in the HCQ-treated 
cells was absent compared to the controls (Figure 1C). During culture, evaluation of the cells 
showed an altered morphology in the 5 µg/ml HCQ-treated cells compared to the controls at 
day 14 (Figure 1D). We performed vinculin stainings at day 5 of culture to analyze for differ-
ences in cell-surface attachment between HCQ-treated cells and controls. HCQ-treated cells 
showed significantly less staining compared to the controls indicating less cell-surface attach-
ment due to HCQ (Figure 1E). Furthermore, there is no evidence for a difference in apoptotic 
events between the conditions (data not shown) or cytoskeletal malformations (actin) between
controls and HCQ-treated cells based on rhodamine-phalloidin staining (Figure 1E).
Gene Forward primer Reverse primer
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCCGTTG
TNC CACAGCCACGACAGAGGC AAAGGCATTCTCCGATGCCA
ALP TAAAGCAGGTCTTGGGGTGC GGGTCTTTCTCTTTCTCTGGCA
ACAT2 GAGCTTTGCCTAGCTTGCAG TGAAGGAACCTATGATGGTCCG
DHCR7 GAGGTGTGCGCAGGACTTTA CTTCTTGAACCGGCCCCTTA
CTSK TGCCCACACTTTGCTGCCGA GCAGCAGAACCTTGAGCCCCC
CTNS AACGCGGTGCATTCCTGA GCGTCTCCAAAGCAATCTGA
GPNMB 
HMGCR
TAAACCTTGAGTGCCTGCGT 
TCTAGTGAGATCTGGAGGATCCAA
TGAAATCGTTTGGCGGCATC 
GGATGGGAGGCCACAAAGAG
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Figure 1 – Effect of HCQ on MSC-derived osteoblast differentiation and mineralization
All experiments are performed twice with N = 4 for every condition. A ALP measurement at day 7. B Mineraliza-
tion at day 18 C Alizarin red staining and von Kossa staining in controls vs. HCQ-treated cells D Morphology of 
MSC- derived osteoblasts at day 14 of culture in controls vs. 5 µg/ml HCQ-treated cells. E DAPI/Actin/Vinculin 
staining in controls vs. 5 µg/ml HCQ-treated cells. Data are presented as mean ± SEM. * = P < 0.05, ** = P < 0.01.
Abbreviations: HCQ, hydroxychloroquine; ALP, alkaline phosphatase
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Microarray analysis of HCQ-treated hMSCs yields 4 regulated processes in MSC-derived osteoblasts
In order to gain insight into processes regulated by HCQ during osteoblast differentiation, we per-
formed microarray gene expression analysis using Illumina Human HT-12 v4 expression arrays. 
hMSCs were cultured and treated without or with HCQ (1 or 5 µg/ml) for 5 days as described 
above. Next, whole-genome analysis of mRNAs was assessed following induction of osteogenic 
differentiation. When evaluating 2-fold up- and downregulated genes in HCQ-treated cells vs. 
controls, a clear dose response between 1 µg/ml and 5 µg/ml HCQ treatment was observed (Fig-
ure 2A-B). In addition, none of the genes was stronger regulated by 1 µg/ml HCQ compared to 5 
µg/ml HCQ. Therefore, we excluded the 1 µg/ml HCQ-treated cells from further analysis. A total 
of 119 gene probes corresponding to 72 genes were differentially expressed (q < 0.05 and 2-fold 
change) at day 5 compared to controls. GO analysis of these gene probes resulted in a significant 
overrepresentation of 14 functional categories. Evaluation of the regulated genes within the cate-
gories showed a large overlap between the GO terms and using REVIGO, we narrowed them down 
based on the largest number of genes to four main processes, namely 1) lipid metabolic process 
(GO:000629),  2) developmental process (GO:0032502), 3) lysosome (GO:0005764) and 4) extra-
cellular matrix (GO:0031012) (Table 2).
Figure 2 – Dose response curve of gene expression profiles between 1 and 5 µg/ml HCQ compared to con-
trols 
All experiments are performed with N = 4 for every condition. The dotted line indicates the threshold of 2-fold up- or 
downregulation. A Dose response for all genes that are negative regulated by HCQ. B Dose response for all genes that 
are positive regulated by HCQ. Abbreviations: HCQ, hydroxychloroquine
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Table 2 – GO term enrichment analysis of 5 µg/ml HCQ treatment vs. control at day 5 of MSC-derived 
osteogenesis 
Abbreviations: GO, gene ontology
PCR validation of HCQ-regulated genes underlying selected GO terms from microarray analysis 
From every GO term we selected two genes of interest for PCR validation (Table 2). For the 
GO term ‘lipid metabolism’ process we selected acetyl-CoA acetyltransferase 2 (ACAT2) and 
7-dehydrocholesterol reductase (DHCR7), which encode the first and last enzyme involved in 
the cholesterol biosynthesis pathway 32. For the GO term ‘extracellular matrix’ we selected te-
nascin C (TNC) and alkaline phosphatase (ALP) since these genes were highly regulated by HCQ 
and are known to be involved in osteoblast differentiation. Genes belonging to the GO term 
‘lysosome’ include cathepsin K (CTSK) (a cysteine proteinase) and cystinosin, lysosomal cystine 
transporter (CTNS) (a small lysosomal membrane protein). All selected genes were also regulat-
ed in the GO term ‘developmental process’ and therefore we only selected glycoprotein Nmb 
(GPNMB) from this GO term, since this was the strongest regulated gene upon HCQ treatment 
in our experiment. We validated these seven genes using real-time PCR. Although expression 
of two genes (ALP and TNC) did not reach significance between controls and HCQ treatment, 
all genes showed the same direction of regulation compared to our results from the microarray 
analysis (Figure 3A-G).
Simvastatin decreases osteoblast differentiation and mineralization alone and in combination with 5 
µg/ml HCQ 
Since HCQ upregulates the cholesterol synthesis pathway, we hypothesized that SIM (a cho-
lesterol synthesis inhibitor) would antagonize the inhibitory effects of HCQ on osteoblast dif-
            Chapter 5
GO Name Fold enrichment Number of genes P-value
Biological process
GO:0006629 Lipid metabolic process 4.1 20 0.0002
GO:0032502 Developmental process 2.0 37 0.014
Cellular 
component
GO:0005764 Lysosome 9.9 11 0.0002
GO:0031012 Extracellular matrix 5.5 10 0.012
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Figure 3 – Validation of multiple genes regulated using real-time qPCR
All experiments are performed with N = 4 for every condition. Total RNA was isolated from by 5µg/ml HCQ-treated 
hMSCs at day 5 followed by qPCR for A ACAT2, B DHCR7, C CTSK, D CTNS, E ALP, F TNC and G GPNMB. Gene 
expression was corrected for the housekeeping gene GAPDH. Data are presented as mean ± SEM. * = P < 0.05, ** = P 
< 0.01. Abbreviations: HCQ, hydroxychloroquine
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ferentiation and mineralization. Therefore, we treated MSCs with SIM in multiple doses in the 
presence or absence of 5 µg/ml HCQ to evaluate the effects of SIM alone and in combination 
with HCQ on MSC-derived osteoblasts. We found that SIM doses of 100 nM and 10 nM were 
ineffective, while SIM doses above 1 µM increased cell death in the early phase of the culture 
probably due to its cellular toxicity (data not shown). 
We showed that 1 µM SIM significantly decreased osteoblast differentiation, as measured by 
ALP activity, compared to untreated controls (0.67 ± 0.038 mU/µg for 1 µM SIM vs. 1.9 ± 0.33 
mU/µg for the controls, P < 0.001) (Figure 4A). The effect of 1 µM SIM was similar to the effect 
of HCQ only as well as to the combination of these two drugs. Additionally, both 0.2 and 1 µM 
SIM significantly decreased osteoblast mineralization compared to the controls (1.49 ± 0.072 
nmol/µg for 0.2 µM SIM and 1.63 ± 0.018 nmol/µg for 1 µM SIM vs. 2.67 ± 0.32 nmol/µg for the 
controls, P < 0.001 for both) (Figure 4B). However, the observed decreased mineralization by 
both doses of SIM was less severe compared to the HCQ treatment. The combination of HCQ 
with either SIM doses significantly decreased the mineralization compared to either SIM dose 
alone and is similar to the cells treated with HCQ only (1.63 ± 0.18 nmol/µg for 1 µM SIM vs. 
0.78 ± 0.59 nmol/µg for HCQ and 0.77 ± 0.047 nmol/µg for 1 µM SIM + HCQ, P < 0.05 for both). 
We also analyzed gene expression for HMGCR (the enzyme inhibited by SIM) in HCQ and/or 
SIM-treated cells compared to control. Although gene expression in SIM-treated cells was 
higher, the effect was not significant. HCQ significantly increased HMGCR gene expression 
compared to controls (P < 0.05) (Figure 4C). In addition, the combination with SIM and HCQ 
resulted in a significantly increased expression compared to either drug alone and to controls 
(P < 0.05 and P < 0.001, respectively). Furthermore, we analyzed gene expression of ALP and 
DHCR7 in HCQ- and/or SIM-treated cells compared to control. Expression of ALP was signifi-
cantly increased by 0.2 µM SIM compared to control (P < 0.001) (Figure 4D). The combination 
of SIM and HCQ was similar to HCQ alone, but significantly lower compared to control (P < 
0.001). Expression of DHCR7 was significantly increased by both HCQ and 1 µM SIM compared 
to control (P < 0.01 and P < 0.05, respectively) (Figure 4E). The combination of SIM and HCQ 
showed a synergistic effect leading to an increased DHCR7 expression compared to control (P 
< 0.001) (Figure 4E).
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Figure 4 – Effect of 5 µg/ml HCQ and SIM on MSC-derived osteoblast differentiation and mineralization
All experiments are performed twice with N = 4 for every condition. SIM doses are 0.2 µM and 1 µM.  A MSC-derived 
osteoblast differentiation, as measured by ALP, at day 7 in HCQ- and/or SIM-treated cells compared to control. B 
MSC-derived osteoblast mineralization, as measured by calcium incorporation, at day 21 in HCQ and/or SIM-treat-
ed cells compared to control. qPCR analysis of  C HMGCR, D ALP and E DHCR7 in HCQ- and/or SIM-treated cells 
compared to control. Data are presented as mean ± SEM. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
Abbreviations: HCQ, hydroxychloroquine; SIM, simvastatin; ALP, alkaline phosphatase
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Discussion
In the present study we demonstrated that HCQ suppresses both MSC-derived osteoblast 
differentiation and mineralization in vitro. Although some of the pharmacodynamics of HCQ 
may apply to specific biological processes in MSC-derived osteoblasts, we did not come across 
studies reporting the direct effects of HCQ on MSC-derived osteoblast differentiation or ac-
tivity. Furthermore, we demonstrated results of the microarray analysis comparing 5 µg/ml 
HCQ-treated hMSCs to controls. Upregulation of genes belonging to the cholesterol biosyn-
thesis pathway, lysosomal pathway and extracellular matrix were the most significantly influ-
enced processes by 5 µg/ml HCQ treatment. Since SIM is a cholesterol synthesis inhibitor and 
beneficial for osteoblast differentiation and mineralization, we evaluated whether SIM could 
antagonize the negative effects of HCQ and enhance MSC-derived osteoblast function simul-
taneously. Contrary to expected, SIM significantly decreased both MSC-derived osteoblast dif-
ferentiation and mineralization and the combination of SIM and HCQ yielded similar outcomes 
compared to HCQ treatment alone.
Since patients with pSS, of which the majority is using HCQ, have a higher BMD compared to 
healthy controls, we hypothesized that HCQ is beneficial for either MSC-derived osteoblast 
differentiation or mineralization 21. However, our in vitro work showed that both MSC-derived 
osteoblast differentiation (as measured by ALP activity) and mineralization (as measured by 
calcium incorporation and shown by mineralization stainings) are significantly decreased by 5 
µg/ml HCQ treatment compared to controls. 
We performed microarray analysis on both control and 5 µg/ml HCQ-treated cells to assess 
potential mechanisms causing decreased MSC-derived osteoblast differentiation and mineral-
ization. We showed that the upregulation of genes involved in the cholesterol metabolism path-
way was the most significantly regulated process by 5 µg/ml HCQ compared to control samples. 
From this pathway, 10 out of 24 enzymes were significantly upregulated. Indeed, we confirmed 
the upregulation of this pathway by validating two of the involved genes (ACAT2 and DHCR7) 
using RT-PCR. Based on this finding, we speculate that either 1) HCQ has a direct positive reg-
ulatory effect on cholesterol synthesis or 2) HCQ causes an intracellular cholesterol depletion 
leading indirectly to increased cholesterol synthesis or increased cholesterol uptake. The latter 
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is in agreement with the observed depletion of LDL cholesterol in vivo in patients that receive 
HCQ 5, 6. 
The role of cholesterol in MSC-derived osteoblast differentiation has mainly been studied by the 
use of statins (e.g. SIM). SIM inhibits 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and 
thereby blocks the synthesis of mevalonate and its downstream products leading to decreased 
levels of cholesterol 32. SIM activates Ras signaling by inhibiting the synthesis of cholesterol 
leading to overexpression of BMP-2 through the PI3K/Akt/MAPK pathway. BMP-2 upregulates 
the expression of RUNX2, and phosphorylated RUNX2 stimulates a series of bone-specific gene 
transcriptions and promotes the differentiation of osteoblasts 33-35. Indeed, both in vitro and in 
vivo studies have reported the beneficial effects of statins on osteoblast differentiation and 
mineralization 36, 37. Additionally, in vivo studies showed that statins are a potential treatment 
for osteoporosis 38, 39. Based on these studies, we expected to find improved MSC-derived os-
teoblast differentiation and/or mineralization and we speculated that SIM may antagonize the 
negative effects of HCQ. However, we found that both MSC-derived osteoblast differentiation 
and mineralization were significantly decreased in SIM-treated cells compared to controls. Fur-
thermore, MSC-derived osteoblast mineralization was significantly decreased by the combina-
tion of SIM and HCQ compared to cells treated with SIM only. A potential explanation might be 
that HCQ leads, due to an unknown mechanism, to an intracellular cholesterol depletion result-
ing in upregulation of cholesterol synthesizing enzymes as described earlier. Treatment with 
SIM would then block this compensatory mechanism of the cell which may lead to decreased 
MSC-derived osteoblast development and activity. Indeed, gene expression of HMGCR is sig-
nificantly increased in HCQ and SIM-treated cells and it seems that both drugs have synergistic 
effects supporting our hypothesis. It remains unclear, however, why SIM did not have beneficial 
effects on MSC-derived osteoblasts in our experiments. Another possible explanation might be 
the use of hMSCs, since many studies showing beneficial effects of SIM used different type of 
cell-lines 40. A third explanation might be that 1µM SIM has still toxic effects leading to impaired 
MSC-derived osteoblast activity without leading to apoptosis. Despite using a dose response 
experiment for SIM and following the methods as described in other papers, we could not con-
firm previously reported beneficial effects of SIM. 
We showed a highly significant upregulation of the endosomal/lysosomal system by HCQ com
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pared to the controls in our microarray analysis. Surprisingly, the most upregulated gene was 
CTSK, a lysosomal protease, which is predominantly known to be involved in bone resorption 
by osteoclasts 41, 42. The role of CTSK in osteoblasts is less well understood and the majority of 
these studies are performed in mice. Mandelin et al. reported that osteoblast-like cells indeed 
produce CTSK mRNA and release processed cathepsin K into culture media in vitro 43. A study 
performed in a CTSK knockout mouse showed a significantly increased number of osteoblasts 
in the fracture callus with associated increased callus mineral density and strength compared to 
wild-type mice 44. Since we demonstrated a significantly decreased MSC-derived osteoblast dif-
ferentiation and mineralization and a significant upregulation of CTSK expression in HCQ-treat-
ed MSC-derived osteoblasts, a direct relation between CTSK upregulation and the observed 
phenotype is too premature at this stage.  
According to literature, HCQ has been associated with increased LMP leading to apoptosis 
20. LMP is caused by loss of cholesterol in the lysosomal membrane leading to the release of 
cathepsins and protons from the lysosomal lumen into the cytosol where they participate in 
apoptosis signaling 45. This may lead to the observed upregulation of CTSK gene expression in 
order to compensate for the loss. Additionally, cholesterol is identified as a stabilizer of the ly-
sosomal membrane and may therefore counter LMP. 
Finally, the decreased mineralization may be caused by HCQ-induced alteration in the extracel-
lular matrix (ECM) gene expression profile as this was one of the regulated GO terms following 
HCQ treatment. Eijken et al. reported  that activin signaling in human osteoblasts changes the 
expression of a specific range of ECM proteins prior to the onset of mineralization, leading to 
a matrix composition with reduced or no mineralizing capacity 28. In agreement with this, we 
found similar ECM gene expression alterations due to HCQ treatment compared to controls 
in our microarray experiment (downregulation of ALPL and CLEC3B; upregulation of POSTN, 
MMP7 and MMP15). In addition, we showed that staining for yet another ECM protein, vinculin, 
was significantly decreased in HCQ-treated cells compared to controls. Therefore, we specu-
late that HCQ leads to reduced cell-surface attachment and altered ECM composition leading 
to decreased matrix mineralization.
Based on these findings, our final hypothesis is that HCQ ‘attacks’ the lysosomal membrane by 
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removing cholesterol leading to decreased osteoblast differentiation and mineralization. As a 
compensatory mechanism, both the cholesterol synthesis pathway and the lysosomal pathway 
are upregulated in an attempt to restore osteoblast function. In addition, HCQ may also affect 
ECM composition leading to decreased cell attachment, differentiation and matrix mineraliza-
tion. The discrepancy between high BMD and decreased MSC-derived osteoblast function due 
to HCQ treatment might be caused by systemic factors that stimulate bone formation and/or 
systemic or local factors that reduces bone resorption which is lacking in cell cultures. In fact, 
we have shown that HCQ strongly suppresses bone resorption in vitro and in vivo and in women 
with an high bone turnover state, this may lead to a net increase in bone mass 25.
The strength of this study is that we performed an unbiased evaluation of potential mechanisms 
of action for the observed decreased MSC-derived osteoblast differentiation and mineraliza-
tion using microarrays. Additionally, genetic data from the microarray was translated into func-
tional experiments, but the precise mechanism remains elusive.
In conclusion, we demonstrated that HCQ suppresses MSC-derived osteoblast differentia-
tion and mineralization in vitro. Furthermore, we reported results of our microarray analysis 
showing significant upregulation of the cholesterol biosynthesis and lysosomal pathway. Sur-
prisingly, treatment with SIM and HCQ also resulted in decreased MSC-derived osteoblast dif-
ferentiation and mineralization. A potential mechanism could be HCQ-induced LMP leading to 
decreased MSC-derived osteoblast development and activity. 
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Abstract 
We recently showed that patients with primary Sjögren syndrome (pSS) have significantly high-
er bone mineral density (BMD) compared to healthy controls. The majority of those patients 
(69%) was using hydroxychloroquine (HCQ), which may have favorable effects on BMD. The aim 
of the study was to evaluate whether HCQ modulates osteoclast function. Osteoclasts were 
cultured from PBMC-sorted monocytes for 14 days and treated with different HCQ doses (con-
trol, 1 and 5 µg/ml). TRAP staining and resorption assays were performed to evaluate osteoclast 
differentiation and activity, respectively. Staining with an acidification marker (acridine orange) 
was performed to evaluate intracellular pH at multiple timepoints. Additionally, a fluorescent 
cholesterol uptake assay was performed to evaluate cholesterol trafficking. Serum bone resorp-
tion marker β-CTx was evaluated in rheumatoid arthritis patients. HCQ inhibits the formation 
of multinuclear osteoclasts and leads to decreased bone resorption. Continuous HCQ treat-
ment significantly decreases intracellular pH and significantly enhanced cholesterol uptake in 
mature osteoclasts along with increased expression of the lowdensity lipoprotein receptor. Se-
rum β-CTx was significantly decreased after six months of HCQ treatment. In agreement with 
our clinical data, we demonstrate that HCQ suppresses bone resorption in vitro and decreases 
the resorption marker β-CTx in vivo. We also showed that HCQ decreases the intracellular pH 
in mature osteoclasts and stimulates cholesterol uptake, suggesting that HCQ induces osteo-
clastic lysosomal membrane permeabilization (LMP) leading to decreased resorption without 
changes in apoptosis. We hypothesize that skeletal health of patients with increased risk of os-
teoporosis and fractures may benefit from HCQ by preventing BMD loss.
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Introduction
Hydroxychloroquine (HCQ) has primarily been registered for prevention and treatment of ma-
laria 1. In recent decades, HCQ was found to be effective in inflammatory diseases as well. Now-
adays, HCQ is used to treat many autoimmune diseases such as systemic lupus erythematosus 
(SLE), primary Sjögren syndrome (pSS) and rheumatoid arthritis (RA) 2–4. However, the exact 
molecular target(s) of HCQ remains unclear. Over the recent decades, the effect of HCQ on 
inflammatory processes has been studied. Important actions of HCQ on the inflammatory re-
sponse are: 1) inhibition of the local inflammatory response (e.g. inhibition of lysosomal enzyme 
release by polymorphonuclear leucocytes); 2) reduced chronic inflammatory response (e.g. re-
duction in lymphocyte proliferation, reduced MHC-antigen presentation and pro-inflammatory 
cytokine production) and 3) cellular effects (e.g. reduced function of intracellular organelles) 5–9. 
In addition to the anti-inflammatory effects, HCQ is also associated with anti-thrombotic and 
anti-atherosclerotic actions and anti-diabetic effects leading to cardioprotective outcomes 10,11. 
Furthermore, HCQ has beneficial effects on the lipid profile by decreasing low density lipopro-
tein (LDL) and triglycerides (TG) as well as increasing high-density lipoprotein (HDL) in patients 
with pSS and RA 12,13.
We recently reported that patients with pSS have a significantly higher bone mineral density 
(BMD) in the lumbar spine (LS) and femoral neck (FN) compared to age/sex matched healthy 
controls 14. Of this predominantly female cohort, 72% was postmenopausal, a period known to 
manifest with elevated bone turnover due to increased osteoclast (bone resorbing cells) activity 
15. Most of these patients were using HCQ (69%), which could be a potential explanation for our 
findings since a positive association between HCQ and BMD has been reported before in SLE 
16,17. However, we could not accurately analyze the effect of HCQ on BMD between HCQ-users 
(N = 23) and non HCQ-users (N = 16) due to lack of information concerning dose and duration 
of HCQ treatment. The underlying mechanism of this is unknown.  In vitro studies on the effect 
of HCQ on bone remodeling are very limited. Lee et al. showed that HCQ did not affect human 
osteoclastogenesis 18. Furthermore, Xiu et al. showed reduced osteoclastogenesis by preventing 
TRAF3 degradation following chloroquine (drug from the same family as HCQ) treatment in 
mice 19. A study from 1978 showed by using acridine orange staining that HCQ is 
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capable of increasing the lysosomal pH in macrophages 20. In addition, it was shown that HCQ 
is able to increase lysosomal pH in mice osteoclasts that is associated with decreased signaling 
and nuclear translocation of the key osteoclast marker NFATc1, leading to an impairment of 
osteoclastogenesis 21.  Recent reports suggest, however, that HCQ does not affect lysosomal pH 
22,23. To our knowledge, studies concerning the direct effect of HCQ on bone resorption in vitro 
have not been performed yet.
We hypothesized that HCQ affects osteoclastogenesis and/or bone resorption leading to de-
creased bone turnover resulting in net less bone loss. This would be a potential explanation for 
our BMD findings in pSS patients. The aim of the current study is therefore to evaluate the ef-
fects of HCQ on human osteoclasts in vitro and bone resorption in vivo as well as to investigate 
underlying mechanisms.
Methods
Cell cultures
Human peripheral blood mononuclear cell (PBMCs)-sorted monocytes, using a CD14 anti-
body-conjugated magnetic bead system (Miltenyi Biotec, Germany) were cultured towards 
osteoclasts as described before 24. The media were refreshed twice a week as described previ-
ously and cells were treated without and with 5 µg/ml HCQ. After 14 days of culture, cells were 
fixed in 10% formalin and stained for tartrate-resistant acid phosphatase (TRAP). Cells were 
counted and categorized according to the number of nuclei (1, 2, 3-5 and ≥6 nuclei). 
Bone resorption assay
Osteoclasts were cultured on an osteoassay surface plate (Corning, USA) for 14 days and treat-
ed as described above. In this way, the capability of mineral resorption by acid secretion can be 
assessed. Briefly, cells were washed with water and the wells were stained for 30 minutes with 
5% silver nitrate (in bright daylight), incubated for one minute in 5% sodium carbonate in 25% 
formalin and finally for two minutes in 5% sodium thiosulphate. Pictures were obtained and the 
area of the resorption pits was quantified using ImageJ (version 1.47).
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Acidification assay
Cell cultures were performed as described above. In addition, some plates received only a single 
HCQ treatment three days prior to the assay to assess whether the effect of HCQ is achieved 
after a single dose or repetitive treatment is required. At different time points, 5 µg/ml acridine 
orange (Sigma Aldrich, The Netherlands) was added for 15 minutes as described before 25. Cells 
were then washed with phosphate buffer solution and fixed with 10% formalin following DAPI 
staining. Plates were kept in the dark and analyzed, using a Zeiss Axiovert 200 MOT fluorescent 
microscope (Zeiss, the Netherlands). Depending on the intracellular pH, the acridine orange 
staining changes color which can be analyzed under a fluorescent microscope using 485 nm 
(neutral pH) and 535 nm (acidic pH) filters. Using the DAPI filter (365 nm), any staining in the 
nuclei for the other two wavelengths was excluded, leaving the cytoplasm for analysis. Images 
were made for each experiment using both wavelengths. Quantification and comparison of the 
intensities (expressed as 485:535 ratio) of each plate individually was performed using ImageJ 
(version 1.47). 
Phalloidin staining protocol
Cell cultures were performed as described above. Briefly, cells were washed with phosphate 
buffer solution (PBS) and fixed with 10% formalin. PBS + Triton-X100 was added for 10 minutes, 
followed by PBS + 0.05% Tween and 1% BSA for 30 minutes. Cells were then incubated with 
rhodamine-conjugated phalloidin antibodies for 1 hour and washed with PBS + 0.05% Tween 
followed by DAPI staining. Staining of the cytoskeleton was visualized under a Zeiss Axiovert 
200 MOT fluorescent microscope using the 535 nm filter (Zeiss). A 365 nm filter was used to 
evaluate any apoptotic events (e.g. nuclear fragmentation, chromatin condensation).
Cholesterol uptake assay
Cell cultures were performed as described above. Twenty-four hours before cholesterol up-
take evaluation, medium was replaced by serum free medium with the addition of fluorescent 
cholesterol (1:50) from the Cholesterol Uptake Cell-Based Assay Kit (Cayman Chemical, Michi-
gan, USA). Thirty-two hours after incubation, medium was removed and cells were washed with 
phosphate buffer solution. Fluorescent intensities (excitation 485 nm and emission 535 nm) 
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were measured using a plate reader and expressed as relative units (RU). Images were made by 
using a fluorescent microscope at the best optical settings for each experiment with excitation 
and emission at 485 nm and 535 nm, respectively.
Quantitative real-time PCR analyses
The methods used for RNA extraction and cDNA synthesis and RT-PCR have been described 
previously 26. Real-time qPCR was performed using the ABI Prism 7900 sequence detection 
system (Applied Biosystems), and the results were analyzed using SDS version 2.3 software 
(Applied Biosystems). Data are presented as relative mRNA levels calculated by the formula: 
2-Δ(Ct of gene of interest - Ct of housekeeping gene). All primer sequences used are summarized in Table 1.
Table 1 – Primer sequences of the analyzed genes
Abbreviations: GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; TM7SF4, Transmembrane 7 Superfamily 
Member 4; CTSK, Cathepsin K; LDLR, Low Density Lipoprotein Receptor; BAX, BCL2 Associated X Protein;  BCL2, 
B-Cell CLL/Lymphoma 2; CASP3, caspase 3
Patient cohort
Serum from patients was obtained from the tREACH study, which included only RA patients 
with intermediate disease activity 27. From those subjects, baseline serum and serum after six 
months of treatment with HCQ was used to measure beta C-terminal telopeptide (β-CTx) as 
marker for bone resorption. As control group we used serum from patients from the same da-
tabase (same time points) who were treated with methotrexate (MTX) since joint inflammation 
can lead to local bone destruction associated with increased serum β-CTx levels. A reduction in 
disease activity with any kind of treatment will then lead to a decrease of serum β-CTx. We re-
Gene Forward primer Reverse primer
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCCGTTG
TM7SF4 AAGCAGCCGCTGGGAGAAGT TTTTCAGGACTGGAAGCCAGAAATGAA
CTSK TGCCCACACTTTGCTGCCGA GCAGCAGAACCTTGAGCCCCC
LDLR CTACCCCTCGAGACAGATGGTC GCGAGGTCTCAGGAAGGGTT
BAX CTGAGCAGATCATGAAGACAGG CTGCTCGATCCTGGATGAAA
BCL2 AGTACCTGAACCGGCACCT ACAGTTCCACAAAGGCATCC
CASP3 TGGAATTGATGCGTGATGTT TGGCTCAGAAGCACACAAAC
            Chapter 6
  115
trieved serum levels of C-reactive protein (CRP) from the patient medical record. Patients were 
not instructed to be fasting.  
Additionally, we recruited patients from the outpatient clinic of the departments of Internal 
Medicine (division of clinical immunology) and Rheumatology of Erasmus Medical Center, Sint 
Franciscus Gasthuis and Maasstad Hospital in Rotterdam, The Netherlands. From those pa-
tients, we measured serum β-CTx at baseline and after three months of HCQ treatment to eval-
uate a potential early change in serum β-CTx. In addition, CRP levels were also measured. All 
subjects had to meet the following inclusion criteria: age > 18 years with either inflammatory 
arthritis, pSS, sarcoidosis, RA, SLE or osteoarthritis and starting with HCQ. The exclusion crite-
ria were: use of immunosuppressive drugs except for corticosteroids equivalent of < 7.5 mg in 
the last year, severe renal insufficiency (glomerular filtration rate < 30ml/min), known risk fac-
tors for osteoporosis (vitamin D level < 20 nmol/L, untreated hyperthyroidism, hyperparathy-
roidism, use of bisphosphonates, multiple myeloma, mastocytosis). All participants were asked 
about menopausal status (if applicable) and use of medication. The study was approved by the 
Medical Ethics Committee of the Erasmus Medical Center (MEC-2015-046). Informed consent 
was obtained from every participant. 
Statistics
All results are expressed as means with standard error of the mean (SEM). Comparisons of the 
continuous variables were performed using two-way analysis of variance (two-way ANOVA) 
with the least significant difference post-hoc test. Comparisons between baseline and after 
treatment (three and six months) and comparisons between both treatment regimens were 
performed using the paired-T-test and the students-T-test, respectively. Linear regression anal-
ysis was used to estimate the effect of treatment on serum β-CTx levels before and after adjust-
ment for CRP and age. A P-value < 0.05 was considered significant. All analyses were performed 
in SPSS (version 21, IBM). 
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Figure 1 – Effect of HCQ on osteoclastogenesis and osteoclast activity
All experiments are performed twice with N = 4 for every condition (control vs. HCQ). A TRAP stained osteoclasts. 
Scale bar = 50 mm. B TRAP staining reveals no difference in mono- and multinuclear osteoclast numbers between 
HCQ treatment and controls. C VonKossa staining of controls vs. 5 µg/ml HCQ treated osteoclasts D Surface resorp-
tion is significantly decreased by HCQ treatment (both doses) compared to control with a significant dose depen-
dent effect. E Expression of CTSK is significantly decreased in 5 µg/ml HCQ compared to control with a significant 
dose dependent effect. F Expression of the fusion marker TM7SF4 is increased in 5 µg/ml HCQ compared to control. 
* = P < 0.05, ** = P < 0.01
Abbreviations: HCQ, hydroxychloroquine; TRAP, tartrate-resistant acid phosphatase; CTSK, cathepsin K; TM7SF4, 
Transmembrane 7 Superfamily Member 4
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Results
Effect of HCQ on human osteoclasts in vitro
HCQ inhibits osteoclast activity, but not differentiation
The osteoclasts were stained for TRAP at day 14 and sorted by number of nuclei (1, 2, 3-5 and 
≥6 nuclei) (Figure 1A). Quantification of the TRAP staining showed a significant increased num-
ber of mononuclear osteoclasts in the HCQ group compared to the controls (P < 0.01). Addi-
tionally, multinuclear osteoclasts were significantly less observed in the HCQ group compared 
to the controls (P < 0.05) (Figure 1B). Surface resorption (as measured by VonKossa staining) 
showed a significant dose dependent decreasing trend with increasing HCQ dose (P = 0.005) 
(Figure 1C). The difference in amount of surface resorption was significant between HCQ dose 
1 and 5 µg/ml vs. controls (4.3 ± 1.0% for HCQ dose 1 µg/ml and 1.6 ± 0.8% for HCQ dose 5 
µg/ml vs. 16.2 ± 3.2% for the controls, P = 0.037 and P = 0.011, respectively), but not between 
1 and 5 µg/ml (Figure 1D). The expression of cathepsin K (CTSK) mRNA at day 14 displayed a 
significant dose dependent decreasing trend with increasing HCQ dose (P = 0.003), however, 
a significant effect was only observed between the 5 µg/ml HCQ treated cells compared to the 
controls (P = 0.006) (Figure 1E). Gene expression of the osteoclast fusion marker TM7SF4 at day 
14 was significantly increased in the cells treated with 5 (but not 1) µg/ml HCQ compared to the 
controls (P = 0.002) (Figure 1F). 
HCQ affects the intracellular pH of osteoclasts  
We performed a staining on the osteoclasts with an acidification marker (acridine orange) to 
visualize the intracellular acidification (Figure 2A). In total, seven time points were evaluated 
with either continuous or single HCQ treatment. We found that the 485 nm : 535 nm ratio in 
the 5 µg/ml HCQ group was significantly lower at day 12 and day 14 following continuous HCQ 
treatment compared to the controls (day 12: 0.87 ± 0.03 for 5 µg/ml HCQ vs. 1.06 ± 0.05 for the 
control, P = 0.034 and day 14: 0.59 ± 0.03 for 5 µg/ml HCQ vs. 0.92 ± 0.03 for the controls, P = 
0.037) (Figure 2B-C). In contrast, the intracellular pH (485:535 ratio) in both immature osteo-
clasts (day 7) and mature osteoclasts (day 13), which received a single HCQ treatment, was not 
significantly different between the controls and HCQ treatment groups (Figure 2D). 
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Figure 2 – Effect of HCQ on intracellular pH
All experiments are performed twice with N = 4 for every condition (control vs. HCQ). (A) Osteoclasts stained with 
the acidification marker acridine orange (green is neutral pH and red is acidic pH). Scale bar = 50 mm. (B) Intracel-
lular pH at day 12 is decreased after continuous treatment with HCQ compared to control. (C) Intracellular pH at 
day 14 is decreased after continuous treatment with HCQ compared to control. (D) In immature osteoclasts and 
after a single dose of HCQ, the intracellular pH is similar to the control. Abbreviations: HCQ, hydroxychloroquine;
Tx, treatment
HCQ stimulates cholesterol uptake by osteoclasts
Since osteoclasts lack the capacity to synthesize cholesterol endogenously, we speculated that 
HCQ-induced lysosomal membrane permeabilization (LMP) leads to increased LDL cholesterol 
significantly increased in the cells treated with 5 µg/ml HCQ compared to the controls (day 7: 
31673 ± 1922 RU for 5 µg/ml HCQ vs. 14583 ± 3217 RU for the control, P = 0.0015, day 11: 
18297 ± 229.7 RU for 5 µg/ml HCQ vs. 4902 ± 259.6 RU for the controls, P = 0.0003 and day 
21: 6474 ± 747.5 RU for 5 µg/ml HCQ vs. 3720 ± 651.0 RU for the controls, P = 0.023) (Figure 
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3A). Additionally, at day 11 also 1 µg/ml HCQ caused a significant increase in cholesterol uptake 
compared to the controls (Figure 3A). Although the same trend was observed as the other days, 
at day 14 the cholesterol uptake was not significantly different. We also evaluated the mRNA 
expression of the LDL receptor (LDLR) at day 7 and 14 showing an significantly increased ex-
pression at day 14 in cells treated with 5 µg/ml HCQ compared to the controls (0.22 ±  0.05 for 
5 µg/ml HCQ vs. 0.093 ± 0.013 for the controls, P = 0.03) (Figure 3B). 
Figure 3 – Effect of HCQ on cholesterol uptake
All experiments are performed twice with N = 4 for every condition (control vs. HCQ). (A) Cholesterol uptake is sig-
nificantly increased by osteoclasts treated with HCQ compared to the controls at multiple time points. (B) 
Expression of LDLR is significantly increased in HCQ treated osteoclasts compared to the controls. Abbreviations:
HCQ, hydroxychloroquine; LDLR, low-density lipoprotein receptor 
HCQ does not affect actin ring formation and/or apoptosis in osteoclasts
We performed phalloidin staining at day 17 to analyze a potential effect of HCQ on the forma-
tion of actin rings. We did not find any differences in appearance and/or number of actin rings 
between the HCQ-treated osteoclasts compared to the controls (Figure 4A). Furthermore, we 
performed additional DAPI staining, which provided us with the opportunity to evaluate pos-
sible apoptotic events in the nuclei of osteoclasts at multiple time points. Based on the DAPI 
staining there was no evidence for a difference in apoptotic events between the controls and 
HCQ treated cells (Figure 4B). In addition, we analyzed the gene expression of the apoptotic 
markers BAX/BCL2 and CASP3. In agreement with the morphologic aspect of the cells, both 
apoptotic markers were not significantly different in the HCQ groups compared to the controls 
at day 14 (Figure 4C-D). 
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Figure 4 – Effect of HCQ on actin ring formation and apoptotic markers
All experiments are performed twice with N = 4 for every condition (control vs. HCQ). Scale bar = 50 mm. (A) Phal-
loidin and DAPI double staining of osteoclasts on bone surface. Scale bar = 50 mm. (B) DAPI staining of osteoclasts 
(C) Expression of the BAX/BCL2 ratio was not significantly affected by HCQ compared to controls at day 14 (D) 
Expression of the CASP3 was not significantly affected by HCQ compared to controls at day 14
Effect of HCQ on bone turnover in vivo
Study cohort and baseline characteristics
We obtained serum from 63 RA patients (tREACH database) at baseline and after six months of 
treatment. Of those, 33 subjects received HCQ and thirty subjects were treated with MTX. We 
recruited another 17 patients from the outpatient clinics of all three hospitals. Of those, 7 pa-
tients were excluded due to the use of immunosuppressive drugs (N = 6) or use of bisphospho-
nates (N = 1). In total, 10 patients whom used HCQ for three months were included. Baseline 
characteristics from all subjects are shown in Table 2. 
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Table 2 – Characteristics of the study cohort
Data are presented as mean ± standard error of the mean (SEM) and no. (%)
¶ Data are presented as the difference between the two time points (after treatment - baseline)
* P < 0.05
HCQ decreases bone resorption in vivo
β-CTx was measured in all subjects at baseline and treatment (HCQ or MTX). β-CTx was not 
significantly different between both treatment regimens after six months (P = 0.16). β-CTx was 
significantly decreased after six months of HCQ treatment compared to baseline (0.363 ± 0.167 
µg/L at baseline vs. 0.300 ± 0.166 µg/L after six months, P = 0.01) (Table 2). Although we ob-
served a decreasing trend of serum β-CTx, no significant difference after six months of MTX 
treatment (P = 0.24) was measured (Table 2). Additionally, in those 10 patients who received 
HCQ for three months, serum β-CTx was not significantly decreased (P = 0.14) (Table 2). Since 
both HCQ and MTX reduce inflammation, the observed decrease in serum β-CTx may be ex-
plained by a decrease of inflammation-induced bone resorption. Therefore, we adjusted serum 
β-CTx for the decrease in serum CRP after six months compared to baseline and age. Serum 
β-CTx was not significantly associated with a decrease of CRP in the HCQ group, suggesting 
that HCQ has a direct inhibitory effect on bone resorption (β = 0.001 ± 0,001 µg/L, P = 0.44) 
(Table 3). In contrast, serum β-CTx was significantly associated with a decrease in serum CRP in 
the MTX group (β = 0.004 ± 0,001 µg/L, P = 0.003) (Table 3). 
3 months 
treatment
6 months treatment
HCQ (N = 10) HCQ (N = 33) MTX (N = 30)
Demographics
Age, years ± SEM 59.1 ± 3.7 49.3 ± 2.7 55.9 ± 2.5
Female gender, n (%) 9 (90) 18 (55) 15 (50)
Postmenopausal, n (%) 6/9 (67) 6/18 (33) 9/15 (60)
Biochemical
Serum CRP, mg/L ± SEM 
¶
-4.08 ± 2.6 -11.7 ± 3.6* -14.0 ± 4.4*
Serum β-CTx, µg/L ± 
SEM ¶
-0.037 ± 0.02 -0.063 ± 0.2* -0.038 ± 0.3
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Table 3 – Linear regression analysis of factors related to serum β-CTx between HCQ treatment (N = 33) 
and MTX treatment (N = 30)
Abbreviations: Std. error, standard error of the mean; β-CTx, beta C-terminal telopeptide; HCQ, hydroxychloroquine; 
MTX, methotrexate; CRP, C-reactive protein
¶ Data are presented as the difference between the two time points (after treatment - baseline)
* P < 0.05
Discussion
In the present study we demonstrated that HCQ suppresses bone resorption in vitro and de-
creases the resorption marker β-CTx in vivo. We searched the available literature but were not 
able to find another study reporting an association between HCQ and human osteoclast ac-
tivity. We report here that HCQ treatment leads to a decreased number of multinuclear os-
teoclasts and diminished resorptive activity. Furthermore, we demonstrated a significantly de-
creased intracellular pH and increased cholesterol uptake in osteoclasts upon HCQ treatment 
compared to controls, which has been reported before in cells undergoing LMP. LMP may lead 
to decreased bone resorption due to decreased delivery of the required protons and lysosomal 
enzymes. Supporting our in vitro data, we showed a significant decrease in serum β-CTx after six 
months of HCQ treatment compared to baseline, which was not the case for MTX treatment.
Our in vitro work showed that osteoclast activity is inhibited by increasing doses of HCQ as 
measured by bone resorption assay and by reduced gene expression of the resorption mark-
er CTSK. We also showed that HCQ leads to a decreased number of multinuclear osteoclasts, 
which indicates a disturbance in cell fusion leading to decreased resorption. We indeed found 
that gene expression of the fusion marker TM7SF4 was significantly increased by HCQ com-
pared to the controls. We speculate that the upregulation of TM7SF4 is a compensatory mech-
anism in an attempt to increase the number of multinuclear osteoclasts. Despite reduced bone 
resorption, phalloidin staining did not show a difference in either the formation or morphology 
Serum β-CTx (µg/L) HCQ MTX
B Std. Error Beta B Std. Error Beta
(Constant)  0.127 0.070 0.032 0.012
CRP (mg/L) ¶  0.001 0.001 0.126 0.004 0.001    0.530*
Age -0.004 0.001  -0.435* 0.000 0.002 -0.024
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of the actin ring between the HCQ treated cells and the controls. 
Another potential mechanism for the decreased osteoclast activity could be an increase in ly-
sosomal pH, which is a known but disputed effect of HCQ in mice osteoclasts, leading to de-
creased secretion of acid 21. Therefore, we stained the osteoclasts with an acidification marker 
at multiple time points and with different treatment regimens. Contrary to expectation, we 
found that mature osteoclasts with continuous HCQ treatment have a lower intracellular pH 
compared to the controls, which was not occurring in immature osteoclasts and in mature os-
teoclasts receiving a single dose of HCQ.  
A potential explanation for this is the association of HCQ with increased LMP 30. LMP is caused 
by loss of cholesterol in the lysosomal membrane leading to the release of cathepsins and pro-
tons from the lysosomal lumen into the cytosol where they participate in apoptosis signalling 
and lead to a decreased intracellular pH, respectively 31,32. We hypothesize that the acid re-
quired for resorption canot leave the cell due to LMP leading to decreased bone resorption. 
Additionally, cholesterol is identified as a stabilizer of the lysosomal membrane and therefore 
counters LMP 33,34. Since osteoclasts lack the capacity to synthesize cholesterol endogenous-
ly, we speculated that HCQ-induced LMP leads to increased LDL cholesterol uptake in order 
to prevent HCQ-induced LMP 29,35. Indeed, HCQ has beneficial effects on cholesterol metabo-
lism in vivo 13,36. We reported a significant increase of LDLR expression in the HCQ treated cells 
compared to the controls. In addition, we evaluated the cholesterol uptake by osteoclasts at 
multiple time points, which showed a significantly increased uptake due to HCQ treatment sup-
porting our hypothesis. Nevertheless, we could not find evidence of increased apoptosis due to 
LMP in the HCQ treated cells compared to the controls. 
It may be possible that the osteoclast is capable of defending itself from apoptosis (e.g. by in-
creasing cholesterol uptake). Additionally, BAX-dependent mitochondrial membrane permea-
bilization (MMP), downstream of LMP, is an obligatory step of LMP-triggered apoptosis 30. MMP 
may be a rate limiting step in HCQ-induced apoptosis. Indeed, we found no significant differ-
ence in BAX/BCL2 and CASP3 expression due to HCQ treatment. 
Summarizing our in vitro work, we propose a mechanism of action for HCQ in osteoclasts lead-
ing to increased LMP (not leading to apoptosis), which would be in agreement with the observed 
lower intracellular pH (due to LMP) and increased cholesterol uptake as a mechanism to pre-
vent HCQ-induced LMP (Figure 5). 
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Figure 5 – Proposed model of the mechanism of action for HCQ in the osteoclast
1) Lysosomes containing H+-ATPases on the surface, cathepsins and acid move intracellularly to the ruffled border. 
2) Lysosomes fuse with the ruffled border and build in the H+-ATPases in order to secrete protons. In addition, the 
lysosomal enzymes (e.g. cathepsins) are released in the resorption pit. 3) HCQ treatment may lead to an increased 
rate of LMP leading to leakage of protons (decreased pH) and enzymes into the intracellular space. Additionally, 
a decreased number of lysosomes will move to the ruffled border leading to decreased bone resorption. 4) Since 
cholesterol is a stabilizer of the lysosomal membrane, mRNA expression of the LDLR and cholesterol uptake are 
increased to counter HCCQ-induced LMP.
Abbreviations: HCQ, hydroxychloroquine; LMP, lysosomal membrane permeabilization; LDLR, low-density lipopro-
tein receptor
We also analyzed the effect of HCQ on bone resorption in vivo by measuring the serum resorp-
tion marker β-CTx in patients with RA. Although the subjects in the HCQ group were relatively 
younger and more often premenopausal compared to the subjects in the MTX group, there was 
no significant difference in age and postmenopausal rate between both groups. In this cohort, 
we did find a modest, but very significant, lower serum level of β-CTx after 6 months of HCQ 
treatment compared to baseline. In addition, the effect remained significant after correction 
for the decrease in serum CRP. In contrast, MTX did not lead to a significant reduction of serum 
β-CTx. Based on these findings, we conclude that HCQ has a direct effect on bone resorption 
since the decrease in serum β-CTx was not explained by a decrease in inflammation-induced 
bone resorption. Additionally, our findings in vivo are in agreement with our in vitro data, sug-
gesting that HCQ has a direct inhibitory effect on bone resorption by inhibiting osteoclast func-
tion.
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The strength of this study is that we demonstrated both in vivo and in vitro effects of HCQ on 
bone resorption. In addition, we evaluated a potential mechanism of action for HCQ on osteo-
clast function. A limitation of this study is that β-CTx measurements were taken at random mo-
ments during the day without fasting, which may have influenced the test results. Rather, we 
speculate that measurement of β-CTx in patients who fast and from whom blood is collected in 
the morning, may result in a stronger effect than what has been demonstrated currently.
In conclusion, we demonstrate that HCQ suppresses bone mineral resorption both in vitro and 
decreases the bone resorption marker β-CTx in vivo. We also showed that HCQ decreases the 
intracellular pH in mature osteoclasts and stimulates cholesterol uptake. We postulate that 
HCQ induces osteoclastic LMP leading to decreased bone resorption. Based on these findings, 
we hypothesize that skeletal health of patients with increased risk of osteoporosis and frac-
tures, including postmenopausal women and patients with inflammatory diseases such as pSS 
and RA, may benefit from HCQ by preventing BMD loss.
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General discussion and clinical implications
Evaluation of metabolic disturbances – renal involvement
We showed that the prevalence of dRTA in pSS is high as measured by the AMCL urinary acidi-
fication test.  It is unknown whether dRTA is also more prevalent in other autoimmune diseases 
such as RA and SLE. Determining the prevalence of dRTA and its complications is important be-
cause there is an effective treatment with potassium citrate for both the symptoms and compli-
cations of dRTA, by restoring acid-base balance with potassium citrate 1,2. Unfortunately, there 
is no curative therapy for dRTA available. The symptoms of dRTA in pSS patients are compara-
ble to patients without pSS and include fatigue, muscle weakness and hypercalciuria (leading 
to nephrolithiasis and decreased BMD), which are caused by the metabolic acidosis 3–5. First, 
since fatigue is a major problem for patients with pSS and is associated with a low quality of 
life, we speculate that dRTA may contribute (partially) to the fatigue complaints of pSS patients 
6,7. Treatment of dRTA would then hopefully lead to an improved quality of life of pSS patients, 
which can be measured by questionnaires concerning fatigue and/or depression over time. 
Secondly, we did not find a case of hypercalcemia and none of the patients had documented 
nephrocalcinosis / nephrolithiasis in their medical history or had complaints of ongoing neph-
rolithiasis. Unfortunately, we did not measure urinary calcium excretion. Still, we observed 
that patients with complete dRTA had a decreased glomerular filtration rate (GFR) compared 
to those without dRTA or with incomplete dRTA. A potential explanation for decreased GFR 
would be tubulointerstitial nephritis, which is a common renal manifestation of pSS, although 
this was not confirmed by a kidney biopsy. Therefore, treatment with corticosteroids may lead 
to improvement of renal function and possibly resolve dRTA with it. In addition, since patients 
with even a mild acidemia and higher urinary pH may predispose to kidney stone formation, it 
may be interesting to perform an ultrasound examination of the kidneys in patients with dRTA. 
Currently, dRTA is diagnosed using the AMCL urinary acidification test, although studies re-
port a more patient-friendly alternative using FF 8. After comparison of both tests, we recom-
mend to use AMCL to test urinary acidification in pSS, but the use of FF may be considered 
as screening test, given its reasonable negative predictive value and better tolerability. Fur-
thermore, it is unclear whether the FF test should be repeated after a certain period of time in 
case of a normal test result. There are no data to indicate what the disease-free period is after
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a negative test result. Therefore, at present, we recommend to leave it to the discretion of the 
treating physician to repeat the FF test after a few years.
Evaluation of metabolic disturbances – bone involvement
Some recent studies report an increased prevalence of low BMD in patients with dRTA 9,10, 
while other studies did not report a significant difference in patients with dRTA 11,12. Although 
metabolic acidosis leads to bone loss, we showed that patients with a urinary acidification 
defect (complete and incomplete dRTA combined) did not have a significantly different BMD 
in the lumbar spine (LS) and femoral neck (FN) compared to patients without a urinary acid-
ification defect 13. A potential explanation may be that patients with incomplete dRTA may 
have an intermittent metabolic acidosis instead of chronic academia, which does not lead to 
increased bone loss. Furthermore, only three patients had complete dRTA in our cohort making 
it unreliable to draw any conclusions concerning the effect of complete dRTA on BMD. There-
fore, the same study should be repeated with a larger cohort of patients with complete dRTA.
Contrary to expectation, we found that pSS patients have significantly higher BMD than healthy 
age- and sex-matched controls. A possible explanation for the high BMD could be that patients 
receive lifestyle advice and/or medication from their doctor to improve their condition that also 
is beneficial for bone health. Also, it has been shown before that seasonal fluctuation of vitamin 
D is associated with differences in bone metabolism (e.g., during summer time more sun expo-
sure leading to higher vitamin D, which may result in to a higher BMD) 14,15. The BMD data of the 
controls was obtained throughout the whole year without peaks in a certain season and our pa-
tients were tested during summer time. However, we used three age- and sex matched controls 
for every pSS patient to reduce the likelihood of comparing BMD data obtained in different sea-
sons. In addition, it is unlikely that such small fluctuations will lead to a significantly higher BMD. 
Another explanation would be the use of medications by the pSS patients. In our cohort, the 
most prevalent drug used was HCQ (69%). According to literature, the use of HCQ in SLE pa-
tients was associated with increased BMD of the hip compared to the non-users 16,17. In both 
studies, disease activity and use of corticosteroids were not significantly different between 
both groups, which may suggest a disease-independent effect of HCQ on bone. Indeed, we 
demonstrated that HCQ treatment leads to a significantly lower serum level of the resorp-
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tion marker β-CTx compared to baseline independent from the reduction of inflammation. 
Based on these findings, we suggest that HCQ has a direct inhibitory effect on bone resorp-
tion since the decrease in serum β-CTx was not explained by a decrease in inflammation-in-
duced bone resorption. This is in agreement with the observed higher BMD in pSS patients. 
Hydroxychloroquine decreases bone turnover
HCQ has primarily been registered as an antimalarial drug which was found to be effective in 
inflammatory diseases as well. Nowadays, HCQ is used to treat many autoimmune diseases 
such as primary Sjögren syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA) 18–20. It has been reported that HCQ is capable of TLR inhibition, especially TLR 7 
and 9, which are involved in the pathogenesis of both pSS and SLE 21–23. These TLRs are localized 
intracellular on the surface of lysosomes and their activation depends on lysosomal acidifica-
tion. Multiple studies have reported that HCQ is associated with an increased lysosomal pH 
leading to TLR inhibition 24,25. Recent reports suggest, however, that HCQ does not affect lyso-
somal pH but rather have a direct inhibitory effect on the TLRs 26,27. Additionally, HCQ has ben-
eficial effects on the lipid profile by decreasing low density lipoprotein (LDL) and triglycerides 
(TG) as well as increasing high-density lipoprotein (HDL) in both patients with pSS and RA 28,29. 
The effect of HCQ on bone is unknown, whereas studies concerning the effects of HCQ on 
bone are limited. In vitro studies on the effect of HCQ on bone remodeling are very limited. 
It was shown that HCQ is able to increase lysosomal pH in osteoclasts that is associated with 
decreased signaling and nuclear translocation of the key osteoclast marker NFATc1, leading 
to an impairment of osteoclastogenesis 24,25. Furthermore, HCQ has been identified to be an 
autophagy inhibitor by blocking the degradation of autophagosomes and promoting apopto-
sis, which is essential during osteoblast mineralization and bone homeostasis 30–32. Also, both 
cell types express TLR 2, 4 and 9 33. While the activation of TLRs in committed osteoclast 
precursors, mature osteoclasts and osteoblasts results in increased osteoclastogenesis (and 
is probably the mechanism by which pathogen-induced bone loss occurs, activation of TLRs 
in early osteoclast precursors exerts an anti-osteoclastogenic effect). This may suggest that 
inhibition of TLR 9 by HCQ (or other TLR-inhibitors) will affect bone remodeling depending in 
what stage of differentiation HCQ is introduced. We studied the effect of HCQ on both osteo-
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clasts (bone resorbing cells) and osteoblasts (bone forming cells). Since we report-
ed a favorable effect of HCQ on bone in vivo, we hypothesized that HCQ will have ei-
ther a beneficial effect on the osteoblast and/or an inhibitory effect on the osteoclasts. 
Contrary to expectation, we demonstrated a significantly decreased osteoblast differen-
tiation and mineralization due to HCQ treatment compared to controls. However, we in-
deed demonstrated that HCQ significantly decreased bone resorption by osteoclasts. 
In the osteoblasts, we performed microarray analysis to elucidate the mechanism of HCQ, 
which showed a highly significant upregulation of both the cholesterol biosynthesis pathway 
and the lysosomal system. We also showed that SIM treatment led to decreased osteoblast dif-
ferentiation and mineralization. The beneficial effects of SIM in osteoblast has been studied 
extensively before 45. We searched the literature for studies reporting similar observations, 
however, we could not find these. A potential explanation might be that we used a different 
type of cell-line compared to previous studies reporting beneficial effects of SIM on osteo-
blasts 46, 47. Despite using a dose-response experiment for SIM and following the methods as 
described in other papers, we could not discriminate between the effects of HCQ and SIM.
In the osteoclasts, we showed that continuous HCQ treatment leads to a lower intracel-
lular pH and increased cholesterol uptake compared to the controls. We analysed the dif-
ference of pH in the resorption pit using acridine orange stained osteoclasts cultured on 
mouse bone instead of plastic; however, it was difficult and inaccurate to assess the resorp-
tion pits under the fluorescence microscope. We searched literature and we did find a differ-
ent method to analyse the pH in the resorption pit, but this method involved custom made 
acid-sensing probes 34. Although this experiment may validate our hypothesis, we were not 
able to get access to these probes. Therefore, we were unable to demonstrate an increased 
pH in the resorption pit due to HCQ treatment. We did not evaluate the effects of SIM on 
osteoclasts since osteoclasts lack the capacity to synthesize cholesterol endogenously 35,36. 
Based on our results, we speculate that the potential mechanism for decreased osteoclast and 
osteoblast function would be HCQ-induced lysosomal membrane permeabilization (LMP). LMP 
is caused by loss of cholesterol in the lysosomal membrane leading to the release of cathep-
sins and protons from the lysosomal lumen into the cytosol and lead to a decreased intracel-
lular pH 37,38. Additionally, cholesterol is identified as a stabilizer of the lysosomal membrane 
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and therefore counters LMP 39,40. In the osteoclasts we demonstrated a decreased intracel-
lular pH compared to controls. In both the osteoclast and the osteoblast we showed that the 
cholesterol metabolism is significantly influenced by HCQ (cholesterol uptake, microarray). 
Furthermore, we reported that HCQ affects the gene expression of lysosomal membrane 
proteins and lysosomal enzymes in both cells. We hypothesize that the upregulation of both 
pathways are a compensatory mechanism to protect the cell from LMP-induced apoptosis.
LMP has been studied before with immunostaining for cathepsin B and a lysosomal mem-
brane protein in mouse embryonic fibroblasts 41. Since the function of osteoclasts depends 
on lysosome secretion, we speculate that these cells contain more lysosomes compared 
to fibroblasts. Therefore, interpretation of the previously described immunostaining may 
not be accurate in osteoclasts. Additionally, since LMP leads to apoptosis, we expect-
ed more apoptotic cells due to HCQ treatment compared to the controls. We observed 
an altered phenotype in the HCQ-treated osteoblasts; however, both DAPI and phal-
loidin staining appeared to be normal. We suggest that the rate of LMP may not be suf-
ficient enough to detect by staining methods. Furthermore, it may be possible that the 
compensatory mechanisms are keeping the cells alive although the function is decreased.
In conclusion, we demonstrated that HCQ decreases bone turnover (by inhibiting both osteo-
clast and osteoblast activity), which may be caused by HCQ-induced LMP. Since the cholesterol 
pathway seems to be affected the most in both cells, we proposed a combination therapy of 
HCQ and SIM, in which SIM could antagonize the effects of HCQ. SIM would only attenuate 
the negative effect of HCQ on osteoblasts and have no effect on osteoclasts since these cells 
are not capable of synthesizing cholesterol. However, treatment with SIM alone and/or com-
bined with HCQ also decreased osteoblast differentiation and mineralization. Based on this 
finding, our proposed combination therapy with HCQ and SIM seems to be not valid. Although 
both cells are inhibited by HCQ, we hypothesize that skeletal health of patients with increased 
risk of osteoporosis and fractures, including postmenopausal women and patients with inflam-
matory diseases such as pSS and RA, may benefit from HCQ by preventing BMD loss.
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Future research 
Potassium citrate reduces fatigue in pSS patients?
The most prevalent general symptom in pSS is fatigue, occurring in up to 70-80% of all pa-
tients 11. Fatigue in pSS has been well studied using the multidimensional fatigue inventory 
(MFI) on which pSS patients score twice as bad at all dimensions when compared to healthy 
controls 22,23. Fatigue has also been reported as symptom of (incomplete) dRTA. In chapter 3, 
we reported a high prevalence of dRTA in pSS patients. Therefore, we speculate that treat-
ment of (incomplete) dRTA with potassium citrate may reduce fatigue complaints in pSS pa-
tients. The outcome parameters for this observational study should include the MFI scale 
as tool to evaluate the effects of treatment on fatigue. Furthermore, periodic blood and 
urine measurements for pH evaluation and to prevent hyperkalemia should be performed. 
A new therapy for osteoporosis?
In chapter 4, we reported a higher BMD in pSS patients compared to controls. In chapter 5 and 
6 we demonstrated that HCQ decreases bone turnover by inhibiting both osteoblasts and os-
teoclasts. We finished our work by suggesting that HCQ would be beneficial for patients with 
increased risk of osteoporosis and fractures. We searched the available literature but did not 
find another study reporting HCQ as potential new therapy. Follow-up research on this topic 
would be a clinical trial comparing HCQ to the current gold standard (bisphosphonates). The 
study population should consist subjects who are catabolic, such as patients with a chronic in-
flammatory disease or postmenopausal women, leading to decreased BMD. DEXA scanning to 
measure T-scores and serum bone markers (β-CTx and PINP) could be used as main outcome 
parameters. We hypothesize that HCQ at least equals the current gold standard in this pop-
ulation. HCQ may then be a more favorable treatment since it is known to have a relative few 
side effects and can be used throughout life. The latter is not the case for bisphosphonates. 
HCQ-induced dRTA?
In this thesis, we studied the mechanism of action for HCQ on bone cells. Overall, we found 
that HCQ is associated with upregulation of the cholesterol synthesis pathway and the ly-
sosomal pathway in both cell lines. We showed that HCQ is associated with 1) decreased 
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intracellular pH, 2) increased uptake of exogenous cholesterol and 3) upregulation of cho-
lesterol synthesizing enzymes and lysosomal enzymes gene expression, which may be ex-
plained by HCQ-induced LMP. In the osteoclast, we hypothesized that HCQ-induced LMP 
leads to a decreased availability of lysosomes at the ruffled border as potential explana-
tion for the observed decreased bone resorption. Lysosome trafficking and fusion with 
the ruffled border are an essential step in both the development of the ruffled border and 
consequently bone resorption 42. The lysosomes have H+-ATPases on their surface, which 
are built in the ruffled border membrane in order to secrete protons in the resorption pit. 
A similar process occurs in the α-intercalated cells (α-ICs) located in the collecting duct of the 
kidney. The α-ICs main function is to secrete protons into the tubular lumen via H+-ATPases, 
which are stored on the surface of lysosomes located in the cytoplasm. Upon stimulation (e.g. 
metabolic acidosis, hyperaldosteronism), these lysosomes move to the apical membrane in order 
to build in their H+-ATPases for proton secretion.  In chapter 3 we reported a high prevalence of 
dRTA in pSS patients. We hypothesize that HCQ-induced LMP also occurs in the α-ICs leading to 
decreased availability of H+-ATPase on the apical membrane causing dRTA. Recently, LMP and 
lysosomal dysfunction have been reported to be induced by proteinuria and also to be involved 
in the pathogenesis of diabetic nephropathy 43,44. However, no studies have reported the ef-
fects of HCQ on renal tubular cells. dRTA has also been reported in patients with the extremely 
rare carbonic anhydrase type 2 (CA2) deficiency syndrome 45,46. CA2 is present in many tissues 
(e.g. kidney, bone) and catalyzes the reaction leading to the formation of protons and bicarbon-
ate ions. Patients with CA2 deficiency develop dRTA and osteopetrosis (a condition in which 
BMD is significantly elevated). We showed that HCQ affects intracellular pH and is associated 
with a higher BMD. Although CA2 deficiency is a rare and devastating disease, we postulate 
that there are similarities between the effects of HCQ treatment en CA2 deficiency syndrome. 
Based on our findings on bone cells, it would be interesting to study the effect of HCQ on renal 
tubular cells with special aim to cells present in the collecting duct. A first step would 
be to evaluate the effect on proton secretion to the medium, but also pH chang-
es intracellular. Consequently, a staining for the presence of H+-ATPase on the api-
cal membrane would potentially show decreased expression of H+-ATPase due to HCQ.
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Summary
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, which is characterized 
by lymphocytic infiltration of the secretory glands. The pathogenesis of pSS is currently not 
well understood, but increased activation of B cells followed by immune complex formation 
and autoantibody production are thought to play important roles 1. pSS is diagnosed using the 
American-European consensus group (AECG) classification criteria for pSS including subjective 
symptoms and objective tests such as histopathology and serology 2. The symptoms of pSS in-
clude sicca syndrome (dry eyes and/or oral cavity) and systemic manifestations, such as pulmo-
nary, articular, renal and neurological involvement 3. Systemic involvement is not always easy 
to recognize by the physician in a complex disease as pSS, since symptoms can be non-specific. 
Renal involvement, with distal renal tubular acidosis (dRTA), is common in pSS 4,5. The symp-
toms of dRTA (e.g. fatigue and/or muscle weakness) are non-specific, and are also occurring 
in pSS without systemic involvement. Untreated dRTA leads to metabolic acidosis, which 
is associated with hypercalciuria. During acute metabolic acidosis, protons are exchanged 
for calcium ions from bone. In case of chronic metabolic acidosis, a cell mediated process, 
increased activity of osteoclasts, may lead to decreased bone mineral density (BMD) 6,7. 
pSS patients are often treated with the immunomodulatory agent hydroxychloroquine (HCQ). 
The most important effects on the immune system is reducing inflammatory pathways in-
cluding Toll-like receptor (TLR) activation. In addition to its anti-inflammatory effects, HCQ 
is also associated with anti-thrombotic and anti-atherosclerotic actions, anti-diabetic effects 
and beneficial effects on the lipid profile leading to cardioprotective outcomes 8–10. Further-
more, HCQ has also been reported to positively affect BMD in systemic lupus erythemato-
sus patients 11,12. In vitro studies on the effect of HCQ on bone remodeling are very limited. 
Lee et al. showed that HCQ did not affect human osteoclastogenesis 13. Xiu et al. showed re-
duced osteoclastogenesis by preventing TRAF3 degradation following chloroquine (drug from 
the same family as HCQ) treatment in mice 14. In addition, it was shown that HCQ is able to 
increase lysosomal pH in mice osteoclasts that is associated with decreased signaling and
nuclear translocation of the key osteoclast marker NFATc1, leading to an impairment of osteo-
clastogenesis 15.   
                                                                     Summary / Samenvatting     
8
    146
In this thesis, we addressed three clinical important issues: 
1) the prevalence and consequences of distal renal tubular acidosis in pSS patients; 
2) the effect of pSS on bone metabolism; 
3) the effect of HCQ on bone metabolism.
Part 1; includes the clinical studies of this thesis and is dedicated to the eval-
uation of dRTA and its consequences in pSS and the effect of pSS on bone.
Chapters 1 and 2 provide an overview of pSS and dRTA, respectively, concerning the patho-
genesis, diagnosis and treatment. Chapter 3 is the first original article in which we determined 
the prevalence of dRTA in pSS. We found a positive urinary acidification test with ammonium 
chloride (AMCL) in 30% of 57 pSS patients. The prevalence of complete dRTA (urinary acidifi-
cation defect with acidosis) was 5% (3 out of 57). All three patients also had an impaired kidney 
function. The prevalence of incomplete dRTA (urinary acidification defect without acidosis) was 
25% (14 out of 57). Furthermore, we compared the ammonium chloride test with a more pa-
tient-friendly test using the combination of furosemide and fludrocortisone (FF). Compared to 
AMCL, the positive and negative predictive values of FF were 46 and 82%, respectively. There-
fore, we suggest that FF cannot replace AMCL to test urinary acidification in pSS, but may be con-
sidered as screening tool, given its reasonable negative predictive value and better tolerability. 
In chapter 4 we focused on the association between dRTA and BMD, since multiple studies 
report a decrease of BMD in dRTA patients, which is disputed by other studies. Therefore, 
we compared the BMD of the lumbar spine (LS) and the femoral neck (FN) between pSS pa-
tients with and without dRTA as measured by Dual Energy X-ray Absorptiometry (DXA). We 
demonstrated that patients with a urinary acidification defect (complete and incomplete 
dRTA combined) did not have a significantly different LS- and FN- BMD compared to patients 
without a urinary acidification defect. Since epidemiologic data on BMD in pSS are lacking, 
we also compared BMD of the complete pSS cohort (with and without dRTA combined) to an 
age- and sex matched healthy control group. Unexpectedly, pSS patients had a significantly 
higher LS- and FN-BMD compared to healthy controls, which remained significant higher af-
ter adjustment for body mass index and smoking. We speculated that the use of HCQ (in our 
cohort 69%) is a potential explanation for the observed higher BMD. Unfortunately, we could 
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not analyze the association between HCQ use and BMD since information (patient history of 
referring hospitals) about the duration and dose of HCQ treatment in our cohort was lacking.
Part 2; includes the laboratory studies of this thesis in which we demon-
strate the effects of HCQ on human bone cells both in vivo and in vitro.
In chapter 5 we studied the effects of HCQ on human osteoblasts in vitro. We demonstrated 
a significantly decreased differentiation and mineralization of the HCQ-treated osteoblasts 
compared to controls. Furthermore, we studied the potential mechanism of action for HCQ 
in osteoblasts using microarray analysis and additional PCR validation. We reported a highly 
significant upregulation of the cholesterol biosynthesis and lysosomal pathways in the 5 µg/
ml HCQ treated cells compared to the controls. Based on this finding, we speculate that ei-
ther 1) HCQ has a direct positive regulatory effect on cholesterol synthesis, or 2) HCQ caus-
es an intracellular cholesterol depletion leading indirectly to increased cholesterol synthesis 
and/or increased cholesterol uptake. Since simvastatin (SIM, a cholesterol synthesis inhibitor) 
has reported to be beneficial for osteoblast differentiation and mineralization, we evaluated 
whether SIM could antagonize the effects of HCQ. Contrary to expectation, we showed that 
SIM significantly decreased both osteoblast differentiation and mineralization and that the 
combination of SIM and HCQ was similar to HCQ treatment alone. We speculate that the po-
tential mechanism would be HCQ-induced LMP leading to decreased osteoblast development 
and activity. As a compensatory mechanism, both the cholesterol synthesis pathway and the 
lysosomal pathway are upregulated to restore osteoblast function. It appears that the pos-
itive effect of HCQ on BMD cannot be explained by a stimulating effect on the osteoblast.
Chapter 6 focuses on the effects of HCQ on human osteoclasts both in vivo and in vitro. In 63 
rheumatoid arthritis (RA) patients who received either HCQ or methotrexate (MTX) treat-
ment for six months, we found a significant lower level of serum β-CTx (the bone resorption 
marker) compared to baseline in the HCQ group, but not in the MTX group. Since both HCQ 
and MTX reduce inflammation, the observed decrease in serum β-CTx may be explained by a 
decrease of inflammation-induced bone resorption. Serum β-CTx was not significantly associ-
ated with a decrease of C-reactive protein (CRP) in the HCQ group, suggesting that HCQ has 
a direct inhibitory effect on bone resorption. In contrast, CRP reduction in the MTX group was
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associated with β-CTx. 
We also demonstrated that HCQ significantly decreases bone resorption by human osteo-
clasts in vitro. Furthermore, we showed a significantly decreased intracellular pH and in-
creased cholesterol uptake in osteoclasts upon HCQ treatment compared to controls, which 
has been reported before in cells with lysosomal membrane permeability (LMP). LMP may 
lead to decreased bone resorption due to decreased delivery of the required protons and 
lysosomal enzymes. We postulate that HCQ-induced LMP leads to decreased bone resorp-
tion. Based on these findings, we hypothesize that bone health of patients with increased 
risk of osteoporosis and fractures, including postmenopausal women and patients with in-
flammatory diseases such as pSS and RA, may benefit from HCQ by preventing BMD loss.
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Samenvatting
Primair Sjögren syndroom (pSS) is een systemische autoimmuunziekte gekarakteriseerd door 
ontstekingsreacties in de vocht producerende klieren. De pathogenese (oorzaak van de ziekte) 
is nog onbekend, maar onderzoek wijst uit dat verhoogde activitiet van B-cellen gevolgd door 
de vorming van immuuncomplexen een belangrijke rol hierin speelt. De diagnose pSS wordt 
gesteld door middel van de Amerikaanse-Europese classificatie criteria waarin zowel de klach- 
ten (droge ogen en droge mond) als objectieve testen (aanwezigheid van autoantistoffen en his-
topatholgisch onderzoek) staan. Naast de droge ogen en mond (sicca syndroom) kunnen in pa-
tiënten met pSS meerdere orgaansystemen zoals de nieren, gewrichten, zenuwstelsel en longen, 
tot klachten leiden. Gezien deze klachten meestal aspecifiek zijn, is dit moeilijk te herkennen. 
Nierfunctiestoornissen komt vaak voor in pSS en uit zich meestal door distale renale tu-
bulaire acidose (dRTA), wat een bekende complicatie is van pSS. De klachten die passen bij 
dRTA (b.v. moeheid en spierzwakte) zijn aspecifiek en komen ook voor bij patiënten met pSS 
die geen dRTA hebben. Onbehandelde dRTA kan leiden tot een metabole acidose wat geas-
socieerd wordt met hypercalciurie (veel kalk in de urine). Ten tijde van acute metabole aci-
dose worden protonen uitgewisseld voor calciumionen uit bot. Chronische metabole acidose 
leidt tot een cel-gemedieerd proces (verhoogde activiteit van osteoclasten, botresorberen-
de cellen) en kan resulteren in een verlaagde botmineraaldichtheid (botontkalking, BMD).
Patiënten met pSS worden vaak behandeld met het immuunmodulerende medicijn hydroxy-
chloroquine (HCQ). De belangrijkste acties op de ontstekingsreactie zijn: 1) remming van de 
lokale onstekings respons; 2) verminderde chronische ontsteking en 3) cellulaire effecten. 
Naast deze effecten wordt HCQ ook geassocieerd met verminderde thrombotische en athero-
sclerotische processen, anti-diabetische effecten en een gunstig effect op het vetspectrum wat 
resulteert in een beschermend effect voor hart- en vaatziekten. Verder is beschreven dat HCQ 
ook een gunstig effect heeft op de BMD van patiënten met systemische lupus erythematodes 
(SLE). Er zijn tot nu toe weinig in vitro studies (studies met cellen) gedaan naar het effect van 
HCQ op botcellen. De studie van Lee et al. toonde dat HCQ geen effect had op de ontwikke-
ling van menselijke osteoclasten. Xiu et al. toont aan dat chloroquine behandeling van muizen 
leidt tot een verminderde ontwikkeling van osteoclasten door remming van TRAF3 afbraak. 
Daarnaast is aangetoond dat HCQ in staat is om de lysosomale pH te verhogen in muis osteo-
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clasten wat geassocieerd wordt met verlaagde activiteit en nucleaire translocatie van de be-
langrijke osteoclast marker NFATc1 met als gevolg een verminderde osteoclast ontwikkeling. 
In dit proefschrift hebben we drie onderwerpen onderzocht: 
1) de prevalentie en complicaties van dRTA in pSS patiënten; 
2) het effect van pSS op botmetabolisme; 
3) het effect van HCQ op botmetabolisme. 
Deel 1 van dit proefschrift bevat de klinische studies en betreft het onderzoek 
naar dRTA en de complicaties hiervan bij pSS patiënten en de effecten op bot.
Hoofdstuk 1 en 2 geven een overzicht van respectievelijk pSS en dRTA waarin de pathoge-
nese, diagnose en behandeling worden beschreven. Hoofdstuk 3 is het eerste originele ar-
tikel waarin we de prevalentie van dRTA in pSS hebben onderzocht. Uit ons onderzoek blijkt 
dat 30% van de pSS patiënten (17 van 57) een positieve zuurbelastingstest met ammoniak-
chloride (AMCL) had. De prevalentie van complete dRTA (positieve zuurbelastingstest en 
metabole acidose) was 5% (3 van de 57 patiënten). Deze drie patiënten hadden ook nierfunc-
tiestoornissen. De prevalentie van incomplete dRTA (positieve zuurbelastingstest zonder 
metabole acidose) was 25% (14 van de 57 patiënten). Verder hebben we de AMCL test verge-
leken met een meer patiënt vriendelijke test, welke gebruik maakt van de combinatie fu-
rosemide en fludrocortison (FF). Vergeleken met de AMCL test heeft de FF test een positief 
en negatief voorspellende waarde van respectievelijk 46% en 82. Daarom concluderen we 
dat de FF test de AMCL test niet kan vervangen. Gezien de redelijke negatief voorspellende 
waarde en betere verdraagbaarheid kan de FF test wel worden gebruikt als screeningstest.
In hoofdstuk 4 hebben we de associatie tussen dRTA en BMD onderzocht. In de literatuur 
hebben meerdere studies een verlaagde BMD in dRTA patiënten beschreven, echter andere 
studies beschrijven geen effect van dRTA op BMD. Daarom hebben we de BMD van de lage 
ruggenwervels (LR) en de heupkop (HK) vergeleken tussen pSS patiënten met- en zonder dRTA 
door gebruik te maken van een DXA-scan. We hebben aangetoond dat patiënten met een 
een positieve zuurbelastingstest (complete en incomplete dRTA gecombineerd) geen signi-
ficant veranderde LR- en HK-BMD hebben in vergelijking met patiënten met een negatieve
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zuurbelastingstest. Gezien er geen epidemiologische data is betreffende BMD en pSS, heb-
ben we ook de BMD van de complete pSS cohort (patiënten met en zonder dRTA gecombi-
neerd) vergeleken met een gezonde leeftijd- en geslacht overeenkomende controlegroep. 
Onverwachts vonden we dat pSS patiënten een significant hogere LR- en HK-BMD hadden in 
vergelijking met de gezonde controlegroep, wat significant bleef, na correctie voor roken en 
body-mass index. We hypothetiseren dat het gebruik van HCQ (69% in onze pSS cohort) een 
mogelijke verklaring voor de hogere BMD. Helaas kunnen we deze associatie niet in onze co-
hort analyseren omdat informatie over de duur en dosering van HCQ behandeling ontbreekt.
Deel 2 van dit proefschrift bevat de studies gedaan in het laboratorium waar-
bij we de effecten van HCQ op menselijke botcellen (in vivo in in vitro) beschrijven.
In hoofdstuk 5 hebben we de effecten van HCQ op menselijke osteoblasten (bot aanmakende 
cellen) in vitro bestudeerd. We hebben een significant verminderde differentiatie (ontwikke-
ling) en mineralisatie van de HCQ-behandelde osteoblasten aangetoond in vergelijking met de 
controles. Verder hebben we de mogelijke werkingsmechanismen van HCQ op osteoblasten 
onderzocht door middel van microarray analyse en PCR validatie. Hieruit bleek dat zowel de 
cholesterol biosynthese pathway als de lysosomale pathway significant actiever waren in de 5 
µg/ml HCQ behandelde cellen in vergelijking met de controles. Gebaseerd op deze bevindin-
gen speculeren we dat of 1) HCQ een direct positief regulerend effect heeft op de choleste-
rol synthese, of 2) HCQ veroorzaakt een intracellulaire cholesterol verlaging wat indirect leidt 
tot toename van de cholesterol synthese of toename van de cholesterol opname. In de litera-
tuur is beschreven dat simvastatine (SIM, een cholesterol synthese remmer) gunstige effecten 
heeft op de osteoblast differentitatie en mineralisatie. Om deze reden hebben we onderzocht 
of SIM de effecten van HCQ teniet kan doen. Echter, we hebben ontdekt dat SIM de osteo-
blast differentitatie en mineralisatie significant verlaagd. Tevens was de combinatie van SIM en 
HCQ behandeling vergelijkbaar met alleen HCQ behandeling. We speculeren dat HCQ-geïn-
duceerde lysosomale membraan permeabilisatie een mogelijke verklaring is voor de vermin-
derde osteoblast ontwikkeling en activiteit. Om de osteoblast functie te herstellen worden de 
cholesterol biosynthese pathway en de lysosomale pathway geactiveerd als een compensatie-
mechanisme. Uit onze resultaten kunnen we concluderen dat het positieve effect van HCQ op 
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de BMD niet kan worden verklaard door een stimulerend effect van HCQ op de osteoblast. 
In hoofdstuk 6 hebben we de effecten van HCQ op menselijke osteoclasten in vitro en in vivo 
bestudeerd. We hebben 63 patiënten met rheumatoïde arthritis (RA) zes maanden behandeld 
met HCQ of methotrexaat (MTX). We vonden dat de serum marker β-CTx (een botresorptie 
marker) significant was verlaagd na zes maanden HCQ behandeling, in vergelijking met de start 
van behandeling. Dit was niet het geval bij de MTX behandelde patiënten. Aangezien HCQ 
en MTX de ontstekingsreactie verminderen kan de daling van β-CTx verklaard worden door-
dat er minder bot door de ontsteking wordt geresorbeerd. Er was geen associatie tussen de 
HCQ-geïnduceerde daling van β-CTx en daling van CRP, wat suggereert dat HCQ een direct 
remmend effect heeft op de botresorptie. In tegenstelling tot HCQ, was de daling van CRP 
MTX wel geassocieerd met een daling van β-CTx. Daarnaast hebben we aangetoond dat os-
teoclasten na HCQ behandeling significant minder bot resorberen in vergelijking met de con-
troles in vitro. Verder vonden we dat HCQ behandeling van osteoclasten leidt tot een signifi-
cant lagere intracellulaire pH en een toename van cholesterol opname in vergelijking met de 
controles. Deze observaties worden ook beschreven in cellen met LMP. LMP kan resulteren 
in een verminderde botresorptie doordat de benodigde protonen en lysosomale enzymen 
minder naar de resorptie pit worden getransporteerd. Onze hypothese is dat HCQ-geïndu-
ceerde LMP leidt tot verminderde botresorptie. Gebaseerd op deze bevindingen denken we 
dat de kwaliteit van het bot van patiënten met een verhoogd risico op osteoporose (botont-
kalking) en botbreuken, dus ook postmenopauzale vrouwen en patiënten met een inflamma-
toire ziekte zoals pSS en RA, kan worden verbeterd doordat HCQ botverlies helpt voorkomen.
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ACR American College of Rheumatology
AE-1 Chloride-bicarbonate cotransporter
AECG American-European consensus group
AIH Autoimmune hepatitis
AIT Autoimmune thyroiditis
ALP Alkaline phosphatase
AMCL Ammonium chloride
ANA Anti-nuclear antibodies
ANOVA one-way analysis of variance
AQP1 Aquaporin 1
BAFF B cell activating factor
BAP Bone-specific alkaline phosphatase
BMD Bone mineral density
BMI Body mass index
BTM Bone turnover marker
CAII Carbonic anhydrase type 2
CI Confidence interval
CRP C-reactive protein
CT Computed tomography
CTSK Cathepsin K
DMARDs Disease-modifying antirheumatic drugs
dRTA Distal renal tubular acidosis
DXA Dual-energy X-ray absorptiometry
ENaC Epithelium Na+ channel
ERF Erasmus Rucphen Family
ESSDAI EULAR Sjögren syndrome Disease Activity Index
FF Furosemide and fludrocortisone
FN Femoral neck
GO Gene ontology
GWAS Genome-wide association studies
HCQ Hydroxychloroquine
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HDL High density lipoprotein
HMCGR 3-hydroxy-3-methylglutaryl-CoA reductase
hMSCs Human mesenchymal stromal cells
IFN Interferone
IL Interleukin
ILD Interstitial lung disease
LDL Low density lipoprotein
LDLR LDL receptor
LMP Lysosomal membrane permeabilization
LS Lumbar spine
MALT Mucosa-associated lymphoid tissue
MFI Multidimensional fatigue inventory
MMP Mitochondrial membrane permeabilization
MS Multiple sclerosis
MTX Methotrexate
NaPi Sodium-phosphate cotransporter
NBCe-1 Sodium-bicarbonate cotransporter
NH3 Ammonia 
NH4+ Ammonium 
NHE3 Na+-H+ exchanger isoform 3
NKCC2 Na+-K+-(2Cl-) cotransporter
NSIP Nonspecific interstitial pneumonia
NTX N-terminal crosslinking telopeptide of type I collagen
PBC Primary biliary cirrhosis 
PBMC Peripheral blood mononuclear cell
PCR Polymerase chain reaction
pDC Plasmacytoid dendritic cells
PI3K Phosphatidylinositol 3–kinase
PINP N-terminal propeptide of type I procollagen
pSS Primary Sjögren syndrome
RA Rheumatoid arthritis
RF Rheumatoid factor
ROMK Ba2+-sensitive K+ channels
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SEM Standard error of the mean
SIM Simvastatin
SLE Systemic lupus erythematosus
SMR Standardized mortality ratio
Th1 T-helper 1 cell
Th17 T helper 17 cell
TLRs Toll-like receptors
TRAP Tartrate-resistant acid phosphatase
Treg Regulatory T cells
β-CTx Beta C-terminal telopeptide
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Dankwoord
Dit is dan het laatste maar zeker niet het minst leuke deel van het boekje om te mogen schrijven. 
Want het maken van zo’n boekje had ik natuurlijk niet alleen gekund. Allereerst wil ik begin-
nen met het bedanken van alle Sjögren patiënten die hebben deelgenomen aan het onderzoek. 
Zonder de patiënten was het onderzoek niet mogelijk geweest, jullie zijn de basis van dit boekje.
 Mijn co-promotor, Dr. Van Daele, beste Paul, bedankt voor je enthousiaste en goede 
begeleiding de laatste jaren. Ik kon met name je flexibiliteit zeer waarderen. Een jaartje van je 
kamer gebruik maken, appen, skypen in de avonduren, het kon allemaal om het onderzoek in 
goede banen te leiden. Zelfs een blind-date regelen vond je een taak voor de co-promotor.   Be-
dankt voor alle klinische lessen en wetenschappelijke ondersteuning. Je bent voor mij een voor-
beeld hoe ik later als medicus gezien wil worden.
 Mijn co-promotor, Dr. van der Eerden, beste Bram, bedankt voor je intensieve be-
geleiding gedurende het tweede deel van het promotietraject, want die kon ik als onervaren 
laborant wel gebruiken. In korte tijd hebben we veel werk verzet wat tot twee mooie artikelen 
heeft geleid. Ik waardeer je positiviteit over alle nieuwe data en je beschikbaarheid om deze dan 
ook te bespreken. Ik heb veel van je geleerd in die periode. Ik heb met plezier op je lab gewerkt.
 Mijn promotor, Prof. dr. van Hagen, beste Martin, bedankt voor je onvoorwaardelijke 
steun en vertrouwen. Eens in de zoveel tijd even met een verfrissende blik de voortgang van de 
onderzoeken doornemen. Het was erg prettig dat je altijd al het boekje voor je zag tijdens deze 
besprekingen en op basis daarvan feedback gaf.
 Beste Prof. dr. Zietse, Dr. Zillikens en Prof. dr. Baeten, bedankt voor het plaatsnemen 
in de leescommissie en daarmee bedankt voor jullie tijd en moeite voor het lezen en beoordelen 
van het proefschrift. Beste Bob, bedankt dat je de taak als secretaris op je hebt genomen wat 
zelfs nog meer tijd en moeite vergt. Tevens wil ik je bedanken voor de steun en het vertrou-
wen, maar zeker ook de gezelligheid en gastvrijheid op je kamer tijdens de besprekingen, bij het 
schrijven van mijn eerste artikelen over de betrokkenheid van de nieren. Beste Carola, ook jou 
wil ik graag bedanken voor je inzet bij het schrijven van de artikelen die te maken hebben met de 
botten, zowel klinisch als fundamenteel. Als blijk van je vertrouwen in mij heb je zelfs je DEXA-
scan aan me toevertrouwd. Bedankt voor je enthousiasme en gezellige besprekingen met daar-
bij goede feedback op de data en artikelen. 
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 Mijn paranimfen, Lennart en Wouter, die aan mijn zijde staan op de belangrijkste 
dag van mijn onderzoekscarrière. Het was mooi om jullie zo enthousiast te zien nadat ik jullie 
gevraagd had om mij vandaag te ondersteunen. Jullie zijn allebei bezig aan een mooie medische 
carrière, een cardioloog en collega internist in wording. Heel veel succes verder hiermee.
 Onderzoek doen en artikelen schrijven doe je niet alleen en daarom wil ik alle co-au-
teurs bedanken die de afgelopen jaren hebben meegeschreven. Een aantal wil ik specifiek be-
noemen. Beste Prof. dr. Hoorn, beste Ewout, graag wil ik ook jou bedanken voor je hulp bij het 
analyseren van de data en schrijven van mijn eerste original article. Verder wil ik je bedan-
ken voor je hulp bij het schrijven van de aanvraag voor de toegekende subsidie bij de nierstich-
ting. Beste Dr. Versnel, beste Marjan, bedankt voor je kritische blik op de immunologische stuk-
ken van het proefschrift. Beste Dr. Dalm en Dr. van Laar, beste Virgil en Jan, bedankt voor het 
meeschrijven aan de stukken maar zeker ook voor de gastvrijheid en gezelligheid tijdens mijn 
verblijf op de D-vleugel. Verder wil ik jullie bedanken voor het meekijken en meedoen op de 
poliklinieken, ik heb hier veel van de klinische immunologie geleerd. Beste Prof. dr. van 
Leeuwen, beste Hans, bedankt voor de besprekingen waarbij weer met een frisse blik naar de 
vergaarde data werd gekeken resulterend in nieuwe experimenten. Beste Dr. van de Peppel, 
beste Jeroen, bedankt voor het helpen met schrijven van het laatste stuk voor het boekje. Jouw 
hulp bij het uitvoeren van de microarray en vervolgens de analyses van de data was onmisbaar. 
Verder wil ik Dr. Lam uit het Sint Franciscus Gasthuis en Dr. Weel uit het Maasstad ziekenhuis 
bedanken voor hun hulp bij het rekruteren van patiënten en het nakijken van het manuscript. 
 Onderzoek doen is een teamprestatie en daarom wil ik graag nog de betrokken ana-
listen en verpleegkundigen benoemen. Allereerst wil ik graag de analisten van het calcium en 
botlab bedanken. Beste Marijke en Iris, bedankt voor jullie hulp bij het uitvoeren van de expe-
rimenten, zonder jullie was het zeker niet gelukt in de korte tijd. Verder natuurlijk ook bedankt 
voor de gezelligheid en vele kopjes koffie. Beste Sandra, bedankt voor je hulp bij het maken en 
beoordelen van al die DEXA-scans. Verder bedankt voor de goede uitleg over de werking van 
de DEXA-scan zodat ik de scans zelf kon maken. Verder wil ik alle verpleegkundigen van af-
deling 5-Midden bedanken voor de flexibiliteit en  service die jullie hebben verleend aan het 
onderzoek. Ook wil ik Ursula van de prikkamer bij de Interne Geneeskunde bedanken voor de 
coördinatie en afname van alle bloedmonsters gedurende het onderzoek. Als laatste wil ik de
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en voorbereiden van de patiënten tijdens het klinische onderzoek.
 Beste leden van de Nierstichting, bedankt voor de subsidie in de eerste fase van mijn 
onderzoek. Ook wil ik de Nationale Vereniging Sjögrenpatiënten (NVSP) bedanken voor jullie 
interesse, deelname aan het onderzoek en financiële bijdrage voor zowel het onderzoek als het 
drukken van dit boekje. Op de landelijke contactdag werd ik altijd door alle leden vriendelijk 
ontvangen en ik voelde me vereerd om bij jullie een presentatie over mijn onderzoek te mogen 
geven.
 Beste PhD-buddy’s, Marieke, Tim (van der Houwen), Zana, Naomi, Andreas, Marta 
en Shorouk, bedankt voor de gezellige tijd, het meedenken de afgelopen jaren, de vele kopjes 
koffie en lunches en de vele andere leuke dingen die we hebben gedaan naast het onderzoek. 
Succes met het afronden van jullie eigen proefschriften. Beste Paco, door jou ziet mijn boekje 
er artistiek verantwoord uit. Bedankt voor je tijd en deskundigheid. Beste geneeskunde vrien-
den, Gijs, Daphne, Elise en Marleen, ik ben zeer dankbaar voor jullie vriendschap en luisterende 
oren de laatste jaren. Altijd is er interesse in het onderzoek tijdens de vele hapjes en drankjes. 
Het is erg leuk om te zien dat iedereen zijn/haar interessegebied heeft gevonden en wie weet 
zal daarbij ook ooit nog een boekje onder jullie eigen naam uit voort komen. 
 Lieve schoonfamilie, Hans, Gerrie, Kristin en Hauke, bedankt voor jullie interesse in 
het onderzoek, gezelligheid en gastvrijheid in het verre noorden. Steenwijk(erwold) is echt als 
een tweede thuis gaan voelen. Lieve broers en schoonzussen van me, Stefan, Mirella, Jeroen en 
Magda, natuurlijk wil ik ook jullie bedanken voor de interesse in mijn opleiding en onderzoek. Al 
jaren houden we onze “broers” avond. Lekker om ook eens niet aan geneeskunde of onderzoek 
te denken. Bedankt voor jullie gezelligheid en hulp bij niet-medische dingen. 
 Lieve Pap, jij bent echt de beste vader die je maar kan wensen. Je staat (net als mam) 
altijd voor me klaar en weet altijd alles positief te benaderen wat mij hielp als het eens tegen 
zat met het onderzoek of in mijn privéleven. De spontane telefoontjes vanuit de vrachtauto om 
even te horen hoe het met me ging kan ik erg waarderen en stopt hopelijk niet na je naderende 
pensioen.
 Lieve Mam, wat ben ik toch gezegend met een moeder zoals jij. Wat was je trots toen ik 
vertelde dat ik onderzoek ging doen bij de interne geneeskunde. Elke keer als er weer een publi-
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catie in je mail stond belde je me direct op om te feliciteren en dat je je best ging doen om het 
te lezen. Ik kon altijd bij je terecht met problemen maar ook met de leuke verhalen vanuit het 
onderzoek en de studie. Jullie, jij en pap, hebben met jullie steun en zorg ervoor gezorgd dat ik 
dit heb kunnen bereiken. 
 Lieve Michelle, mijn allerliefste mevrouwtje van de hele wereld en omstreken. Van ie-
dereen die ik net heb genoemd wil ik jou nog het allermeest bedanken. Eventjes een presentatie 
met je oefenen, dan weer een artikel controleren, je bleef me altijd helpen. Al ruim drie jaar 
luister je naar alle verhalen en ervaringen uit het ziekenhuis, ik kan me voorstellen dat je daar 
gek van wordt. Je staat altijd voor me klaar, ik ben gelukkig met je, ik hou van je.
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Name of PhD student: T. Both PhD period: January 2011 – November 2017
Erasmus MC Department: Internal Medicine Promotor: Prof. dr. P.M. van Hagen
1. PhD training
Year Workload 
Hours
General academic skills
Basic course Organization Clinical research 2012 20
Research Integrity 2016 8
Research skills
Biostatistical Methods I: Basic Principles [CC02] 2013 40
In-depth courses (e.g. Research school, Medical Training)
Masterclass on Future Therapeutics in Immune-Mediated Diseases - IMID 
Molecular Immunology – EMC
2012 
2013
36 
24
Presentations
Distal renal tubular acidosis in primary Sjögren syndrome - IMID 2012 Poster
Distal renal tubular acidosis in primary Sjögren syndrome - Wetenschapsdagen 2013 Poster
Distal renal tubular acidosis in primary Sjögren syndrome - research meeting 
immunology
2013 Oral
Distal renal tubular acidosis in primary Sjögren syndrome 2014 Poster
Bone mineral density in Sjögren syndrome patients with and without distal renal 
tubular acidosis - Wetenschapsdagen
2016 Poster
Bone mineral density in Sjögren syndrome patients with and without distal renal 
tubular acidosis – ECTS 
Beyond the dryness – Reference meeting clinical immunology and allergology, EMC 
Meer dan alleen droogteklachten - Research meeting Internal Medicine, EMC  
Bone involvement in pSS patients: effects of HCQ - Research meeting Calcium and 
Bone lab and Orthopedics lab, EMC 
Sjögren syndroom: meer dan alleen droogte – Annual patients meeting NVSP 
2016 
2016 
2016 
2016 
2016
Poster 
Oral 
Oral 
Oral 
2016
International conferences
Seventh European Workshop on Immune-Mediated Inflammatory Diseases 
Noordwijk aan Zee, Netherlands
2012 20
Ninth European Workshop on Immune-Mediated Inflammatory Diseases, 
Amsterdam, Netherlands
2015 20
Wetenschapsdagen Antwerpen, Belgium 2012 16
Wetenschapsdagen Antwerpen, Belgium 2016 16
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Benlysta Sjogrens Syndrome Investigator Meeting Barcelona, Spain 2016 16
European Calcified Tissue Society Congress Rome, Italy 2016 32
American College of Rheumatology Congress Washington DC, USA 2016 32
Seminars and workshops
Disturbances in elektrolyte regulation Course 2012 8
Symposium sarcoïdosis & IPF 2012 8
National Sjögren Patient Society – Nomination Sjögren Award 2013 8
National Sjögren Patient Society 8
Winterschool Kidney foundation 2014 36
Allergology and Clinical Immunology Congress 2014 8
National Sjögren Patient Society - Nomination Sjögren Award 2016 8
2. Teaching activities 
Lecturing
Renal involvement in primary Sjögren syndrome (oral at Research Master Infection 
and Immunity)
2014 8
Extraglandular manifestations of primary Sjögren syndrome (oral at Research 
Master Infection and Immunity)
2015 8
Bone and renal involvement in primary Sjögren syndrome (oral at Research Master 
Infection and Immunity)
2016 8
Diagnosis of thyroid disorders (Medical students) 2016 8
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